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Abstract 
 
Introduction 
National guidance recommends patients receive a dental assessment, 
and necessary treatment prior to haematopoietic stem cell transplant 
(HSCT), due to the resulting immunosuppression and increased risk of 
sepsis. It is uncertain from the current literature what benefits pre-HSCT 
dental interventions have on patients’ outcome post-HSCT. This study aimed 
to evaluate the effect of dental treatment for allogeneic HSCT recipients on 
medical outcomes and quality of life. 
Methodology 
 The study was conducted in two parts. The first study was a 
retrospective review of medical and dental records for 37 patients who 
received allogeneic HSCT in 2016, and may or may not have received pre-
HSCT dental treatment. 
 The second study was mixed-methods in design exploring seven 
patients’ views of dental services and their post-HSCT medical outcomes 
using quality of life questionnaires and face-to-face semi-structured 
interviews.  
Results 
 The first study highlighted positive engagement with dental services 
from both patients and the medical team, with patients having dental needs 
prior to transplant. The study revealed more time was available to complete 
dental treatment prior to transplant. Importantly, although patients 
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experienced post-HSCT oral complications there was no indication that any 
diagnosis of sepsis resulted from organisms of odontogenic origin.    
From the second study, four key themes emerged: preventing 
transplant related complications, patient experience of care received, 
consequences of medical management and psychological impact of 
treatment. Additionally patients in this cohort expressed a good overall quality 
of life. 
Conclusions  
The study was consistent with available evidence, highlighting the 
need for pre-HSCT dental assessment and review of post-HSCT oral 
complications. Continuing to provide and improve the current dental service 
in liaison with medical teams will reassure patients during this vulnerable 
period. It is still remains unclear what the overall impact provision of dental 
treatment has on post-HSCT outcomes and therefore, future prospective 
research is required.  
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1 Chapter 1: Introduction 
The diagnosis and treatment of a haematological malignancy is a very 
challenging time for patients, both emotionally and medically, as there are 
multiple competing demands on their time with numerous hospital 
appointments to optimize their best opportunity for a successful 
haematopoietic stem cell transplant (HSCT). Dental assessment and 
intervention has been recommended in national guidance to improve both 
intra- and post-transplant outcomes (The Royal College of Surgeons England 
/ British Society of Disability and Oral Health, 2018). Currently however, there 
is limited low quality evidence available, as to the extent to which dental 
treatment improves medical outcomes and quality of life.  
1.1 Background 
Cancer Research UK reports that there were 9,918 new cases of 
leukaemia,  5,657 new cases of myeloma, 2,086 new cases of Hodgkin 
lymphoma and 13,886 new cases of non-Hodgkin lymphoma between 2014-
2016 within the United Kingdom (Cancer Research UK, 2016).  
 Haematopoietic stem cell transplant (HSCT) is used in the treatment 
of many haematological conditions (British Society of Blood and Bone 
Marrow Transplantation, 2013, NHS Commisioning Board, 2015 ). It is also 
used in the treatment of non-malignant and non-haematological disorders 
including autoimmune disease (British Society of Blood and Bone Marrow 
Transplantation, 2013, World Network for Blood and Bone Marrow 
Transplantation, 2013, NHS Commisioning Board, 2015 ). Currently over 
50,000 HSCTs are carried out annually worldwide, with 50% of these 
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occurring in Europe (World Network for Blood and Bone Marrow 
Transplantation, 2013). In 2016, across the British Isles a total of 3,959 stem 
cell transplants (2,603 autografts and 1,356 allografts) were completed for 
adult patients (British Society of Blood and Bone Marrow Transplantation, 
2016). 
1.2 Haematopoietic stem cell transplant  
HSCT is the process whereby diseased or malignant blood cells are 
replaced with healthy stem cells. There are two types of HSCT, allogeneic 
and autologous, involving different treatment methods and with differing 
morbidity and mortality rates. The NHS Commissioning Board Document: 
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplant (NHS 
Commisioning Board, 2015 ), defined the types of transplant as: 
Allogeneic – “…replacing the bone marrow stems cells of a patient 
following high dose therapy, with stem cells from a tissue-type matched or 
mismatched donor…the transplant begins with conditioning therapy… the 
aim of conditioning is to: 
 Kill leukaemia or cancer cells (in malignant disease) 
 Eradicate existing bone marrow tissue (in order to provide 
space for engraftment of transplanted donor cells) 
 Suppress the patient’s immune system, as to minimise the risk 
of graft rejection. 
... Bone marrow, peripheral blood or umbilical cord blood stem cells may be 
used as donor stem cell sources.” (NHS Commisioning Board, 2015 ). 
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 Autologous – “…the patient’s own stem cells, which are harvested 
prior to high dose therapy… the therapy destroys the patient’s remaining 
stem cell tissue” (NHS Commisioning Board, 2015 ).  
HSCT is frequently used in the treatment of certain types of 
leukaemia, lymphoma and multiple myeloma (British Society of Blood and 
Bone Marrow Transplantation, 2013, World Network for Blood and Bone 
Marrow Transplantation, 2013). 
1.3 Haematopoietic stem cell transplant process  
The HSCT process is both complex and specialised with six main stages: 
i. Pre-transplant work up: involves assessing the suitability and fitness 
for transplant of both the recipient and the donor, including tissue 
typing of the donor where applicable (NHS England, 2013). 
ii. Mobilisation/ harvest stage: collecting the stem cells from; bone 
marrow, umbilical cord or peripheral circulating blood from either the 
patient themselves (autologous) or from a matched or mismatched 
donor (allogeneic) (NHS England, 2013). 
iii. Conditioning: using cytotoxic drugs, with or without total body 
irradiation (TBI) (NHS England, 2013, Burke et al., 2014). Dependant 
on the patient, the regime is either myeloablative (standard regime), or 
reduced intensity conditioning (RIC) which uses lower doses of 
cytotoxic drugs and radiation (British Society of Blood and Bone 
Marrow Transplantation, 2013). The patients are immunosuppressed 
following conditioning and therefore are admitted to isolation units 
within the haemato-oncology wards (Burke et al., 2014).  
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iv. Infusion: the harvested stem cells are transferred to the patient via 
intravenous (IV) infusion. The patient continues to be 
immunosuppressed and can require blood and platelet transfusions 
until recovery is confirmed (Burke et al., 2014).  
v. Engraftment: sign of recovery when sufficient neutrophil numbers are 
present to reduce infection risk (NHS England, 2013).  
vi. Post-transplant follow-up: dependant on the patient and transplant 
type along with any witnessed adverse events such as infection or 
Graft versus Host Disease (GvHD) which may need further input from 
the multidisciplinary team (NHS England, 2013).  
1.4 Complications 
1.4.1 Implications for dental assessment  
In line with national guidance, it is recommended that patients receive an 
oral health assessment and appropriate dental treatment prior to undergoing 
HSCT (The Royal College of Surgeons England / British Society of Disability 
and Oral Health, 2018). This aims to exclude any sources of dental pathology 
that could lead to sepsis during the HSCT process (The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018). 
In addition, as a consequence of the conditioning treatment, patients who 
undergo HSCT become immunosuppressed and thrombocytopenic, placing 
them at increased susceptibility to infections and bleeding (The Royal 
College of Surgeons England / British Society of Disability and Oral Health, 
2018). 
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1.4.2 Bisphosphonates 
Patients diagnosed with myeloma have additional risks including renal 
failure and bone disease (National Institute for Health Care and Excellence, 
2016). NICE guidelines (National Institute for Health Care and Excellence, 
2016) recommend the use of IV bisphosphonates for the treatment of the 
bone lesions.  
The use of IV bisphosphonates impacts on dental management, a 
potential complication being medication related osteonecrosis of the jaw 
(MRONJ) (British Society of Disability and Oral Health, 2012, Scottish Dental 
Clinical Effectiveness Programme, 2017a). It is recommended that, prior to 
administration of bisphosphonates, dental assessment and appropriate 
treatment should be provided to reduce the risk of MRONJ for these patients 
(National Institute for Health Care and Excellence, 2016, Scottish Dental 
Clinical Effectiveness Programme, 2017b). 
1.4.3 Post-transplant oral complications  
 Oncology patients undergoing chemotherapy, radiotherapy and HSCT 
are at increased risk of post-treatment complications (The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018). 
These complications can include mucositis, xerostomia, candida (fungal) 
infections and an increased risk of dental caries (The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018). 
Therefore targeted pre-operative dental treatment, with particular focus on 
prevention, is essential to reduce the risk and severity of these complications 
and to enable patients to manage these complications when they occur (The 
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Royal College of Surgeons England / British Society of Disability and Oral 
Health, 2018). 
 Patients undergoing allogeneic HSCT are at risk of the 
aforementioned complications and, additionally, Graft versus Host Disease 
(GvHD). GvHD results in a painful mucocutaneous rash as graft cells attack 
host cells due to a mismatch between the human leukocyte antigen (HLA) of 
the donor and recipient (Petti et al., 2013, Scully, 2014, The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018). 
GvHD is the leading cause of morbidity and mortality in this patient cohort 
and can be defined as either acute or chronic (Filipovich et al., 2005, 
Imanguli et al., 2008, Apperley and Masszi, 2012).  
Acute GvHD (aGvHD) has previously been defined by its onset, 
typically within 100 days of transplantation. Currently its diagnosis is based 
upon clinical and pathological features (Filipovich et al., 2005, Apperley and 
Masszi, 2012). The lesions of aGvHD usually affect the skin, oral mucosa, 
gastrointestinal tract, liver or a combination of these organ systems 
(Filipovich et al., 2005, Imanguli et al., 2008, Apperley and Masszi, 2012).  
Chronic GvHD (cGvHD) presents after 100 days post-transplant. 
However, it should be diagnosed by its presentation as opposed to the time 
of onset (Filipovich et al., 2005, Apperley and Masszi, 2012).  Chronic GvHD 
can affect any organ system and is the leading cause of death in long-term 
survivors following HSCT (Imanguli et al., 2008, Apperley and Masszi, 2012). 
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 Therefore, in line with national guidance, there is a need for a dental 
assessment prior to HSCT to identify and treat any potential causes of 
infection from the oral cavity (The Royal College of Surgeons England / 
British Society of Disability and Oral Health, 2018). This includes providing a 
preventative regime, restoration of teeth and removal of any teeth of poor 
prognosis (which could be as a result of acute or chronic infection). It is also 
important to review these patients with regard to prevention due to the risk of 
oral complications, mucositis, GvHD and xerostomia, following the transplant 
period (The Royal College of Surgeons England / British Society of Disability 
and Oral Health, 2018). 
1.5 Care Pathway 
There are 55 units across the UK that provide HSCT, of which 10 units 
solely treat paediatric patients (British Society of Blood and Bone Marrow 
Transplantation, 2011). The Stem Cell Transplantation and Cellular Therapy 
Unit, Clatterbridge Cancer Centre (CCC) NHS Foundation Trust, in Liverpool, 
is one of thirty-seven Haematology units that provides both allogeneic and 
autologous transplants in the UK (British Society of Blood and Bone Marrow 
Transplantation, 2011).  
Previously the HSCT service was provided by the Royal Liverpool and 
Broadgreen University Hospitals NHS Trust (RLBUHT). In July 2017 the 
service was transferred to Clatterbridge Cancer Centre. The service is still 
operated from the Royal Liverpool University Hospital site, with 
improvements in diagnostics and the range of services available to patients. 
At the time of the study the HSCT service was a recognised accredited 
centre with the Joint Accreditation Committee International Society for 
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Cellular Therapy and European Society for Blood and Bone Marrow 
Transplant (JACIE) (JACIE, 2019).  
1.5.1 JACIE  
JACIE is a mutual committee between the European Society for Blood 
and Marrow Transplantation (EBMT) and the International Society for Cellular 
Therapy (ISCT). Accreditation with JACIE ensures that the centre is working 
within their standards of excellence for patient care and allows for an 
effective quality management system (FACT-JACIE, 2015). As part of the 
quality management process auditing is encouraged. EBMT recommended 
the use and collation of patient data using minimal essential data-AB (MED-
AB) forms, allowing patient data to be collected on to a central registry 
(European Society for Blood and Bone Marrow Transplantation, 2017a). The 
MED-AB form is separated into: 
 HSCT MED-A forms collect the minimum essential data that is 
required for EBMT. It collects data at Day 0 (date of transplant), 
Day 100 and annual follow up. The Day 0 form must be received 
by EBMT within 10 days of the date of transplant, and the Day 100 
form must be received as close to 100 days following transplant or 
as close to the date of patient death as possible (European Society 
for Blood and Bone Marrow Transplantation, 2017b).  
 HSCT MED-B forms have two specific forms. There is a disease 
specific form and a transplant specific form (European Society for 
Blood and Bone Marrow Transplantation, 2017b).  
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The Med-A form has been in use since January 2016 in the Stem Cell 
Transplantation and Cellular Therapy Unit, Clatterbridge Cancer Centre 
(CCC) NHS Foundation Trust in Liverpool.  
1.5.2 Patient journey  
There has been an established care pathway between the Stem Cell 
Transplantation and Cellular Therapy Unit (CCC) and the Special Care 
Dentistry Department in Liverpool University Dental Hospital since 2013 
(Appendix 3). The care pathway was initially developed between Mr A. 
Kwasnicki, Consultant in Special Care Dentistry, and Dr R. Salim, Consultant 
Haematologist.  
Patients are seen on a referral basis prior to their HSCT and any 
necessary dental treatment is completed. The dental treatment provided is 
dependent on the time constraints of the patient’s HSCT; some receive 
comprehensive dental care, others receive essential dental treatment, some 
require no treatment and others are not referred. Patients are also assessed 
and treated following emergency referral or post-HSCT. Re-referral post-
HSCT allows for review and completion of any non-urgent dental treatment. 
Within Liverpool there is currently no data on the impact of dental 
interventions prior to HSCT on outcomes for this patient cohort, or if the 
service provided is beneficial from a patient’s perspective. 
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2 Chapter 2: Literature review 
A literature review was completed using the databases Ebsco, 
Medline, PsycInfo and Scopus. The searches were limited from year 2000 to 
present. Any papers that solely included children, or were unavailable due to 
limitations in journal access, duplications, or were summaries, or were not 
available in the English language were excluded from the literature review 
including book chapters.  Further papers were identified from reviewing lists 
of references within the journals or identified guidance. The literature search 
was completed on five separate occasions during the study period November 
2016 – July 2019, to account for any new publications.  
The key terms used within the databases for the searches completed 
are shown in Appendix 4 and an example search strategy can be found in 
Appendix 5. A summary of the literature acquired from this search can be 
found in Appendix 6. The SIGN level of evidence (Scottish Intercollegiate 
Guidelines Network, 1999-2012) used to review the papers is shown in 
Appendix 7. 
The literature review initially focused on the reasons for dental 
assessment prior to HSCT, the impact of dental treatment on patients 
receiving HSCT and the effect on the quality of life of dental treatment for 
patients undergoing HSCT.  
2.1 Dental assessment and treatment  
It is accepted that a dental assessment and appropriate dental 
treatment prior to HSCT is necessary to remove dental sources of infection 
that could impact on post-HSCT recovery and increase the risk of 
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complications (Epstein et al., 2009, British Society of Disability and Oral 
Health, 2012, Burke et al., 2014, Elad et al., 2015, Abed et al., 2019).  
However, the evidence is limited to show whether dental treatment 
has a positive impact on patients and actually leads to a reduction in intra- 
and post-transplant complications.  
A retrospective study completed in Israel by Elad et al. (2003) 
reviewing the time limitations and challenges in providing ‘infection-
preventing’ dental care to patients prior to HSCT (n=46), found that caries 
was diagnosed in 50% of cases. Of the subjects, 47.8% received oral 
hygiene instruction (OHI) and scaling, 39.1% had restorations and 19.5% 
required extractions. The study also discussed the difficulties in organising 
dental care due to the medical complexities of the patients; although the 
average time from dental assessment to HSCT was 20.65 days. The authors 
suggested consideration of the involvement of the Community Dental Service 
in treating this patient cohort (Elad et al., 2003).  
A retrospective study in Japan, by Morimoto et al. in 2004, considered 
the haematological status of 38 patients prior to dental treatment, as the 
medical treatments received often resulted in decreased neutrophil and 
platelet counts. The authors found that it was safe to provide extractions and 
scaling on patients with platelet counts below 50x109/L or 30x109/L if they 
had received platelet transfusion. In addition, it was possible to provide 
extractions and scaling on patients with neutrophil counts between 1.0-
1.5x109/L if antibiotic cover was provided (Morimoto et al., 2004).  
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The need for dental intervention and haematological consideration for 
this patient cohort was further supported by a retrospective evaluation 
completed in the United Kingdom by Durey et al. in 2009. This study 
reviewed case notes of 94 patients and found that 93.6% of subjects 
assessed prior to HSCT had active dental disease; 74.5% required 
interventional dental treatment and 20.2% received OHI. It also highlighted 
that, although 79.5% of these patients had periodontal disease, screening 
with a basic periodontal exam was often not performed due to insufficient 
information about a patient’s haematological status given the theoretical risk 
of bleeding and infection (Durey et al., 2009).  
De Paula Eduardo et al., in 2011, carried out a survey of Bone Marrow 
Transplant Centres in Brazil. The authors of the study found that all 
responding centres had a dentist as part of their multidisciplinary team. With 
100% of the centres (n=36) providing an oral health assessment prior to 
HSCT. Unfortunately, there was only a 33.3% response rate for this survey 
with only 12 of the 36 centres responding. It was stated that 75% of the 
centres advised that they would delay the transplant due to dental pathology 
whilst 42% felt that oral hygiene was the most important recommendation to 
provide patients with prior to transplant (de Paula Eduardo et al., 2011).   
A retrospective cohort study completed in Brazil, by Pelinsari et al. in 
2014 reviewed the extent to which bleeding complications occurred following 
extractions, for 33 patients prior to HSCT. They found that it was safe to 
provide extractions in patients who were thrombocytopenic. The authors 
advised close liaison with the Haem-oncology team and platelet transfusions 
if the platelet counts were below 50x109/L. This group did not provide 
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antibiotic cover for this patient cohort unless neutrophil levels were below 
0.5x109/L, and found no patient had infective complications. The authors 
highlighted that this differs from other guidance that recommends antibiotic 
prophylaxis if neutrophils are less than 2.0x109/L (Pelinsari et al., 2014). 
A Brazilian patient survey conducted by Nuernberg et al. (2016) 
examined patients views (n=110) on accessing dental services prior to 
HSCT, 66% of those surveyed reported that they had not received guidance 
about oral care prior to HSCT. However, 74% of subjects reported accessing 
oral care within a year prior to their HSCT. The study also highlighted issues 
with oral health care following HSCT with 17% of the subjects being refused 
treatment by their own dentist and 29% of patients stated they would not trust 
a dentist to provide treatment outside of the hospital where the transplant 
took place. Again this study identified the time limitations with regard to 
providing treatment prior to HSCT (Nuernberg et al., 2016).  
Braga-Diniz et al. (2017) reviewed dental records of 188 patients 
between March 2011 and 2016, to assess their haem-oncology 
characteristics and their need for endodontic treatment in Brazil. The 
evaluation found that the need for endodontic treatment pre- and post-HSCT 
was similar (24.3%:24.7% respectively) and was often indicated for multiple 
teeth. The paper highlighted the continued need for dental assessment 
following HSCT, however did not discuss why endodontic treatment was 
completed as opposed to extractions (Braga-Diniz et al., 2017).  
A further Brazilian study by Nuernberg et al. in 2017, assessed the 
prevalence of periodontal disease within a cohort of 36 patients who were 
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planned for allogeneic HSCT. They found that the majority of participants 
(58%) had a diagnosis of periodontal disease with pocket depths >4mm with 
inflammation. In addition, platelet and neutrophil counts had no influence on 
bleeding on probing or diagnosis of periodontal disease respectively. The 
authors highlighted that the patients self-reported that they considered 
themselves to have good oral health, when in fact the oral health of the 
cohort was poor. The study emphasised a dental treatment need within this 
patient cohort, particularly the risk of infection from periodontal pathogens 
during HSCT and the need for improved periodontal health and oral hygiene. 
The sample size in the study was small with only 36 participants being 
included (Nuernberg et al., 2017).  
In 2018, a qualitative study was conducted by Mendes et al. in Brazil 
using face-to-face semi structured interviews to explore patients’ views on 
the meaning of oral health and its importance in HSCT. The authors 
conducted interviews for 17 participants and used content analysis to finalise 
three main themes. The themes highlighted by participants were the 
importance of good oral hygiene, maintaining a good diet, being able to smile 
and being free from pain. Participants stated the importance of dental 
assessment pre HSCT was to reduce oral complications, limit the risk of 
infection and increase the chance of a successful transplant. However the 
study also highlighted that the referral was requested by medical staff and 
that treatment with their own dentist was preferable. It appeared the provision 
of dental treatment was limited for those receiving transplants, as a result of 
medical barriers such as thrombocytopenia and need for additional medical 
treatment (Mendes et al., 2018). 
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Although the literature suggests an overall dental need for these 
patients to undergo dental assessment, this is limited by the time available to 
provide necessary treatment prior to HSCT. Unfortunately, although these 
studies highlighted the dental treatment need within the patient cohort, they 
did not investigate the effect that dental treatment may have on the HSCT 
process.  
2.2 Dental implications on HSCT outcomes 
It is unclear as to what effect dental treatment prior to HSCT has on 
patient outcomes. A retrospective review completed in the United States of 
America by Akintoye et al. (2002) compared patients with <20% radiographic 
crestal bone loss to those with >20% crestal bone loss for levels of 
septicaemia following HSCT (n=77). Although they found that the patient 
cohort as a whole was at a higher risk of septicaemia, there was no statistical 
significance between >20% radiographic crestal bone loss and the incidence 
of septicaemia (Akintoye et al., 2002). 
This was supported by a prospective study completed in Germany by 
Melkos et al. (2003) which compared two groups of patients undergoing 
HSCT. In one group, the subjects either did not require or had completed 
dental treatment (36 subjects) and the other group had no dental treatment 
(22 subjects) prior to undergoing transplant. Although, those patients who 
had not received any dental treatment had a higher incidence of post-
transplant complications (infection, mucositis, relapse, GvHD) 21/22 subjects 
compared to 27/36 subjects, the difference was not statistically significant 
between the groups. Survival rate was also unaffected (Melkos et al., 2003).  
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A prospective evaluation completed in Japan in 2006, assessed 38 
subjects undergoing HSCT, of whom 36 required dental treatment. The aim 
was to preserve teeth and extract only retained roots, teeth with severe 
periodontal involvement, symptomatic third molars and teeth with periapical 
pathology when the time to HSCT was limited. In the study, no subjects 
encountered odontogenic infection during the period of immunosuppression 
and, therefore, the authors concluded that radical dental treatment was not 
necessary. They highlighted a need for early dental screening to allow 
healing prior to HSCT and additionally, that time pressures had an impact on 
the clinical decisions made (Yamagata et al., 2006).  
A novel way of comparing met and unmet dental needs from the 
available literature for patients undergoing HSCT was carried out by Elad et 
al. in 2008, through a decision analysis process. The study showed that by 
not having a dental evaluation there would be an increased risk of dying from 
a dental infection of 1.8 in 1000 patients undergoing a HSCT. Although the 
difference between the groups was small, they concluded that their decision 
analysis would still recommend that dental assessment and treatment was 
carried out prior to HSCT (Elad et al., 2008b). 
Soga et al. (2008) published a case report, in Japan, of a 53 year old 
female with AML which highlighted the challenges faced in providing dental 
treatment. The patient had mild generalised periodontitis with gingival 
hypertrophy, however, treatment was not provided pre-HSCT due to low 
platelet and neutrophil counts. Post-HSCT, the patient became septic and 
died, Stenotrophomonas Maltophilia being identified and implicated. The 
authors highlighted that this patient had no other pre-operative systemic 
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infection other than periodontitis. They also suggested that the gingivae can 
act as a reservoir for multi-drug resistant bacteria and recommended 
periodontal treatment prior to chemotherapy or HSCT to reduce gingival 
inflammation (Soga et al., 2008).   
A prospective study in 2011 conducted by Yamagata et al. in Japan 
supported the findings that dental intervention had no significant statistical 
effect on patient outcome post-HSCT (n=35). This study focused on whether 
leaving asymptomatic impacted third molars in-situ had an effect post-HSCT. 
The authors found that leaving asymptomatic third molars had no effect on 
patient outcomes. A statistical difference was found in relation to the duration 
of post-transplant white cell count being below 1000/µL between those who 
died (median 17 days) and those who survived (median 13 days) (Yamagata 
et al., 2011). 
A retrospective observational study was completed in Japan to attempt 
to associate the risk of odontogenic septicaemia with levels of 
myelosuppression. All subjects (n=37) had a dental assessment and removal 
of unrestorable teeth. The researchers found that subjects who had moderate 
and severe levels of myelosuppression were at higher risk of odontogenic 
sepsis and therefore caution should be taken by the dental team in providing 
dental interventions. However, the sample size in the study was only 37 
subjects and it was therefore concluded that future prospective studies would 
be required to confirm these findings (Masaya et al., 2013).  
In 2014 a further study completed in Turkey, by Ertas et al. compared 
pre- and post- HSCT DMFT (Decayed, Missing or Filled Teeth) for 36 
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patients. The authors found that there was an increase in DMFT following 
HSCT. This study highlighted not only the importance in pre-assessment, but 
the value of continued dental reviews following HSCT due to the increased 
incidence of dentally related complications (Ertas et al., 2014).  
A retrospective review completed in the United States of America, 
examined 11 patients with multiple myeloma who had a diagnosis of 
medication related osteonecrosis of the jaw (MRONJ) found that there was 
no difference in the incidence of post-HSCT complications (fever, positive 
blood cultures, length of hospital stay) between MRONJ and non-MRONJ 
groups. They also found that the staging of MRONJ was not worsened by the 
HSCT process. However, the sample size in this study was only 11 subjects 
over a 9 year period, therefore the authors suggested further prospective 
studies were required (Mawardi et al., 2016).  
In 2016, Toro et al. conducted a retrospective review in the United 
States of America, of patients with myeloma comparing subjects who were 
dentate (n=90) to those who were edentulous (n=45) and found that no 
significant differences in post-HSCT complications were found between the 
groups (Toro et al., 2016).  
Although dental assessment and treatment is generally recommended, 
through local and national guidance prior to HSCT, it is unclear as to the 
effect that it has on patients’ outcomes post-HSCT as there is a paucity of 
evidence in the literature.  
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2.3 Post-transplant complications  
Following HSCT, complications can occur in the short-term e.g. 
sepsis, mucositis, or aGvHD, or in the long-term e.g. xerostomia, cGvHD, or 
secondary malignancies. Both short-term and long-term complications can 
have an impact on the provision of oral health care (Epstein et al., 2009, 
British Society of Disability and Oral Health, 2012).  
2.3.1 Oral Mucositis 
Oral mucositis is a common early post-transplant complication of 
HSCT, chemotherapy and radiotherapy (Petti et al., 2013, Villa and Sonis, 
2015). Over 50% of patients who have had HSCT will experience mucositis 
(Sonis, 2009, Petti et al., 2013, Villa and Sonis, 2015). Initial presentation is 
redness (erythema) followed by white plaques and then ulceration of the oral 
mucosa (Petti et al., 2013).  
In HSCT oral mucositis presents within 3-4 days following the infusion 
and its presentation tends to peak between 7-14 days and then resolves. For 
patients who have received a combination of chemo-radiotherapy the 
presentation of mucositis is more severe and prolonged with resolution 
occurring within 4 weeks (Villa and Sonis, 2015).  
Sonis et al., (2001) conducted a prospective observational study in the 
United States of America, of patients undergoing both autologous and 
allogeneic HSCT at 8 multinational centres. The severity of mucositis was 
assessed in 92 patients up to 28 days post-transplant with the use of the Oral 
Mucositis Assessment Scale (OMAS). It was found that peak mucositis 
scores were higher among allogeneic transplant patients. Patients having 
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autologous transplants were at an increased risk of infection associated with 
their mucositis. Overall it was observed that a higher mucositis score had a 
3.9 times increased risk of 100 day mortality (Sonis et al., 2001).  
Da Silva Santos et al. (2011) observed the severity and duration of 
mucositis in 70 patients who had or had not received dental treatment prior to 
HSCT in Brazil. Although there was no difference in incidence or severity of 
oral mucositis among subjects, the duration of mucositis in subjects who 
received a dental assessment +/- treatment was shorter. Those patients who 
had received dental treatment experienced mucositis for a median of 10 days 
compared to 20 days in those who did not receive dental treatment (Da Silva 
Santos et al., 2011). 
In comparison, a retrospective analysis conducted in Japan, reviewed 
all subjects (n = 140) who had a HSCT between February 2002 and 
December 2009. The authors found that since the implementation of 
professional oral health care (POHC) in 2006, the incidence of mucositis 
decreased from 93.5% to 66.7%. (Kashiwazaki et al., 2012). 
This was supported by a further observational study in Turkey by 
Gürgan et al. (2013) which compared periodontal health pre- (n = 202) and 
post- HSCT (n = 29). Following periodontal treatment they found that, if a 
subject experienced a reduction in bleeding on probing, the frequency of oral 
mucositis decreased (Gürgan et al., 2013). 
An observational study in Sweden, compared the severity of mucositis 
in patients who had received either myeloablative conditioning (MAC) (n = 
72) or reduced intensity conditioning (RIC) (n = 99) from October 2007 – May 
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2011. It was found that MAC resulted in significantly higher oral mucositis 
scores from days 9-12 than RIC and that, since the implementation of their 
oral health protocol in 2011, the severity of mucositis had decreased. The 
study also showed a significant correlation between high oral mucositis 
scores on days 13-24 and prolonged hospital stay (Legert et al., 2014).  
A prospective longitudinal study carried out by Barrach et al. in 2015 in 
Brazil, reviewed the oral complications, caries, periodontal disease, retained 
roots, oral lesions (mucositis) and infections, for both allogeneic (n = 34) and 
autologous (n = 31) recipients at 20 days prior to transplant, 7 days post-
HSCT and 100 days post-HSCT. No dental interventions were provided, 
however, they found no increase in caries or periodontal disease and none of 
the participants experienced infections of odontogenic origin. They found all 
participants experienced mucositis at day 7 post-transplant, highlighting 
again, that it is a common oral complication of HSCT (Barrach et al., 2015).  
2.3.1.1 Treatment of mucositis  
There is evidence of successful treatments for oral mucositis in the 
period whilst the patient is hospitalised.  
The use of Doxepin rinse in an American study showed it to 
significantly reduce oral pain from mucositis for 9 patients for up to 15 
minutes and pain on eating is reduced if used from the initial visit for a week, 
however the rinse had no effect on the severity of mucositis (Epstein et al., 
2008).  
Low-level laser therapy (LLLT) has been shown to reduce the severity 
and duration of mucositis (Khouri et al., 2009, Elad et al., 2011, Patussi et al., 
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2014). However, when used in comparison to a placebo, it took until the third 
visit for a reported reduction in severity and pain to occur. There was no 
difference between patient satisfaction of the treatments between the groups 
(study group = 10, control group = 10) (Elad et al., 2011). 
2.3.1.2 Patient experiences 
A single qualitative study completed in Australia by Borbasi et al. in 
2002, explored experiences of mucositis for 6 patients. This study involved 
weekly in-depth interviews for 4 weeks following HSCT and then at week 8 
and week 12 or when resolution of mucositis occurred. The patients within 
the study felt that with regard to their oral mucositis it was important that the 
nurses’ reminded them about oral health care and the need for mouth care to 
be considered a therapeutic intervention. They also reported the effect of 
mucositis on the mouth and oesophagus, the distress caused by eating due 
to the difficulties in swallowing, and that patients often wondered if the 
potential curative treatment they had was worthwhile (Borbasi et al., 2002).  
2.3.2 Xerostomia 
Xerostomia, the experience of a dry mouth, is a further complication of 
HSCT, and can be an objective or subjective condition. Hyposalivation, a 
reduced salivary flow rate, is a common experience following HSCT and may 
be due to disease, medications or the conditioning regime (chemotherapy +/- 
radiotherapy) (Mauramo et al., 2017).  
A cross sectional study completed in the Netherlands by Brand et al., 
compared the risk of xerostomia in a group of subjects (n =48) having HSCT 
compared to healthy controls (n = 41). The researchers found that those who 
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had treatment with HSCT experienced significantly higher levels of 
xerostomia (Brand et al., 2009). 
 This finding is supported by a further longitudinal study carried out in 
Switzerland in 2011, which found that hyposalivation was reported most 
frequently at 6 months (53%) in patients who had an allogeneic HSCT (n = 
228) compared to a control group (n = 141). This symptom continued to 12 
months post HSCT with complaints of hyposalivation occurring in 26% of 
subjects. The study also found that subjects who were conditioned with TBI 
had higher rates of hyposalivation. The authors concluded that stimulated 
salivary flow recovered over time, up to 24 months post-HSCT. (Laaksonen 
et al., 2011). 
Bos-den Braber et al., surveyed 96 subjects following HSCT with 
regards to short- and long-term oral complaints in 2015 in the Netherlands. In 
59% of subjects the most frequently reported short-term oral complaint was 
altered taste. In terms of long-term oral complaints, these were experienced 
by 28% of subjects with the main complaint being of dry mouth (Bos-den 
Braber et al., 2015). 
A prospective Scandinavian case control study in 2007, found that 
hyposalivation post-HSCT (n = 118) was most frequent at 6 months and 12 
months compared to the control group (n = 247). In contrast to some studies 
they also found that stimulated salivary flow improved with time. The authors 
found that subjects were prescribed multiple medications in this time, of 
which antidepressants was the most common, however this did not 
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significantly impact on the rate of hyposalivation. They concluded that 
hyposalivation is multifactorial for this patient cohort (Mauramo et al., 2017).  
2.3.3 Graft versus Host Disease  
GvHD is a complication for allogeneic HSCT recipients. As previously 
described, it presents as a painful rash that affects the skin, oral mucosa, 
gastrointestinal tract and liver and can have an acute or chronic presentation 
(Filipovich et al., 2005, Lew and Smith, 2007, Imanguli et al., 2008, Apperley 
and Masszi, 2012, Scully, 2014).  
Elad S et al. conducted a prospective longitudinal observational study 
in Turkey from September 2000 – June 2001 comparing presentation of oral 
lesions following HSCT, in patients who received autologous HSCT (n = 9) 
compared to allogeneic HSCT with myeloablative conditioning (MAC) (n = 9) 
compared to allogeneic HSCT with reduced intensity conditioning (RIC) (n = 
16) . They noted no difference in the general presentation of oral lesions or 
opportunistic infections, however there was a difference in the presentation of 
oral aGvHD, with this diagnosis being less prevalent in patients who received 
RIC (Elad et al., 2008a).  
A case control study completed in Holland in 2009 observed that 86% 
of allogeneic HSCT subjects (n = 48) reported GvHD that affected the oral 
cavity, and found that mucosal pain was more severe (Brand et al., 2009).  
Mays et al., (2013) reviewed the literature available on pathogenesis, 
therapy and research in GvHD and found that 50% of patients who survive 1 
year post HSCT will develop oral GvHD and the 5 year mortality rate for 
those with cGvHD is 70% (Mays et al., 2013).  
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This is supported by a retrospective study in the United States of 
America, that examined late effects and complications in patients who have 
received a second allogeneic HSCT (n =325), and found that GvHD was the 
overall cause of mortality in 32% of patients over a 10 year period (Duncan et 
al., 2015). 
2.3.3.1 Treatment of GvHD 
In an American case report of a patient who was treated for leukaemia 
with an allogeneic HSCT, who was diagnosed with GvHD 8 months post-
transplant after complaining of painful mucosal lesions, it was found that 
topical corticosteroids were effective in managing the patient’s GvHD 
(Stoopler, 2013).  
Yuan et al., carried out a retrospective data analysis in the United 
States of America, comparing National Institute for Health (NIH) consensus 
guidance (Filipovich et al., 2005) to current practice in two Oral Medicine 
departments and three HSCT centres for 79 patients. The authors found that 
ancillary topical therapies (topical steroids or topical tacrolimus) were 
prescribed to over half the patients who presented with GvHD. They also 
found that those treated with topical therapies were five times more likely to 
have mucositis affecting the oral cavity and three times more likely to have 
pain involvement from the oral cavity. The study also found that a positive 
pain score rather than clinical assessment was more likely to prompt 
treatment in these patients (Yuan et al., 2016).  
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2.3.4 Secondary Malignancies 
Secondary malignancies can be a late complication of allogeneic 
HSCT, particularly in patients who have been diagnosed with chronic GvHD 
(Petti et al., 2013, Nappalli and Lingappa, 2015). It has been found that 
oropharyngeal cancer is the most common secondary malignancy for HSCT 
recipients, with oral cancer being significantly associated with chronic GvHD 
(Petti et al., 2013). 
This finding is supported by a number of case reports in Brazil, Japan 
and China, where patients who were diagnosed with chronic GvHD following 
allogeneic HSCT subsequently presented with oral lesions which were 
confirmed as oral cancer (squamous cell carcinoma) by histopathology 
(Torres-Pereira et al., 2014, Tsushima et al., 2015, Weng et al., 2017). An 
American case report in 2014, presented two cases where the oral cancer 
was highly reactive for p16/HPV querying the need for HPV (human 
papilloma virus) screening for this patient cohort (Katz et al., 2014). These 
case reports highlight the importance of long term surveillance of the oral 
mucosa for HSCT recipients and continued involvement of the multi-
disciplinary team.  
2.3.5 Dental intervention  
Post-transplant complications of HSCT: mucositis, xerostomia, GvHD 
and secondary malignancies, support the need not only for pre-operative 
treatment and prevention advice, but also for long-term dental follow-up 
(Meier et al., 2011, British Society of Disability and Oral Health, 2012). 
Patients who have experienced allogeneic HSCT are at risk of experiencing 
short-term oral pain and difficulties swallowing (dysphagia) due to mucositis 
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(British Society of Disability and Oral Health, 2012, Bos-den Braber et al., 
2015). In addition hyposalivation increases the risk of dental caries for 
patients and those who develop GVHD are not only at risk of rampant caries 
but also of long-term secondary malignancies in particular oral cancer 
(Castellarin et al., 2012, Mays et al., 2013, Petti et al., 2013, Santos-Silva et 
al., 2015, Mauramo et al., 2017).  
2.3.6 Quality of Life 
Whilst there were no papers directly examining quality of life of HSCT 
recipients and their experience of dental treatment, some evidence was 
available in reference to oral health.  
In an observational study in Brazil completed in 2015, 100 subjects 
were asked to complete an Oral Health Impact Profile questionnaire (OHIP-
14) prior to undergoing HSCT. The results were compared to a cohort of 
healthy volunteers (n = 100) and found that, although weak, there was an 
impact on oral health related quality of life for potential HSCT recipients 
especially in the domains of pain and physical disability compared to healthy 
volunteers. Therefore, the authors recommended pre-operative dental 
assessment for this patient cohort prior to HSCT (Tinoco-Araujo et al., 2015).  
Three further papers were identified at the time of the current study 
that examined quality of life in this cohort of patients in relation to post-
transplant complications.  
Silva et al. 2015 completed a randomised control trial in Brazil 
investigating the quality of life for 39 patients who had treatment of mucositis 
with low level laser therapy (LLLT) following HSCT. The study used OHIP-14 
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and Functional Assessment of Cancer Therapy: Bone Marrow Transplant 
(FACT-BMT) questionnaires to evaluate quality of life. The authors found that 
there was no difference in quality of life experience reported by the control 
group (no LLLT) and the study group (treatment with LLLT). However, they 
found that quality of life was reported to be poorest on day 7 post HSCT with 
physical and functional wellbeing scoring worst on the FACT-BMT 
questionnaire (Silva et al., 2015). 
This was supported by a Brazilian prospective observational study in 
2016, investigating the use of LLLT for treatment of mucositis on quality of 
life with the use of OHIP-14 and Patient Reported Outcome Measures 
(PROMS) questionnaires for 69 subjects. They found that quality of life was 
reported to be poorest 5 days post-autologous and 8-days post-allogeneic 
transplant and that quality of life subsequently improved with time. 
Additionally, they found that the domains scoring poorest on the OHIP-14 
were psychological disability, social disability and handicap (Bezinelli et al., 
2016).  
Quality of life in patients with chronic GvHD (n = 569) was investigated 
in 2015 in the United States of America, using FACT-BMT and SF-36, which 
assessed overall health status. They found that there was no significant 
difference in quality of life for subjects who have isolated oral GvHD 
compared to those with GvHD affecting multiple sites. This study did not look 
at the impact of chronic GvHD on oral health related quality of life (DePalo et 
al., 2015).  
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2.4 Summary  
Although there is published evidence in the literature examining the 
provision of dental treatment and the effect on patient outcomes post-HSCT, 
the evidence base is limited. From this literature search it was apparent that 
there were no qualitative studies exploring HSCT and the provision of dental 
treatment from a patient’s perspective. However there has been some work 
looking at oral health reported outcomes with respect to quality of life. 
 A gap in the knowledge base exists as to whether a patient 
understands why dental involvement is important and if they feel the 
recommendations for and provision of dental treatment had a positive impact 
on their quality of life. Therefore this research is justified to explore patient 
views on what affect attending for a pre-HSCT dental assessment had on the 
HSCT process. 
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3 Chapter 3: A retrospective evaluation to 
investigate the incidence of post-HSCT adverse 
events in patients receiving pre-HSCT dental 
intervention prior to allogeneic HSCT 
3.1 Introduction 
 
 The care pathway between the Stem Cell Transplantation and Cellular 
Therapy Unit (CCC) and the Special Care Dentistry Department has been 
established since 2013. During this time neither department had investigated 
the service that was being provided for this particular vulnerable group of 
patients, therefore the initial part of this project was to evaluate current 
practice in order to inform service provision and improvement but also to 
inform future research.  
3.2 Title 
A retrospective evaluation to investigate the incidence of post-HSCT 
adverse events in patients receiving pre-HSCT dental intervention prior to 
allogeneic HSCT. 
3.3 Research question 
Does dental intervention prior to allogeneic stem cell transplantation 
influence the incidence of subsequent morbidity and mortality, including graft 
versus host disease and other oral complications? 
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3.4 Null Hypothesis 
The type of dental treatment received has no influence on patient 
post-HSCT outcomes. 
3.5 Objectives  
i. Identify a cohort of patients that received dental intervention prior to 
allogeneic stem cell transplantation. 
ii. Identify and complete patient morbidity and mortality outcome data 
within the departmental database, using EBMT patient data collection 
forms. 
iii. Investigate the dental intervention factors (including prevention advice 
and dental treatment) that have been associated with subsequent 
post-transplant outcomes 
iv. Identify if there were any dental interactions on subsequent oral 
symptoms and complications, including graft versus host disease and 
sepsis due to oral organisms. 
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3.6 Methodology 
 
3.6.1 Study design 
Ideally a retrospective cohort study would allow comparisons between 
patients who have received differing levels of dental intervention and those 
who did not. However, given that the majority of patients are referred to the 
Dental Hospital for an assessment, an initial retrospective evaluation was 
required to assess the current patterns and trends for these patients. 
Therefore, this study was a retrospective study aimed to evaluate patients 
who had previously received HSCT at Clatterbridge Cancer Centre, Liverpool 
and who may or may not have received a dental intervention.  
The patient cohort was selected and then categorised depending on 
the dental intervention that they received prior to HSCT from SCD LUDH. 
The study focused on assessing post-HSCT adverse events to ascertain if 
there was any difference between those who received dental treatment and 
those that did not (Appendix 8).  
As the study was retrospective, patient data was already available in 
patient medical and dental records together with electronic patient 
databases.  
3.6.2 Setting  
This study included patients under the care of the Stem Cell 
Transplantation and Cellular Therapy Unit (CCC), Liverpool with the dental 
care being provided in the Special Care Dentistry Department, RLBUHT, 
Liverpool. 
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3.6.3 Population 
The study focused on patients who had received an allogeneic HSCT 
for a haemato-oncological diagnosis (e.g. leukaemia, myeloma, and 
lymphoma). Allogeneic HSCT recipients were selected as they experience 
more post-transplant related complications than autologous recipients. 
 The patients were initially grouped into five cohorts of patients 
dependant on the different dental intervention that they received prior to 
allogeneic HSCT.  
Those that did not receive dental intervention were considered as the 
control group. Descriptions of the patients included in each group can be 
seen in Appendix 8. 
3.6.4 Inclusion and Exclusion Criteria 
3.6.4.1 Inclusion Criteria  
 Adult patients (>18years) 
 Allogeneic haematopoietic stem cell transplant  
 Patients treated in the Stem Cell Transplantation and Cellular Therapy 
Unit (CCC) 
 HSCT provided from 1st January 2016 – 31st December 2016 
3.6.4.2 Exclusion Criteria  
 Autologous haematopoietic stem cell transplant  
 Patients not receiving allogeneic HSCT at Clatterbridge Cancer 
Centre, Liverpool 
 HSCT provided outside the period of 1st January 2016 – 31st 
December 2016 
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 Patients who had a dental intervention but were deceased prior to 
commencing HSCT 
 Patients who were edentulous (missing all their teeth), as referring 
patients who are edentulous for a dental assessment is currently 
discouraged.  
3.6.5 Outcomes  
The study evaluated the incidence of adverse events post-allogeneic 
HSCT and whether this was influenced by the dental intervention received.  
The outcomes of interest in this study were: 
i. Experience of sepsis  
ii. Experience of mucositis 
iii. Experience of xerostomia 
iv. Experience of acute GvHD and chronic GvHD 
v. Experience of infections (bacterial, viral and fungal) 
vi. Experience of mortality at 100 days 
vii. Experience of mortality at 1 year  
3.6.6 Data Collection Period 
In January 2016, the Stem Cell Transplantation and Cellular Therapy 
Unit (CCC), Liverpool, introduced the use of the EBMT MED-A Day 0 and 
Day 100 forms. These forms increased the amount and variety of data that 
was collected for a haematological diagnosis and the HSCT process, 
therefore the service evaluation took place for 1 year following the 
introduction of these forms as it was felt that the data would be complete and 
comparable with other studies within Europe.  
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The data collection period for this study was the 1st January 2016 – 
31st December 2016. 
3.6.7 Data Collection forms 
 An initial data collection form was developed to capture data on social, 
medical and dental information: 
 Patient demographics 
 Medical history 
 Social history  
 Haematological diagnosis, stage, treatment to date (chemotherapy, 
radiotherapy, bisphosphonates) 
 Proposed date of transplant 
 Referral for dental intervention; assessment, treatment 
completed/outstanding  
 Transplant process – date, any delay to transplant  
 Adverse events – mucositis, xerostomia, neutropenic sepsis, aGvHD, 
cGvHD, mortality at 100 days and 1 year 
 Feeding regime  
 Discharge date  
This form was sent electronically and reviewed by the HSCT team. The 
data that was planned for collection was discussed at a meeting on the 27th 
February 2017 with the Stem Cell Transplantation and Cellular Therapy Unit 
(CCC) Data Coordinator, Mrs L Laing, and Haemato-oncology Specialist 
Nurse, Mrs C Hawkins, together with Mrs C Wilson-Dewhurst and Professor 
S Thompson.  
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The discussion highlighted the EMBT MED A Day 0 and Day 100 forms 
and as such the data collection form was adapted to capture additional 
information and potential confounders to the current and future studies. A 
final draft of the data collection form can be found in Appendix 9. 
3.6.8 Data sources 
Within Clatterbridge Cancer Centre and LUDH, there were multiple 
patient databases that were available for review. The different data sources 
available were also discussed at the meeting on the 27th February 2017, to 
plan the most accessible way to capture all the data that would be required. 
The data sources were cross referenced to ensure robust data collection for 
this study. 
The data sources used are listed below with a description of their use: 
1. EBMT MED A Day 0 and Day 100 forms: introduced to the Stem Cell 
Transplantation and Cellular Therapy Unit (CCC) in January 2016 to 
collect a standardised dataset for each Haematological diagnosis.  
2. Haematology (EBMT) data base: along with the MED A forms, this 
was a separate database to record patient details and diagnoses. 
3. Patient electronic notes system (PENS): recording of patient notes in 
both inpatient and outpatient settings.  
4. Unity 2.1: Used by nurses to record clinical notes and observations. 
5. Sunquest Integrated Clinical Environment® (ICE): used within the 
Trust to request special investigations and review blood and histology 
results. 
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6. Epro® Digital Dictation: used by the Trust to dictate and view clinical 
correspondence.  
7. Haemato Oncology Diagnostic System (HODS): used by the Stem 
Cell Transplantation and Cellular Therapy Unit (CCC) to record 
information on cytogenetics and molecular bone marrow.  
The department of SCD was not using electronic patient records at the 
time of the study. Therefore paper dental patient records were reviewed for 
those patients identified as having attended for dental assessment and/or 
dental intervention.  
Although radiographs are taken as part of the dental assessment process 
in the special care dentistry department, data regarding the radiographs 
taken for this patient cohort did not form part of the data collection for this 
service evaluation.  
3.6.9 Method of data collection 
Patients who received an allogeneic stem cell transplant in the year 
2016 were identified from the Haematology (EBMT) database.  Each case 
was reviewed against the inclusion criteria and excluded as appropriate. 
Once identified the cases were assessed as to whether the patient received 
a dental intervention prior to their allogeneic HSCT, and if so the type of 
dental intervention they received. Those who had not received a dental 
intervention were considered as part of the control group (Appendix 8).  
The medical records of all of the patients who received allogeneic 
HSCT were reviewed and data was collected from the various data sources, 
as per the data collection form. Any absent information was recorded as 
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missing or unknown. Those who received a dental intervention had their 
dental records reviewed as part of the data collection process. Patient 
information was anonymised and each patient was assigned a unique 
identification number.  
The review of patient identifiable records (medical and dental case 
notes) was completed by CW-D.  
3.6.10 Data Analysis  
The primary outcome of this study was to compare the incidence of 
morbidity (mucositis, xerostomia, aGvHD, cGvHD, infections and sepsis) and 
mortality (at 100 days and 1 year) across the groups identified.  
Statistical advice from a Senior Biostatistician in the University of 
Liverpool, Dr Girvan Burnside, was sought throughout the project. At the 
initial meeting it was highlighted that the sample to be reviewed, 37 patient 
records, was too small for any further statistical analysis other than 
descriptive statistics. Therefore, descriptive statistics such as mean, mode, 
median along with standard deviation, were used to describe the 
demographics of the patient cohort and also the experience of each separate 
adverse event, to provide an overview of the data collected. It was advised 
that the data should be presented in graphs and tables and for a Kaplan-
Meier curve to be used to demonstrate mortality.  
Due to the complexities of this treatment and patient cohort there were 
multiple potential confounders to this study for example: 
 Nature of the disease 
 Age  
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 Donor type and quality of match  
 Conditioning regime  
 Additional medical complexities 
Due to the number of confounders it was considered possible to use 
directed acyclic graphs (DAG) to provide an overview of each adverse event 
and how the variables could affect both the exposure and the outcomes 
(Greenland et al., 1999, Suttorp et al., 2015). From the DAG, the variables 
which would need to be adjusted to allow for statistical analysis to be 
completed and applied in future projects (Greenland et al., 1999). 
Confounders found within the study could be presented as directed acyclic 
graphs (DAGs). These DAGs could then be used in future prospective 
research studies to allow for statistical adjustment of the confounders.  
Data was initially collected, with assigned unique ID, in a password 
protected Microsoft Office database, it was then transferred to a Microsoft 
Excel® spreadsheet and then to IBM SPSS® statistical software package for 
analysis, presenting results in tables.  
3.6.11 Ethical approval 
The study involved review of medical records for NHS patients 
therefore sponsorship was agreed with Clatterbridge Cancer Centre 
(Appendix 2). The dental data was available from a larger service evaluation 
completed within the Dental Hospital in agreement with the RLBUHT audit 
team (audit reference AO2845).  
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Full IRAS application was completed leading to a full ethical review 
with the Health Research Authority and Health and Care Research Wales 
(Appendix 1). Ethical approval was gained on the 17th April 2018. 
3.6.12 Data management  
 Patient records were reviewed on hospital password protected 
computers, each case was provided with a unique identification (ID) and 
transferred to a password protected database. CW-D was the only person 
with access to the database.  
Following completion of the study all of the data, including raw data, 
was transferred to the Research and Development team within Clatterbridge 
Cancer Centre for archiving. The sponsorship team have a contract with Iron 
Mountain® archiving and so this was arranged by the Research and 
Development team. Any paper based data with patient identifiable 
information will be destroyed after one year following completion of the study.  
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3.7 Results  
 
For the year 2016, 37 patients received an allogeneic HSCT as treatment 
for a haemato-oncology diagnosis, within the Stem Cell Transplantation and 
Cellular Therapy Unit (CCC).  
3.7.1 Demographics 
Of these 37 patients, 19 were male and 18 were female (Table 1), their 
ages ranged from 24 years to 68 years and the majority (n=13) of patients 
were in the age category 60-69 years. The mean age of this patient cohort 
was 52 years (Table 2). 
 No. patients Percentage 
Male 
 
19 51.4 
Female  
 
18 48.6 
Total 37 100.0 
Table 1: Gender of patients who received an allogeneic HSCT in 2016 
 No. patients Percentage 
18-29 
 
3 8.1 
30-39 
 
2 5.4 
40-49 
 
8 21.6 
50-59 
 
11 29.7 
60-69 
 
13 35.1 
Total 37 100.0 
Table 2: Age of patients who received an allogeneic HSCT in 2016 
 
 Most patients lived within the counties of Merseyside and Cheshire, 
with 2 patients commuting from the Isle of Man for treatment (Figure 1) 
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(ArcGIS, 2018). Figure 2 shows the Index of Multiple Deprivation for 
Merseyside and Cheshire, as be seen on the map the patients in this cohort 
live in areas that ranged from the most to the least deprived (CDRC maps, 
2015). 
3.7.2 Medical history  
There were 30 patients who reported additional medical comorbidities 
at the time of dental assessment with 7 patients reporting they had no other 
medical condition than that of their haemato-oncological diagnosis (Table 3). 
The additional comorbidities ranged from allergy (n=11), respiratory 
conditions (n=7), arthritis (n=7) to other diagnosis of cancer (n=3); breast 
cancer (n=2), renal tumour (n=1). Nine patients reported problems with 
bleeding, 8 patients were thrombocytopenic, and 1 patient had pancytopenia 
(Table 4). 
 No. patients Percentage 
Yes 
 
30 81.1 
No 
 
7 18.9 
Total 37 100.0 
Table 3: Any additional medical comorbidities for patients receiving 
allogeneic HSCT in 2016 
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Figure 1: Map of geographical distribution of patients within this cohort 
 
 
 
https://www.arcgis.com/home/webmap/viewer.html?useExisting=1  
https://maps.cdrc.ac.uk/#/geodemographics/imde2015/default/BTTTFTT/10/
-2.8462/53.4670/  
 
Figure 2: Map to show Index of Multiple Deprivation for Merseyside 
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 No. patients (n=30) Percentage 
Allergy 11 36.7 
Hayfever 5 16.7 
Respiratory conditions 
-asthma 
-aspergillous infection 
-shortness of breath 
-history of pseudomonas lung abscess 
-history of pneumonia  
7 23.3 
2 6.7 
1 3.3 
1 3.3 
1 3.3 
2 6.7 
Cardiac conditions 
-myocardial infarction 
-atrial fibrillation 
-hypertension  
4 13.3 
1 3.3 
1 3.3 
2 6.7 
Renal conditions 
-renal impairment  
2 6.7 
2 6.7 
Liver conditions 
-alcoholic liver disease 
-hepatitis C 
-fatty liver 
-Gilbert’s syndrome  
4 13.3 
1 3.3 
1 3.3 
1 3.3 
1 3.3 
Diabetes 
-T1DM 
-T2DM 
-previous  
4 13.3 
2 6.7 
1 3.3 
1 3.3 
Cancer 
-breast cancer 
-kidney tumour 
3 10.0 
2 6.7 
1 3.3 
Arthritis 
-osteoarthritis  
-polymyalgia rheumatic 
6 20.0 
5 16.7 
1 3.3 
Osteoporosis  2 6.7 
Mental health problems  
-bipolar 
-depression 
2 6.7 
1 3.3 
1 3.3 
Bleeding conditions  
-thrombocytopenia 
-pancytopenia 
-subdural haemorrhage 
-subclavian thrombus 
11 36.7 
8 26.7 
1 3.3 
1 3.3 
1 3.3 
Neurological conditions  
-right sided Bell’s palsy 
-cerebrovascular accident 
-peripheral neuropathy 
3 10.0 
1 3.3 
1 3.3 
1 3.3 
Other 
-cholecystectomy 
-eczema 
-fibromyalgia 
-GORD 
-hypothyroidism  
-IBS 
-splenomegaly 
7 23.3 
1 3.3 
1 3.3 
1 3.3 
1 3.3 
1 3.3 
1 3.3 
1 3.3 
Table 4: Other medical diagnoses for patients receiving allogeneic HSCT in 
2016 
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Five patients were not taking medication other than their chemotherapy 
agent(s) at the time of their dental assessment. The majority of patients were 
taking between 1 and 5 medications (n=26) although 1 patient was taking 
over 10 medications a day (Table 5).  
 No. patients  Percentage 
0 5 13.5 
1-5 26 70.3 
6-10 5 13.5 
>10 1 2.7 
Table 5: The number of medications taken by patients receiving allogeneic 
HSCT in 2016 
 
Prior to HSCT, 26 patients were diagnosed as being overweight 
(n=17) or obese (n=9), 11 patients were within the normal weight range (BMI 
18.5 to 24.9) (Table 6). 
 No. patients  Percentage 
Normal weight 11 29.7 
Overweight 17 45.9 
Obese class I 6 16.2 
Obese class II 2 5.4 
Obese class III 1 2.7 
Table 6: BMI classification for patients prior to allogeneic HSCT in 2016 
 
3.7.3 Social history  
At the time of dental assessment, 24 patients reported that they did not 
smoke with 7 patients reporting that they had smoked previously. Three 
patients continued to smoke, and the smoking status was unknown for 3 
patients (Table 7). The number of cigarettes smoked ranged from 2 per day 
to 30 per day. In regards to alcohol consumption, 17 patients reported that 
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they did not drink alcohol, 6 patients rarely drank alcohol and 10 patients 
reported alcohol consumption (Table 8). The units of alcohol consumed 
ranged from 1 unit a week to 14 units per week.  
 No. patients Percentage 
No 24 64.9 
Yes 3 8.1 
Previously 7 18.9 
Unknown 3 8.1 
Table 7: Smoking status at the time of dental assessment for patients 
receiving allogeneic HSCT in 2016 
 No. patients Percentage 
No 17 45.9 
Yes 10 27.0 
Previously 1 2.7 
Rarely 6 16.2 
Unknown 3 8.1 
Table 8: Alcohol consumption at the time of dental assessment for patients 
receiving allogeneic HSCT in 2016 
 
3.7.4 Haemato-oncological history 
The haemato-oncological diagnosis for this patient cohort can viewed in 
Table 9. There were 26 patients with a diagnosis of leukaemia, 6 patients 
had a diagnosis of myeloma and 2 patients had a diagnosis of lymphoma.  
There were 7 patients with a predisposing condition; 6 patients had a 
previous diagnosis of MDS and 1 patient a diagnosis of CML (Table 9). The 
year of haemato-oncology diagnosis ranged from 1999 to 2016, with most 
patients (n=14) being diagnosed in 2015 (Table 9). 
There were 9 patients who had received a previous autologous HSCT, 
3 of these patients had a further autologous HSCT (Table 10). The year of 
the previous HSCT ranged from 2007 – 2016 (Table 10). 
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 No. patients   Percentage 
Haemato-oncological diagnosis   
ALL 4 10.8 
AML 20 54.1 
CML 1 2.7 
CMML 1 2.7 
Follicular lymphoma 1 2.7 
IgG Lamda Myeloma 1 2.7 
Mantle cell Lymphoma 1 2.7 
Multiple Myeloma 5 13.5 
Myelodysplastic syndrome 2 5.4 
Primary myelofibrosis 1 2.7 
Total 37 100.0 
 
Predisposing condition  
No 30 81.1 
Yes 
 MDS 
 CML 
7 
6 
1 
18.9 
85.7 
14.3 
Total 37 100 
 
Year of diagnosis  
1999 1 2.7 
2007 2 5.4 
2009 1 2.7 
2011 1 2.7 
2012 3 8.1 
2013 3 8.1 
2014 3 8.1 
2015 14 37.8 
2016 9 24.3 
Total 37 100.0 
Table 9: Haemato-oncological background for patients receiving allogeneic 
HSCT in 2016 
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 No. patients Percentage 
Number of previous HSCT  
None 28 75.7 
1 6 16.2 
2 3 8.1 
Total 37 100 
 
Year of first HSCT  
2007 1 2.7 
2011 1 2.7 
2012 1 2.7 
2013 2 5.4 
2015 3 8.1 
2016 1 2.7 
Total 9 24.3 
 
Year of second HSCT  
2014 1 2.7 
2015 1 2.7 
2016 1 2.7 
Total  3 3.1 
Table 10: History of previous HSCT for patients receiving allogeneic HSCT in 
2016 
 
 No. patients Percentage 
Conditioning regime  
Myeloablative 3 8.1 
Reduced intensity 34 91.9 
Total  37 100 
 
Contraindication to myeloblative 
therapy 
 
Patient age 33 89.2 
Other comorbidities 1 2.7 
N/A 3 8.1 
Total 37 100 
 
Type of donor stem cells  
Sibling 10 27.0 
Volunteer unrelated donor 27 73.0 
Total 37 100 
Table 11: Conditioning regime and donor type for patients receiving 
allogeneic HSCT in 2016 
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3.7.5 Haematopoietic stem cell transplant  
Of the 37 patients, 34 patients received reduced intensity conditioning 
prior to their HSCT (Table 11). The majority of these 34 patients did not 
receive myeloablative conditioning due to their age; however, 1 patient had 
additional comorbidities which prevented the use of myeloablative 
conditioning (Table 11). In regards to the donor, 27 patients received stem 
cells from a volunteer unrelated donor, and 10 patients received a sibling 
transplant (Table 11).  
3.7.6 Dental assessment  
Within this patient cohort, 36 patients were referred by the Stem Cell 
Transplantation and Cellular Therapy Unit (CCC) for a dental assessment 
within the Department of Special Care Dentistry, 34 patients attended their 
dental assessment (Table 12) 
 No. patients Percentage 
Referral to special care dentistry  
Yes 36 97.3 
No 1 2.7 
Total  37 100 
 
Attended assessment appointment  
Yes 34 91.9 
No 3 8.1 
Total 37 100 
Table 12: Referral and attendance rates to the special care dentistry 
department for patients receiving allogeneic HSCT in 2016 
 
3.7.6.1 Dental history  
There were 23 patients who stated that they had their own general 
dental practitioners, of whom 22 reported regular attendance (Table 13). For 
9 patients their dental attendance was reported as being irregular (>2years), 
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and dental attendance patterns were not recorded for 3 patients (Table 13) 
(National Institute for Health Care and Excellence, 2014).  
 No. patients Percentage Valid percentage 
GDP  
Yes 23 62.2 67.6 
No 11 29.7 32.4 
Total 34 91.9 100 
Missing 3 8.1  
 
Attendance pattern  
Regular 22 59.5 64.7 
Irregular 9 24.3 26.5 
Unknown 3 8.1 8.8 
Total 34 91.9 100 
Missing 3 8.1  
Table 13: Patient reported dental attendance for patients receiving allogeneic 
HSCT in 2016 
 
 Regarding oral hygiene regimes, 27 patients reported toothbrushing 
twice a day, however, toothbrushing was not recorded for 4 patients (Table 
14). Only 4 patients reported using interdental cleaning aids (floss and 
interdental brushes) however, this information was not recorded for 30 
patients (Table 14). There were 9 patients who reported the use of mouth 
wash however, again this information was not recorded for 25 patients (Table 
14). 
3.7.6.2 Clinical examination  
3.7.6.2.1 Extraoral and soft tissue examination 
Extraoral examination was completed for all of the 34 patients who 
attended for dental assessment, for 31 patients nothing abnormal was 
detected however pallor was noted for one patient and 2 patients 
experienced clicks to their temporomandibular joints (TMJs) (Table 15). 
Intraoral examination was documented for all but one patient, 21 patients had 
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a normal appearance to their soft tissues however abnormalities that were 
documented include; plaque induced gingivitis (n=1), pallor (n=1), angular 
chelitis (n=1) and an erythematous lesion on the tip of the tongue (n=1) 
(Table 16).  
 No. patients Percentage Valid percentage 
Toothbrushing  
Twice daily 27 73.0 79.4 
Once daily 2 5.4 5.9 
>Twice daily 1 2.7 2.9 
Unknown 4 10.8 11.8 
Total 34 91.9 100 
Missing 3 8.1  
 
Interdental cleaning  
ID brushes 1 2.7 2.9 
Floss 2 5.4 5.9 
ID brush and floss 1 2.7 2.9 
Unknown 30 81.1 88.2 
Total  34 91.9 100 
Missing 3 8.1  
 
Mouthwash  
Yes 9 24.3 26.5 
Unknown 25 67.6 73.5 
Total 34 91.9 100 
Missing  3 8.1  
Table 14: Patient reported oral hygiene regime for patients receiving 
allogeneic HSCT in 2016 
 
 No. patients Percentage Valid Percentage 
Nothing abnormal  31 83.8 91.2 
Pallor 1 2.7 2.9 
TMJ bilateral click 1 2.7 2.9 
TMJ left click 1 2.7 2.9 
Total 34 91.9 100.0 
Missing 3 8.1  
Table 15: Findings from extra-oral examination completed for patients 
receiving allogeneic HSCT in 2016 
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 No. patients Percentage Valid percentage  
 
Nothing abnormal  29 78.4 85.3 
Angular chelitis left  1 2.7 2.9 
Pallor consistent with 
anaemia 
1 2.7 2.9 
Plaque induced gingivitis 1 2.7 2.9 
Erythematous lesion tongue 
~5mm 
1 2.7 2.9 
Not recorded 1 2.7 2.9 
Total 34 91.9 100 
Missing 3 8.1  
Table 16: Findings from soft tissue examination completed for patients 
receiving allogeneic HSCT in 2016 
 
3.7.6.3 Dental examination 
From the dental clinical examination, 19 patients presented with 58 
carious teeth, giving an average number of carious teeth per patient as 1.71 
for this patient cohort (Table 17).  There were 2 patients who presented with 
retained roots, 1 retained root per patient (Table 17). There were 5 patients 
who presented with mobile teeth (Table 17). A total of 31 mobile teeth were 
documented for these patients; grade 1 mobile teeth (n=11), grade 2 mobile 
teeth (n=16) and grade 3 mobile teeth (n=4) (Table 17).   
3.7.6.4 Periodontal examination 
A basic periodontal examination (BPE) was completed for 23 patients, 
with most patients (n=14) having a highest BPE score of 2 (Table 18). There 
were 2 patients who scored an asterix (*) indicating either recession, 
suppuration or furcation involvement (Table 18) (British Society of 
Periodontology, 2016).  
The patients’ oral hygiene status at assessment was recorded as 
good-excellent for 17 patients, satisfactory for 3 patients, and poor/very poor 
53 
 
for 4 patients. Oral hygiene status was not recorded for 10 patients (Table 
19).  
 No. patients   Percentage Valid percentage 
No. patients with carious teeth  19 51.4 55.9 
Total no. carious teeth 58   
Mean no. carious teeth (n=34) 1.71 (+/- 
2.08) 
  
No. patients with retained roots 2 5.4 5.9 
Total no. retained roots 2   
Mean no. retained roots (n=34) 0.06   
No. patients with mobile teeth 5 13.5 14.7 
Total no. teeth grade 1 11   
Total no. teeth grade 2 16   
Total no. teeth grade 3 4   
Table 17: Findings from dental examination completed for patients receiving 
allogeneic HSCT in 2016 
 No. patients Percentage Valid percentage 
BPE recorded   
Yes 23 62.2 67.6 
Not recorded 11 29.7 32.4 
Total 34 91.9 100 
Missing 3 8.1  
Total 37 100  
 
Highest BPE score recorded  
0 3 8.1 13.0 
1 1 2.7 4.3 
2 14 37.8 60.9 
3 5 13.5 21.7 
Total 23 62.2 100 
Missing  14 37.8  
Total 37 100  
 
Recession, suppuration or 
furcation involvement 
 
Yes 2 5.4 8.7 
No 21 56.8 91.3 
Total 23 62.2 100 
Missing 14 37.8  
Total 37 100  
Table 18: Periodontal assessment for patients receiving allogeneic HSCT in 
2016 
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 No. patients Percentage Valid percentage 
 
Excellent 3 8.1 8.8 
Very good 1 2.7 2.9 
Good 13 35.1 38.2 
Satisfactory 3 8.1 8.8 
Poor  3 8.1 8.8 
Very poor 1 2.7 2.9 
Unknown 10 27.0 29.4 
Total 34 91.9 100 
Missing 3 8.1  
Total 37 100  
Table 19: Operator reported levels of oral hygiene for patients receiving 
allogeneic HSCT in 2016 
 
3.7.7 Dental treatment  
3.7.7.1 Prevention  
Oral hygiene advice was documented as being provided for 26 
patients, 18 patients received diet advice while 29 received a prescription for 
high fluoride toothpaste (Table 20). Fluoride varnish was applied for 1 patient 
(Public Health England, 2017b). 
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 No. patients Percentage Valid percentage 
Oral hygiene advice   
Yes 26 70.3 76.5 
No 8 21.6 23.5 
Total 34 91.9 100 
Missing 3 8.1  
Total 37 100  
 
Diet advice given  
Yes 18 48.6 52.9 
No 16 43.2 47.1 
Total 34 91.9 100 
Missing 3 8.1  
Total 37 100  
 
High fluoride toothpaste 
prescribed 
 
Yes 29 78.4 85.3 
No 5 13.5 14.7 
Total 34 91.9 100 
Missing 3 8.1  
Total 37 100  
Table 20: Documented prevention advice provided to patients receiving 
allogeneic HSCT in 2016 
 
3.7.7.2 Interventive dental treatment  
Table 21 shows the types of treatments received by this patient 
cohort, 12 patients required no interventive dental treatment (i.e. were 
dentally stable or were advised that dental treatment could wait until post-
HSCT) and solely received preventative advice.  
There were 6 patients who completed their dental treatment prior to 
HSCT, 15 patients had part of their treatment plan completed, or received 
urgent care such as extractions and temporary restorations. There was 1 
patient who refused to have interventive dental treatment, however was given 
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oral hygiene advice. As stated previously, there were 3 patients who did not 
attend their dental assessment or were not referred (Table 21).  
Type of dental treatment received No. patients (n=37) 
 
All dental treatment has been completed 
(other than fixed/removable 
prosthodontics), the patient is deemed 
dentally stable (Group 1) 
 
6 
Only urgent care has been provided 
(extractions and dressings) or only part of 
treatment plan has been completed (Group 
2) 
 
15 
No dental treatment was advised pre-
transplant other than prevention advice  
(Group 3) 
 
12 
Refused proposed dental treatment, only 
received prevention advice (Group 4) 
 
1 
No dental treatment received, no 
prevention advice, patient was not referred 
or did not attend assessment (Group 5) 
 
3 
Table 21: Types of dental treatment provided to patients receiving allogeneic 
HSCT in 2016 
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 No. patients Percentage Valid percentage 
Periodontal treatment 
provided 
 
Yes 0 0 0 
No 34 91.9 100 
Missing 3 8.1  
Total 37 100  
 
Restorations provided  
Yes 10 27.0 29.4 
No 24 64.9 70.6 
Total 34 91.9 100 
Missing 3 8.1  
Total  37 100  
Total no. restorations 
completed 
20  
(range 1-6) 
  
 
Extractions provided  
Yes 8 21.6 23.5 
No 26 70.3 76.5 
Total 34 91.9 100 
Missing 3 8.1  
Total 37 100  
Total no. teeth 
removed 
20  
(range 1-5) 
  
 
Antibiotic prophylaxis 
prior to extraction 
 
Yes 7 18.9 87.5 
No 1 2.7 12.5 
Total  8 21.6 100 
Missing 29 78.4  
Total  37 100  
 
Review to assess 
healing 
 
Yes 8 21.6 100 
No 0 0 0 
Missing 29 78.4  
Total 37 100  
Table 22: Dental treatment provided prior to patients receiving allogeneic 
HSCT in 2016 
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3.7.7.2.1 Periodontal treatment  
Other than oral hygiene advice no patients in this cohort received 
interventive periodontal treatment pre-operatively (Table 22).  
3.7.7.2.2 Restorative dental treatment  
Of the patients who presented with carious teeth (n=19), 10 patients 
received temporary (n=4) or definitive restorations (n=16) prior to their HSCT 
(Table 22). A total of 20 restorations were placed for this patient cohort 
ranging from 1-6 teeth being restored for each patient (Table 22). 
3.7.7.2.3 Extractions/surgical dental treatment   
Within this patient cohort, 8 patients had extractions (Table 22). A total 
of 20 teeth were removed ranging from 1-5 teeth being extracted for each 
patient (Table 22). One patient required enucleation of a cyst which was 
completed at his extraction appointment.  
Of these 8 patients, 7 received antibiotic prophylaxis; 6 patients had 
pre-operative and post-operative antibiotic cover and 1 patient had solely 
post-operative antibiotic cover (Table 22).  
The most common pre-operative antibiotic regime was 1g Amoxicillin 
stat dose (n=2) and the most common post-operative antibiotic regime was 
500mg Amoxicillin three times daily (tds) for 5 days (n=5) (Table 23 & 24).  
 No. patients  
500mg amoxicillin, 400mg metronidazole  1 
1g amoxicillin, 400mg metronidazole  1 
1g amoxicllin 2 
2g amoxicillin 1 
400mg metronidazole 1 
Table 23: Pre-operative antibiotic regime (stat dose) for patients receiving 
extractions prior to allogeneic HSCT 
59 
 
 
 No. patients 
500mg amoxicillin tds for 5days 5 
500mg amoxicillin tds + 400mg metronidazole tds for 5 days 1 
400mg metronidazole tds for 5 days 1 
Table 24: Post-operative antibiotic regime for patients receiving extractions 
prior to allogeneic HSCT 
 n No. days Range 
Dental referral and dental assessment 36† 14.9 
 
2 – 63 days* 
Dental assessment and dental treatment  16 5.1  
 
1 – 21 days* 
Extraction and final review of healing  
 
8 12.1 4 – 36 days* 
Discharge from SCD to transplant  34 19.1  
 
6 – 131 days* 
Dental referral to transplant  36† 37.4 13 – 143 days* 
 
Dental assessment to transplant  34 23.7 6 – 131 days* 
 
HSCT and neutrophil recovery  37† 11.9 9 – 19 days 
HSCT and platelet recovery 37† 13.8  10 – 29 days 
 
Admission date and discharge date  37 31.7 21 – 68 days 
Transplant date and discharge date  37 21.9 14 – 43 days 
 
HSCT and aGvHD diagnosis  20 49.0 12 – 85 days 
HSCT and cGvHD diagnosis  16 102.8  86 – 136 days 
 
HSCT and relapse  9† 297.9 111 – 563 days 
Discharge post-HSCT and relapse  9† 276.4  86 – 520 days 
 
HSCT and death  19 235.7  21 – 652 days 
Discharge post-HSCT and death  19 212.2  0 – 624 days 
 
* based on working days: the dental hospital is only open Monday-Friday (9am – 
5pm) † incomplete data set  
Table 25: Average number of days between key stages in the transplant 
process for patients receiving allogeneic HSCT in 2016. 
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Following extractions, all of the patients (n=8) received a review 
appointment to assess and confirm healing (Table 22). The average number 
of days (working days) between extraction and final review of healing was 
12.1 days (Table 25). 
3.7.7.2.4 Dental treatment outstanding  
Items of dental treatment were outstanding in half of the patients 
(n=17) who attended for dental assessment including those patients who 
were advised to wait until after transplant to have their dental treatment 
completed (Table 26). Placement of definitive restorations was delayed most 
frequently until HSCT was completed (n=10). Additionally, periodontal 
treatment was planned pre-HSCT for 4 patients however was not completed 
by either the hygienist or the dentist. Two patients required non-urgent 
extractions, 2 patients required extra-coronal restorations and 2 patients 
required addition to or construction of dentures however again it was not 
possible for this treatment to be completed prior to transplant (Table 27).  
Table 26: Dental treatment that was incomplete at the time of HSCT for 
patients receiving allogeneic HSCT in 2016 
 
 
 
 
 
 No. patients Percentage Valid Percentage 
Yes 17 45.9 50.0 
No 17 45.9 50.0 
Total 34 91.9 100.0 
Missing 3 8.1  
Total 37 100.0  
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 No. patients 
Definitive restoration(s) 10 
Extraction(s) 2 
Periodontal treatment  4 
Advanced restorations  2 
Denture construction/adjustment  2 
Table 27: Types of dental treatment remaining for patients receiving 
allogeneic HSCT in 2016 
 
3.7.7.3 Timeline 
For this patient cohort, the timeline for completion of dental treatment is 
shown in Table 25. There was an average of 14.9 working days between the 
date of referral and the assessment appointment. The time of dental 
assessment to treatment was 5.1 days, with the time between discharge from 
SCD and the date of the patient’s HSCT being 19.1 days. On average, there 
was 37.4 days between referral and transplant and 23.7 days between the 
date of dental assessment and the date of the HSCT.  
3.7.8 Post-HSCT outcomes 
Following review of the dental records, the medical records were 
reviewed from the point where the patient was admitted for HSCT. The 
average length of hospital stay for these patients was 31.7 days with the 
length of time between transplant and discharge from hospital being 21.9 
days (Table 25).  
3.7.8.1 Recovery 
The recovery of patients’ platelet and neutrophil counts were 
reviewed. There were 36 patients whose neutrophil count recovered (>0.5 x 
109/L) and 35 patients whose platelet count recovered (>20 x 109/L) whilst in 
hospital (Table 28). The average number of days between HSCT and 
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neutrophil recovery was 11.9 days and between HSCT and platelet recovery 
was 13.8 days (Table 25).  
 No. patients Percentage  
Incidence of neutrophil recovery   
Yes 36 97.3 
No 1 2.7 
Total 37 100 
   
Incidence of platelet recovery   
Yes 35 94.6 
No 1 2.7 
Unknown 1 2.7 
Total 37 100 
Table 28: Evidence of platelet and neutrophil recovery for patients following 
allogeneic HSCT in 2016 
3.7.8.2 Feeding regime  
The feeding regime was variable, with many patients having more 
than one system for feeding. There were 26 patients who were fed by 
nasogastric tube and this was often in combination with another food source. 
There were 20 patients who had a high protein/high carbohydrate diet, 22 
patients had additional supplements such as Ensure® build up drinks and 11 
patients were described as consuming solid foods (Table 29).  
 No. patients 
High protein/high carbohydrate diet 20 
NG tube 26 
Solid foods 11 
Supplements 22 
Thickened fluids  2 
TPN (total parenteral nutrition) 2 
Table 29: In patient feeding regimes for patients following allogeneic HSCT in 
2016 
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The BMI for patients on discharge from hospital was calculated from 
their height and weight on discharge. The weight was not recorded for 13 
patients and, therefore a BMI was not calculated. There were 16 patients 
who were considered overweight or obese and 9 who were of a normal 
weight (Table 30). Fourteen patients lost weight during the transplant period 
with the average weight loss being 5.1kg, one patient maintained their weight 
throughout and 9 patients gained weight with the average weight gain being 
4.9kg (Table 30). 
 No. patients Percentage 
BMI classification on discharge post-HSCT   
Normal weight 9 24.3 
Overweight 12 32.4 
Obese I 2 5.4 
Obese II 1 2.7 
Unknown  13 35.1 
Total 37 100 
 
Weight change during transplant   
Weight lossed 14 37.8 
Weight gained 9 24.3 
Maintained weight  1 2.7 
Unknown 13 35.1 
Total 37 100 
Average weight loss 5.1kg  
Average weight gain 4.9kg  
Table 30: Changes to patients weight following allogeneic HSCT in 2016 
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 No. patients Percentage 
Experience of mucositis    
Yes 17 45.9 
No  20 54.1 
Total 37 100 
 
Recorded mucositis score   
None 20 54.1 
Mild (1) 8 21.6 
Moderate (2) 3 8.1 
Severe (3) 1 2.7 
Other descriptor 2 5.4 
Unknown 3 8.1 
Total 37 100 
   
Experience of dry mouth 
(xerostomia) 
  
Yes 4 10.8 
No/not recorded 33 89.2 
Total 37 100 
Table 31: Oral complications experienced by patients following allogeneic 
HSCT in 2016 
3.7.9 Post-HSCT complications 
3.7.9.1 Oral complications  
From an oral complication perspective, there was a record of 17 
patients who were diagnosed with mucositis, with the mucositis score mostly 
being recorded as mild (n=8). One patient experienced severe mucositis 
(Table 31). There were 4 patients who reported xerostomia (Table 31). Other 
oral complications that were documented are highlighted in Table 32, with 
oral candida infections (n=10), oral ulceration (n=7) and a generalised sore 
mouth/throat (n=7) being recorded more frequently.  
3.7.9.2 Infections  
Sepsis was documented frequently in this patient cohort, with 25 
cases of sepsis being documented during their inpatient stays post HSCT 
(Table 33). Neutropenic sepsis was only documented clearly in 6 of the 
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cases with 3 patients diagnosed with septicaemia and 16 cases of 
unspecified sepsis (Table 32). The infective organism was identified within 
the notes for 11 patients with sepsis (Table 33). Antibiotics were prescribed 
for 20 patients (Table 33), with multiple combinations being documented 
(Table 34). The most frequent was a combination of Tazocin® and 
teicoplanin.  
There were 27 patients where other types of infection were 
documented, often in combination. The most commonly experienced were 
viral infections (n=16). Bacterial infections were experienced by 14 patients 
whilst 13 patients had fungal infections (Table 33).
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Complication Total no. Examples No. patients 
Oral  45 Mucositis 12 
Sore mouth/throat   7 
Oral/oropharyngeal 
ulceration 
7 
Hyposalivation 4 
Hypersalivation 1 
Oral candida  10 
Dysphagia  1 
Dysguesia  1 
Haemangioma (tongue) 1 
HSV cold sore 1 
Sepsis  25 Neutropenic sepsis 6 
Unspecified sepsis  16 
Septicaemia 3 
Viral 22 CMV reactivation 13 
Astrovirus reactivation 1 
Adenovirus reactivation 3 
BK viraemia 1 
Coronovirus 2 
HSV cold sore 1 
Shingles  1 
Bacterial  7 VRE bacteraemia 4 
CDT infection 1 
C. diff infection 2 
Fungal  13 Oral candida  10 
Other candida 2 
Unspecified fungal 
infection 
1 
Infection 
(other) 
6 Hospital acquired 
pneumonia  
1 
Perianal abscess 1 
Infected sebaceous cyst 1 
Conjunctivitis  1 
UTI 2 
Gastro-
intestinal 
25 Loose stools/ diarrhoea 15 
Nausea/vomiting  5 
Reflux 2 
Oesophagitis  1 
Subacute intestinal 
obstruction 
1 
Malnutrition 1 
Liver  6 Deranged LFTs 5 
Liver failure 1 
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Complication Total no. Examples No.  
Kidney 16 Deranged kidney function 
/ decreased eGFR 
7 
Acute kidney injury 9 
Heart 5 AF exacerbation/new 3 
Tachycardia 1 
Neurological  4 Peripheral neuropathy 1 
Headaches/hallucinations 1 
Pain (muscular) 1 
Electrolyte derangement 1 
Bleeding 3 Subconjunctival 
haemorrhage 
1 
Bleeding from mouth 1 
Acute subdural 
haemorrhage 
1 
Thrombus 2 Superficial thrombus 1 
Internal jugular vein 
thrombus 
1 
Other 21 Engraftment syndrome  5 
aGvHD 7 
Rash 3 
Normocytic anaemia 1 
Oedema 3 
Haematoma 1 
Adverse drug reaction 1 
Table 32: Documented complications experienced by this patient receiving 
allogeneic HSCT in 2016 
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 No. patients Percentage 
Experience of sepsis   
Yes 25 67.6 
No/not recorded 12 32.4 
Total 37 100.0 
Infective organism identified  
Yes 11 29.7 
Unknown 14 37.8 
N/A 12 32.4 
Total 37 100.0 
Experience of other infections   
Yes 27 73.0 
No 10 27.0 
Total 37 100.0 
Type of infection  
Bacterial  2 5.4 
Bacterial/ Fungal 2 5.4 
Bacterial/ Viral 6 16.2 
Bacterial/ Fungal/ Viral 4 10.8 
Fungal/ Viral 4 10.8 
Fungal  3 8.1 
Viral 6 16.2 
Not recorded 10 27.0 
Total 37 100.0 
Evidence of antibiotic 
treatment  
 
Yes 20 54.1 
Not recorded  17 45,9 
Total 37 100.0 
Table 33: Infective complications experienced by patients following 
allogeneic HSCT in 2016 
 
3.7.9.3 GvHD experience  
3.7.9.3.1 Acute Graft vs Host disease (aGvHD) 
All patients received prophylaxis for aGvHD and each patient was 
administered ciclosporin, either alone (n=31) or in combination with another 
drug (n=6) (Table 35).  
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 No. patients (n=21) Percentage 
 
Tazocin 2 9.5 
Tazocin / teicoplanin 2 9.5 
Tazocin / teicoplanin / 
meropenem  
2 9.5 
Tazocin / teicoplanin / 
gentamycin  
2 9.5 
Tazocin / teicoplanin / 
pentamidine  
1 4.8 
Tazocin / teicoplanin / 
meropenem / gentamycin 
1 4.8 
Tazocin / clarithromycin 1 4.8 
Tazocin / teicoplanin / 
meropenem / clarithromycin  
1 4.8 
Teicoplanin  1 4.8 
Teicoplanin / meropenem  2 9.5 
Teicoplanin / meropenem / 
gentamycin/ vancomycin  
1 4.8 
Unspecified IV antibiotics  4 19.0 
Not recorded  1 4.8 
Table 34: Antibiotic regime used in the treatment of infective complications 
for patients receiving allogeneic HSCT in 2016 
 
 No. patients Percentage 
ALG (rabbit), ciclosporin 1 2.7 
ciclosporin 31 83.8 
ciclosporin, Methotrexate 2 5.4 
ciclosporin, Mycophenylate 3 8.1 
Total 37 100.0 
Table 35: Prophylactic medication used for aGvHD for patients receiving 
allogeneic HSCT in 2016 
 
There were 20 patients in this cohort who experienced aGvHD, with 
the grade of aGvHD ranging from 1 – 4 (Table 36). The organs affected can 
be seen in Table 36 and were limited to the skin (n=12), gut (n=12) and liver 
(n=5). The organ affected most severely was the gut with 4 patients having 
an aGvHD score of 4 for this organ.  
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The average number of days between HSCT and a diagnosis of 
aGvHD was 49.0 days (Table 25). 
 No. patients Percentage 
Experience of aGvHD  
Yes 20 54.1 
No 17 45.9 
Total 37 100.0 
Grade aGvHD  
0 17 45.9 
1 6 16.2 
2 6 16.2 
3 4 10.8 
4 4 10.8 
Total 37 100.0 
Organ(s) affected by a GvHD 
and severity 
 
No diagnosis of cGvHD 17 45.9 
Gut (1) 2 5.4 
Gut (2) 1 2.7 
Gut (3) 2 5.4 
Gut (4), Liver (1) 1 2.7 
Gut (4), Liver (2) 1 2.7 
Liver (1) 1 2.7 
Skin (1) 1 2.7 
Skin (1), Gut (1) 1 2.7 
Skin (1), Liver (1) 1 2.7 
Skin (2) 4 10.8 
Skin (3) 1 2.7 
Skin (3), Gut (4) 1 2.7 
Skin(1), Gut (3) 1 2.7 
Skin(2) Gut (1) 1 2.7 
Skin(2) Liver (4) Gut (4) 1 2.7 
Total 37 100.0 
Table 36: Experience of aGvHD for patients receiving allogeneic HSCT in 
2016 
3.7.9.3.2 Chronic Graft vs Host disease (cGvHD)  
Chronic GvHD was diagnosed on average 102.8 days following HSCT 
(Table 25). There were 16 patients who received a diagnosis of cGvHD 
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following transplant (Table 37). The extent of cGvHD was often limited 
(n=12), with 3 patients experiencing extensive cGvHD. The NIH scoring 
system was not frequently used to described cGvHD with 14 patients not 
having a calculated score, the other 2 patients were scored as mild (Table 
37) (Filipovich et al., 2005, Carpenter et al., 2015).  
 No. patients Percentage 
Experience of cGvHD  
Yes 16 43.2 
No 20 54.1 
No (RIP) 1 2.7 
Total 37 100.0 
Extent of cGvHD  
Not diagnosed with cGvHD 21 56.8 
Extensive 3 8.1 
Limited 12 32.4 
Not recorded 1 2.7 
Total 37 100.0 
NIH GvHD score  
Not diagnosed with cGvHD 21 56.8 
Mild 2 5.4 
Not recorded 14 37.8 
Total 37 100.0 
Table 37: Experience of cGvHD for patients receiving allogeneic HSCT in 
2016 
 
3.7.9.4 Relapse  
There were 9 patients who had relapse of their haematological 
malignancy following HSCT (Table 38). The most common reason for relapse 
was haematological however graft failure, disease progression and molecular 
or cytogenetic issues were also causes of disease relapse (Table 38). The 
average number of days between disease relapse and the HSCT was 297.9 
days (Table 25).  
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 No. patients Percentage 
Relapse of haematological 
malignancy 
 
Yes 9 24.3 
No 28 75.7 
Total 37 100.0 
Cause of disease relapse  
No relapse 28 75.7 
Graft failure 1 2.7 
Haematological 3 8.1 
Molecular, Cytogenetic 1 2.7 
Progression 2 5.4 
Unknown 2 5.4 
Total 37 100.0 
Table 38: Experience and reason for relapse in patients receiving allogeneic 
HSCT in 2016 
3.7.9.5 Survival status  
Survival status is recorded at 100 days post-transplant and 1 year 
post-transplant (European Society for Blood and Bone Marrow 
Transplantation, 2017b). At 100 days post-transplant 31 patients were still 
alive (Table 39). Sixteen patients had died 1 year post transplant (Table 39). 
There was an average of 235.7 days between date of HSCT and date of 
death, however this ranged from 21 days to 652 days (Table 25).  
 No. patients Percentage 
Survival at 100 days  
Alive 31 83.8 
Dead 6 16.2 
Total 37 100.0 
Survival at 1 year   
Alive 21 56.8 
Dead 16 43.2 
Total 37 100.0 
Table 39: Survival status at 100 days and 1 year for patients receiving 
allogeneic HSCT in 2016 
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Figure 3 shows a Kaplan-Meier curve for this cohort of patients, as 
can be seen from the graph the mortality rate is steady within the first year 
post-transplant at which point the chances of survival improve. 
 
Figure 3: Kaplan-meier curve to show overall survival for patients receiving 
allogeneic HSCT in 2016 
 
The most prevalent primary cause of death was transplant related 
(n=10) with relapse or progression of the disease being the main cause of 
death for 5 patients. The most common secondary cause of death was 
sepsis (n=9) (Table 40).  
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 No. patients (n=20) Percentage 
Primary cause  
Relapse/progression 5 25.0 
Transplant related 10 50.0 
Other 3 15.0 
Unknown 2 10.0 
Secondary cause  
aGvHD 1 5.0 
Cardiac arrest  1 5.0 
cGvHD 2 10.0 
Frailty 1 5.0 
Sepsis 
-E. coli 
-Pneumonia 
-Cerebral fungal infection 
-Influenza 
-Other cause 
9 45.0 
1 5.0 
1 5.0 
1 5.0 
1 5.0 
5 25.0 
Stroke 1 5.0 
Subdural haematoma 1 5.0 
Unknown 2 10.0 
No secondary cause 4 20.0 
Table 40: Cause of death for patients following allogeneic HSCT in 2016 
 
3.7.9.6 Other complications  
Table 32 shows all of the complications documented for this patient 
cohort. As shown in the table, oral complications were reported frequently, 
ranging from mucositis to a cold sore. Infections were another commonly 
documented complication, and patients also experienced gastrointestinal 
issues, decreased kidney and liver function and complications with bleeding. 
Three patients experienced an exacerbation or new onset of atrial fibrillation, 
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4 patients had neurological symptoms whilst other complications included: 
engraftment syndrome, aGvHD, rashes, allergy and anaemia.  
3.7.10 Directed acyclic graph 
Completing this study confirmed the complex nature of this patient cohort 
with multiple confounding factors preventing a confirmation of the causal path 
between pre-HSCT dental treatment and HSCT outcome. A novel way to 
represent confounding factors is within a directed acyclic graph (DAG). A 
DAG was produced, on advice from the Senior Biostatistician (GB) and with 
the help of a team of Special Care Dentistry clinicians involved in treatment 
planning and providing dental treatment for this patient cohort (figure 4). 
Production of this graph provides information for future studies as to the 
minimal adjustment variables, to allow for a statistical association to be 
confirmed. For this study, the minimal adjustment variables were: 
i. Dental pathology 
ii. Haem-oncology diagnosis 
iii. Medical comorbidities  
iv. Bisphosphonates 
v. Obesity 
vi. Previous HSCT 
vii. Previous chemotherapy 
viii. Socio-economic background 
ix. Thrombocytopenia 
x. Neutropenia  
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Adjustment of these variables will aid in reducing bias in future studies 
due to the number of confounding factors and the complex nature of these 
individuals, their diagnosis and relevant medical treatment. 
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Figure 4: Directed acyclic graph to show potential confounding factors for this patient cohort.
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3.8 Discussion 
3.8.1 Interpretation of results  
In 2016, across the United Kingdom and the Republic of Ireland, there 
were a total of 1,680 allogeneic haematopoietic stem cell transplants 
completed, in the treatment of haematological malignancies and non-
malignancy related diseases. There were 1,603 primary allogeneic HSCT for 
adult patients, 324 were primary allogeneic HSCT for paediatric patients and 
77 were non-primary allogeneic HSCTs (British Society of Blood and Bone 
Marrow Transplantation, 2016).  
Within the Stem Cell Transplantation and Cellular Therapy Unit (CCC) 
a total of 37 allogeneic stem cell transplants were completed for patients with 
a haemato-oncological diagnosis.  
3.8.1.1 Demographics 
The Stem Cell Transplantation and Cellular Therapy Unit (CCC), 
provide allogeneic HSCT for adult patients (>18years).  
Both the gender and the age of the patients seen within this cohort 
reflected haematological malignancies affecting any age group or gender 
(Allart-Vorelli et al., 2015, Bloodwise, 2019). Moreover it highlights the 
relapsing/remitting nature of the disease, with chemotherapy treatment 
prolonging life prior to the decision to proceed to a stem cell transplant (The 
Royal College of Surgeons England / British Society of Disability and Oral 
Health, 2018).  
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As a specialist centre for the treatment of haematological diseases the 
Stem Cell Transplantation and Cellular Therapy Unit (CCC) receives referrals 
from across the North West region of the United Kingdom. From this 
particular study the majority of patients were local, within Cheshire and 
Merseyside (n = 35). Two patients, however, travelled from the Isle of Man 
for their treatment. Although only a short flight from Liverpool, travelling from 
the Isle of Man added a further barrier of care for these two patients. An 
additional referral to the Dental Hospital for a dental assessment and 
necessary treatment would increase the number of journeys made by these 
patients. To reduce this barrier attempts were made to ensure appointments 
were on a day when the patient was already attending the Stem Cell 
Transplantation and Cellular Therapy Unit (CCC), thus decreasing the impact 
on care for these patients and their quality of life.  
Liverpool and the North West is generally considered as being one of 
the more deprived areas of the United Kingdom, with a high Index of 
Deprivation Need (Public Health England, 2017a). More deprived areas tend 
to experience health inequalities relating to their general and dental health, 
including higher caries experience (Liverpool Public Health Observatory, 
2015).  
3.8.1.2 Social history 
Within Great Britain 16.6% of the adult population stated they smoked 
(2018) with 57% of the population (2017) admitting to weekly alcohol 
consumption of varying amounts. In the current study, the frequency of 
alcohol consumption and smoking was much lower at 27.0% and 8.1% 
respectively. This is likely due to the patient’s medical team providing specific 
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health messages at the time of transplant, including smoking cessation 
advice and advice around reducing alcohol consumption, to improve the 
overall medical outcome for the patient. Additionally, this was a retrospective 
study and so it was only possible to collect data that was available hence the 
lower frequency may be due to under reporting.  
Unfortunately within the context of the current study other aspects of 
social history, including current and previous employment status and family 
history, were not collected for this cohort of patients.   
3.8.1.3 Medical history 
Patients within this cohort often had complex medical histories 
resulting in multiple medications, treatments and numerous hospital 
appointments.  
At the time of dental assessment only 7 patients within this cohort 
were fit and well, other than their haematological malignancy. The other 30 
patients had additional comorbidities of varying severity, ranging from allergy 
to diagnoses of other cancers. Within the general population comorbidities 
are common and patients are at risk of developing more than one disease 
(Department of Health, 2014). The increasing use of reduced intensity 
conditioning has led to an increased number of HSCTs being provided for 
older patients and those with additional comorbidities (Alamo et al., 2005).  
In the current study, the number and range of medications taken 
varied considerably amongst patients at the time of the dental assessment 
and this was reflected in the individual nature of the participants. Some 
81 
 
patients required medication, other than their chemotherapy treatment, to 
manage other medical comorbidities.  
Obesity is an increasing health issue, with over 60% of the adult UK 
population being defined as obese in 2017 (Cancer Research UK, 2018, 
NHS Digital, 2019). As with the general population prior to transplant, the 
majority of patients in this cohort were overweight or obese, with only 11 
patients being regarded as a normal weight. In addition, obesity is a risk 
factor for cancer with 6% of cancers being caused by obesity (Cancer 
Research UK, 2018).  
At the time of the dental assessment appointment, there were 9 
patients who stated there were issues with their haematological status. One 
patient stated that they were pancytopenic (reduced red blood cells, white 
blood cells and platelets), and the other 8 stated they were 
thrombocytopenic. Prior to transplant, the expectation would be such that 
more patients had thrombocytopenia due to their chemotherapy treatment or 
the disease process (Burke et al., 2014, The Royal College of Surgeons 
England / British Society of Disability and Oral Health, 2018, Abed et al., 
2019). This suggests that the majority of patients were unaware at the time of 
the dental assessment of their potential increased risk of bleeding. 
Furthermore, it was vital where possible to review the haematological status 
of these participants at the dental assessment appointment prior to dental 
treatment. The haematological values for patients who had their 
haematological investigations at RLUH, could be accessed electronically 
from the Dental Hospital. The most recent results could be documented and 
used to plan dental care for the patient, in liaison with the medical team. 
82 
 
3.8.1.4 Haemato-oncological history 
The most prevalent haemato-oncological diagnosis was acute myeloid 
leukaemia (AML) (n = 20). Acute myeloid leukaemia (AML) is the most 
prevalent type of leukaemia to be diagnosed within the UK (3,100 cases 
diagnosed in 2015) (Cancer Research UK, 2016). Allogeneic HSCT is the 
standard of care for patients with a diagnosis of leukaemia, with first line 
treatment of myeloma and lymphoma being autologous HSCT or being 
dependant on clinical opinion (British Society of Blood and Bone Marrow 
Transplantation, 2013).  
Predisposing conditions to haematological malignancies such as 
myelodysplastic syndrome and chronic myeloid leukaemia, both of which can 
transform to AML, were noted for 7 patients in this cohort.   
The year of haematological diagnosis varied over 7 years. Although 
most patients in this cohort were diagnosed in 2015, there was one patient 
who received their initial diagnosis in 1999. This particular patient had a 
diagnosis of myelofibrosis, which was treated with chemotherapy until the 
allogeneic HSCT in 2016. On the other hand, there were patients within the 
cohort who were diagnosed and received their transplant in 2016. Other 
patients had received a previous autologous stem cell transplant in line with 
the standard of care (British Society of Blood and Bone Marrow 
Transplantation, 2013). These factors highlighted the complex individuality 
and varied nature of each case with regards to the diagnosis, prognosis and 
treatment.  
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3.8.1.5 HSCT 
Prior to the infusion of stem cells, patients who receive an allogeneic 
stem cell transplant undergo a preparatory conditioning regime. Conditioning 
involves a combination of chemotherapy treatment with or without radiation 
(TBI or RIC). The conditioning regime used for allogeneic HSCT is 
dependent on the donor available, whether they are matched or unmatched, 
related or unrelated, and the disease itself (European Society for Blood and 
Bone Marrow Transplantation, 2019a). The ideal conditioning regime for 
allogeneic HSCT is myeloablative, particularly in cases where the donor is 
unmatched or unrelated (European Society for Blood and Bone Marrow 
Transplantation, 2019a). However, myeloablative conditioning regimes have 
a higher risk of transplant related toxicity (TRT) limiting allogeneic HSCT to 
patients under 55 years of age who are in good medical health. Reduced 
intensity conditioning (RIC) regimes have been developed to reduce the TRT 
and are, therefore, effective conditioning regimes for patients over the age of 
55 years or with medical comorbidities (Weisdorf, 2017, European Society for 
Blood and Bone Marrow Transplantation, 2019a).  
Within this cohort of patients, only 3 patients received TBI, the 
remainder of the cohort received RIC due to their age and medical 
comorbidities.  
According to the European Society of Bone Marrow Transplantation, 
the ideal allograft donor is a sibling HLA-identical matched donor, yet this is 
only available in a third of cases worldwide (European Society for Blood and 
Bone Marrow Transplantation, 2019b). Therefore unmatched sibling donors 
and matched/unmatched unrelated donors are used. The greater the 
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disparity in HLA type between recipient and the unmatched donor the poorer 
the outcome post-HSCT. Within the cohort in this study, the majority of 
patients received stem cells from volunteer unrelated donors, however the 
degree of HLA match was unknown as it was not recorded for the purposes 
of this study (European Society for Blood and Bone Marrow Transplantation, 
2019b).  
3.8.1.6 Access to dental care 
 National guidance advises that, prior to chemotherapy, radiotherapy, 
HSCT and commencement of bisphosphonates, all patients receive a dental 
assessment and any necessary dental treatment. The aim is to reduce the 
risk of potential life-threatening infections during the period of 
immunosuppression and to reduce the potential for medication induced 
osteonecrosis of the jaw (The Royal College of Surgeons England / British 
Society of Disability and Oral Health, 2018).  
From this study the implementation of the care pathway between the 
Special Care Dentistry Department and the Stem Cell Transplantation and 
Cellular Therapy Unit (CCC) was encouraging, with 36 out of the 37 patients 
being referred for a dental assessment prior to HSCT. There also appeared 
to be positive engagement from the patients with only 2 patients cancelling or 
failing to attend their assessment appointments. Unfortunately, at present 
there is no evidence of referral uptake in the available literature.  
The reason for the cancelled appointments was unknown for this 
patient cohort. From the evidence, this may be due to conflicts with other 
hospital appointments, medical status or the proximity to their transplant date 
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(Elad et al., 2003, Yamagata et al., 2006, Durey et al., 2009, Nuernberg et 
al., 2016).  
3.8.1.7 Dental history 
 As expected the dental history of the patients within the study was 
varied, with 62% (n=22) of the patients reported having a General Dental 
Practitioner (GDP), and 22 patients stated that they were a regular attenders. 
NICE recall guidance was used to assess the attendance status of patients, 
with regular being classified as seeing a GDP within the last 24 months 
(National Institute for Health Care and Excellence, 2014). This was a higher 
rate of reported regular attendance than in other studies. Durey et al. in 2009 
conducted a retrospective evaluation and found that a regular attendance 
pattern was reported to be much lower at 29.8%. However, they found that 
the patients who saw a dentist regularly required fewer extractions than those 
who were considered irregular attenders (Durey et al., 2009).  
3.8.1.8 Dental examination 
 National guidance for this patient cohort recommends that all patients 
should have a full clinical dental examination prior to HSCT, unless there is 
justification not to, for example, patient refusal or unknown haematological 
status (The Royal College of Surgeons England / British Society of Disability 
and Oral Health, 2018). A clinical examination includes both extra- and intra- 
oral examination of the soft tissues, periodontal tissue assessment and basic 
periodontal examination together with notation, charting of the teeth present 
and relevant radiographic assessment.  
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 Radiographs are taken routinely at assessment for this patient cohort 
however data regarding radiographic assessment was not collected as part 
of this service evaluation.  
3.8.1.9 Dental pathology 
3.8.1.9.1 Periodontal disease  
 Periodontal disease and the associated periodontal pockets have 
been highlighted as possible reservoirs for opportunistic infections during and 
following HSCT (Barrach et al., 2015). Some studies have attributed the 
cause of infection and sepsis to pathogens involved in periodontal disease 
(Akintoye et al., 2002, Soga et al., 2008, Masaya et al., 2013). 
 In addition treatment of periodontal disease, oral hygiene instruction 
and supra- or sub- gingival scaling can improve gingival inflammation and 
reduce the severity and duration of mucositis following HSCT (Soga et al., 
2008, Gürgan et al., 2013).  
 Within the current sample, the majority of patients reported twice daily 
toothbrushing and oral hygiene status was recorded as good-excellent for 17 
patients. However, this was a subjective assessment of oral hygiene and so 
may vary between clinicians. Another study highlighted that although a 
patient reported good oral hygiene the majority of patients had poor oral 
health (Nuernberg et al., 2017). 
Screening for periodontal disease was completed using a basic 
periodontal examination (BPE) (British Society of Periodontology, 2019). For 
patients prior to HSCT the decision to complete a basic periodontal 
evaluation is dependent on the recent haematological values and state of 
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immunosuppression for the patient, platelet counts >50x109/L and 
neutrophils counts >1.0x109/L. For the cohort, BPE scores were recorded for 
68% of patients, with 14 patients having BPE scores of 2 indicating 
periodontal pockets <3.5mm with plaque retentive factors; overhanging 
margins or calculus deposits (British Society of Periodontology, 2019). There 
were 5 patients with BPE scores of 3, indicating periodontal pockets of 
3.5mm-5mm and a diagnosis of periodontal disease (British Society of 
Periodontology, 2019). There were 2 patients who presented with gingival 
recession.  
 In addition to BPE, there were 5 patients who presented with mobile 
teeth ranging from grade 1 (n=11) to grade 3 (n = 4) mobility, again 
suggesting a diagnosis of periodontal disease. Not all of the patients who 
presented with tooth mobility had a BPE score completed due to a likely lack 
of information regarding haematological status.  
 The number of patients presenting with a diagnosis of periodontal 
disease within this study was lower than what has been found from the 
literature where its prevalence ranged from 18.2% - 79.5% (Akintoye et al., 
2002, Durey et al., 2009, Nuernberg et al., 2017). However, one of these 
studies took into account presentation of bone loss on radiographs which 
was not completed for the current retrospective study (Akintoye et al., 2002). 
A further study highlighted that calculus deposits were the most common 
dental finding (Elad et al., 2003). Calculus alone was not documented in the 
current study as it depended on its recording in the clinical notes. In addition, 
the evidence also highlights that periodontal disease may be under reported 
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if it is not possible to complete a BPE screen due to haematological values 
being unavailable (Durey et al., 2009). 
 In the current study, no periodontal treatment, including supra-gingival 
scaling was completed for this cohort of patients, even though treatment was 
indicated from the BPE scores. Scaling and non-surgical periodontal 
treatment have been reported within the literature as routine treatments prior 
to HSCT (Elad et al., 2003, Gürgan et al., 2013, Soga et al., 2008). The lack 
of periodontal treatment prior to HSCT may be due to unstable 
haematological values of the patient, time limitations prior to transplant or 
possible lack of clinical knowledge on the impact that good periodontal health 
may have on oral complications post-HSCT.  
 In contrast, 76% of this patient cohort received OHI which has been 
suggested to be the most important recommendation of a pre-HSCT dental 
assessment (de Paula Eduardo et al., 2011). However, some studies have 
reported that patients deny receiving OHI prior to transplant or the advice 
provided is forgotten even when the patient has received a pre-HSCT dental 
assessment (Nuernberg et al., 2016, Nuernberg et al., 2017).  
3.8.1.9.2 Caries 
A further potential reservoir for infection during HSCT is carious teeth. 
Teeth with cavitated lesions are more difficult to clean and have the potential 
to harbour opportunistic pathogens such as candida. In addition, larger 
carious lesions can lead to pulpitis and pulpal necrosis, placing patients at 
risk of dental pain or periapical infection during HSCT (Barrach et al., 2015).  
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Teeth with dental caries can be deemed restorable or unrestorable 
depending on the amount of coronal structure remaining. The treatment 
options for a tooth are dependent on its restorability, associated symptoms 
and evidence of periapical pathology or associated infection. All of these 
factors are taken in to account when treatment planning patients prior to 
HSCT. The treatment may include simple restorations, endodontic treatment 
and/or extractions though the treatment plan can be limited by the time 
available (Bogusławska-Kapała et al., 2017).  
In the current study, 56% of the sample presented with caries, with a 
total of 58 carious teeth. This was higher than in other studies reporting 
caries experience prior to HSCT, with a number of patients presenting with 
caries ranging from 7.9% to 52%. However, these studies were conducted in 
different countries and had varying sample sizes (Elad et al., 2003, Durey et 
al., 2009, Ertas et al., 2014, Mawardi et al., 2014). In addition to carious 
teeth, there were two patients within the current sample who presented with 
retained roots. Evidence of periapical pathology was noted for 4 patients, one 
of whom presented with a radicular cyst in the upper right quadrant.  
3.8.1.9.3 Prevention advice and dental treatment 
Prevention advice for these patients is fundamental given the high 
incidence of dental caries in the cohort. The increased caries risk following 
the HSCT process results from an increased consumption of carbohydrate 
based food or drink. Additionally post-transplant complications such as the 
experience of mucositis, oral GvHD and xerostomia can increase caries risk 
following transplant. Therefore provision of OHI and diet advice including 
additional fluoride use is recommended (Public Health England, 2017b, The 
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Royal College of Surgeons England / British Society of Disability and Oral 
Health, 2018). However, whilst the haematological values of patients are 
unstable and the patients are at greater risk for infections and bleeding, the 
Stem Cell Transplantation and Cellular Therapy Unit (CCC) advise patients 
against the use of interdental cleaning. Therefore it is important that patients 
understand the importance of effective toothbrushing throughout transplant, 
and that OHI is reiterated following HSCT to include the use of interdental 
cleaning aids.   
Within the Department of Special Care Dentistry, the diet advice is 
tailored to the advice given by the dieticians in the hospital. Weight 
maintenance and weight gain following transplant has been highlighted as 
factors that may influence both morbidity and mortality (European Society for 
Blood and Bone Marrow Transplantation, 2019e). Patients are often 
encouraged to have a high protein/high carbohydrate diet (HPHC), be fed via 
nasogastric tube or consume dietary substitutes during the transplant period. 
HPHC and dietary substitutes have an increase carcinogenicity, however are 
necessary during this period, therefore dental diet advice is focused on 
informing patients of the increased caries risk and to rinse with water 
following build up drinks.  
Although the majority of patients in the current study received oral 
hygiene instruction and the prescription of high strength fluoride toothpaste, 
within the cohort only 18 patients received documented diet advice, therefore 
would not be aware of the increased risk of caries. 
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Ten patients received simple restorations that were either definitive or 
temporary, with 8 patients having extractions of one or more teeth. The 
operative treatment provided overall is similar to what has been documented 
in the literature; with placement of restorations ranging from 21.6 – 45.6% 
and extraction experience ranging from 19.5% - 40.9% (Elad et al., 2003, 
Durey et al., 2009, Mawardi et al., 2014). Endodontic treatment is a further 
option for restoring teeth and it is possible to provide this for transplant 
recipients (Durey et al., 2009, Braga-Diniz et al., 2017). For this cohort no 
endodontic treatment was provided, however lack of coronal seal and/or 
restorability of the tooth or time limitations to transplant may explain why this 
treatment option was not more readily available.  
Antibiotic cover prior to extractions is recommended, in liaison with the 
oncology team, due to the immunosuppressive nature of the patients within 
this cohort, although there is currently no strong evidence to suggest any 
benefit in reducing infection risk. National guidance advises following the 
American Heart Association (AHA) guidance for infective endocarditis, which 
suggests a 2g dose of amoxicillin 1 hour pre-operatively (or 2g cephalexin, 
600mg clindamycin or 500mg clarithromycin if the is a penicillin allergy), 
particularly if the patient has neutrophils less than <2.0x109 (Morimoto et al., 
2004, Wilson et al., 2007, Yamagata et al., 2011, The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018). Other 
studies have suggested not using antibiotic cover unless neutrophil counts 
are <0.5x109 and have not found any additional infective complications (Elad 
et al., 2003, Pelinsari et al., 2014).  
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For the cohort in the current study, 7 of the 8 patients received 
extractions with pre-operative antibiotic cover, however no standardised 
antibiotic regime was followed. Although amoxicillin was the antibiotic of 
choice the dose of the drug was usually only 1g. The second line drug, if the 
patient had an allergy to penicillin, was metronidazole. This varies from the 
guidance available and highlights the need for a standardised antibiotic 
protocol within the department, although the evidence to support the benefit 
of antibiotic prophylaxis for patients is limited (Wilson et al., 2007, The Royal 
College of Surgeons England / British Society of Disability and Oral Health, 
2018). 
 Patients who had extractions required an additional postoperative 
appointment to review healing and ensure that epithelialisation had occurred 
prior to transplant. Therefore, timing of dental treatment needs to be 
considered thoroughly so that the transplant is not delayed. National UK 
guidance recommends the review occurs 10 days following extractions. In 
the current study the average number of days to review healing was 12.1 
days, with some patients required more than one review appointment before 
epithelialisation occurred (The Royal College of Surgeons England / British 
Society of Disability and Oral Health, 2018). Unfortunately, this retrospective 
study did not capture if there were any delays to patients receiving their 
transplant due to delays with the dental treatment.  
3.8.1.9.4 Timing of referral and treatment 
 Currently there is no consistent guide for the timing of dental referral 
prior to transplant other than the recommendation that there are at least 10 
days for healing following extractions (Durey et al., 2009). Some authors 
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describe the referral pattern as “hasty” and thus limits the time available for 
dental treatment, other authors have suggested that referrals made 4-6 
weeks prior to transplant would reduce these limitations but that would be 
dependent on the amount of dental treatment required and availability of 
appointments (Elad et al., 2003, Yamagata et al., 2006, Durey et al., 2009).  
For this cohort the dental referral was made on average, 7 weeks prior to 
transplant however only 6 patients had their full dental treatment plan 
completed. From reviewing the data, the waiting times for assessment and 
treatment were prompt being 3 weeks and 1 week respectively. There was 
an average wait of 4 weeks from discharge from SCD to HSCT during which 
additional dental care could have been provided. Therefore, closer liaison 
with the Haem-oncology team is required to assess the time available in 
order to increase the likelihood of stable oral health.  
3.8.1.10 Medical outcomes 
 There are a number of early and late complications that can affect 
patients following allogeneic HSCT some of which can impact upon overall 
survival.   
Following the HSCT procedure patients remain in hospital for a period 
of time, usually up to 6 weeks (Burke et al., 2014). The length of hospital stay 
was reported to range from 14 – 43 days from the point of transplant to 
discharge. This is similar to that described in the literature with Toro et al 
(2016) reporting hospital stays ranging from 3 – 52 days and Mawardi et al 
(2016) a range of 7 – 22 days.  
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Patients remain in isolation following HSCT due to their state of 
immunosuppression, until signs of engraftment are noted. Engraftment is the 
stage where new bloods cells are formed within the bone marrow including 
platelets and neutrophils. Both platelet and neutrophil recovery are important 
factors in the overall survival for these patients. Platelet recovery is defined 
as platelet count of >20x109/L for 3 consecutive days, neutrophil recovery is 
defined as neutrophils >0.5x109/L over 3 consecutive days (European 
Society for Blood and Bone Marrow Transplantation, 2017b).  
Delayed platelet recovery is likely to occur with higher risk disease and 
mismatched HLA donors and results in reduced overall survival and 
increased non-relapse mortality rates (Poon et al., 2013, Akahoshi et al., 
2018). Delayed neutrophil recovery can place patients at increased risk of 
infection and is often managed by the infusion of growth factors, in particular 
granulocyte colony stimulating factor (Mineishi et al., 2001). A further 
complication at the time of neutrophil engraftment is engraftment syndrome, 
a clinical condition where the patient presents with fever, rash, oedema, 
weight gain and reduced renal and liver function or encephalopathy (Spitzer, 
2001, Chang et al., 2014, European Society for Blood and Bone Marrow 
Transplantation, 2019c). Engraftment syndrome is usually self-limiting, 
however can lead to multi-organ failure (Spitzer, 2001, Chang et al., 2014, 
European Society for Blood and Bone Marrow Transplantation, 2016).  
Within this patient cohort for all but 2 patients platelet recovery 
occurred and only one patient failed to experience neutrophil recovery. There 
were 5 patients who experienced engraftment syndrome and required 
appropriate medical management.  
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3.8.1.10.1 Feeding regime and obesity 
As previously mentioned, nutritional status of a patient and weight 
maintenance has a positive impact on a patient’s recovery from transplant, 
risk of infections and overall survival (European Society for Blood and Bone 
Marrow Transplantation, 2019e). During the transplant process, medical 
interventions such as chemotherapy, TBI and radiotherapy along with post 
HSCT short term complications such as mucositis and aGvHD place 
increased metabolic demands on the patient, with malnutrition being 
highlighted as a major challenge of HSCT (Espinoza et al., 2016). 
Oral/enteral feeding regimes are preferable and in the case of 
gastrointestinal GvHD then parenteral nutrition is necessary (European 
Society for Blood and Bone Marrow Transplantation, 2019e). Currently, there 
are no studies to suggest which additional feeding regime dictates better 
survival rates (Espinoza et al., 2016).  
 Within the Stem Cell Transplantation and Cellular Therapy Unit 
(CCC), nutritional support is readily available with patients having a 
nutritional assessment with the dietician prior to and during transplant. If 
patients are unable to or struggle with enteral feeding then the use of 
nasogastric tubes or total parenteral nutrition (TPN) is encouraged. Within 
the current sample, the feeding regime varied due to the individual nature of 
each patient. In the 26 patients who had nasogastric feeding, this was often 
in combination with a further feeding regime. Weight maintenance also varied 
with some losing whilst other gaining weight.  
At the point of discharge from hospital, dieticians could play a role in 
reiterating diet advice for a patient’s future general and dental health. This 
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would include advice about frequency of eating and consumption of foods 
with cariogenic potential, to help reduce the caries risk for this patient cohort 
(Public Health England, 2017b). 
3.8.1.11 Oral complications of HSCT 
 Oral complications can be an early or late consequence of the HSCT 
process.  
3.8.1.11.1 Mucositis  
 Mucositis is a readily recognised complication of the conditioning 
process regardless of whether the recipient has had MAC or RIC (Legert et 
al., 2014, Petti et al., 2013).  
 Within the existing literature, improvements in oral hygiene and 
periodontal health have resulted in a reduction in the severity and duration of 
mucositis (Da Silva Santos et al., 2011, Kashiwazaki et al., 2012, Gürgan et 
al., 2013). Therefore, this is seen as an important factor in improving pain 
symptoms and quality of life in the immediate post-HSCT process and further 
highlights the importance of a pre-HSCT dental assessment to ensure 
appropriate oral hygiene advice. In addition, continued advice and support 
with oral hygiene has been shown to be necessary to reduce oral discomfort 
throughout HSCT (Borbasi et al., 2002).  
 Furthermore, studies have highlighted different treatment methods in 
order to improve mucositis symptoms. These include mouthwashes such as 
doxepin and palmiferin, with the increasing use of LLLT showing positive 
impacts on patients’ quality of life whilst experiencing mucositis (Epstein et 
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al., 2008, Khouri et al., 2009, Sonis, 2009, Elad et al., 2011, Silva et al., 
2015, Bezinelli et al., 2016).  
 There are a number of scoring systems available to quantify the 
symptoms and severity of mucositis that would allow consistent recording 
and more individualised treatment. These include the World Health 
Organisation Mucositis Scale and the NCI Common Toxicity Criteria both of 
which combine clinician based observations with a measurement of patient 
function and ability to eat (World Health Organisation, 1979, National Cancer 
Institute, 1999, Sonis, 2011). The Oral Mucositis Assessment Scale (OMAS) 
developed in 1996 aimed for a reliable and valid tool for scoring mucositis for 
the purposes of research (Sonis et al., 1999, Sonis et al., 2001).   
 Within the current cohort the recording of mucositis was variable. 
Mucositis was diagnosed for 17 of the patients, however, there were other 
records which described a sore or ulcerated mouth with no formal 
documented diagnosis. There was no consistent mucositis scale in use, with 
some staff using numerical values and others describing mucositis as mild to 
severe. In addition, although not recorded within the study, the main 
treatment for mucositis, within the unit, was the use of diluted chlorhexidine 
mouthwash and benzydamine hydrochloride to manage symptoms. In 
addition the unit recommend the use of ice cubes during chemotherapy 
treatment, to promote vasoconstriction and reduce mucositis symptoms. The 
use of a consistent mucositis symptom scale would improve patient record 
keeping and the provision of treatment for mucositis following HSCT. 
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3.8.1.11.2 Xerostomia   
A further common oral complication of HSCT documented within the 
literature is that of xerostomia (Brand et al., 2009, Laaksonen et al., 2011, 
Mauramo et al., 2017). Again, a consequence of the conditioning regime prior 
to transplant, xerostomia can persist for up to 12 months following HSCT and 
therefore HSCT recipients should be considered as high risk for 
hyposalivation (Laaksonen et al., 2011, Mauramo et al., 2017). Again the 
findings suggest that the symptoms of hyposalivation improve with time with 
fewer recipients complaining of a dry mouth after 12 months post-HSCT 
(Laaksonen et al., 2011, Mauramo et al., 2017).  
Xerostomia is a risk factor for dental caries and therefore for individuals 
where hyposalivation is a risk factor, targeted prevention advice is of upmost 
importance. Studies have shown an increase in caries rate following HSCT 
and thus highlighted the need for continued dental surveillance and 
prevention advice to reduce the risk of dental caries (Castellarin et al., 2012, 
Ertas et al., 2014, Public Health England, 2017b, The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018).  
Xerostomia was not recorded as a frequent complication of HSCT for this 
retrospective patient cohort, with it only being documented in 4 cases. This 
study only collected data of the complications presented during the inpatient 
period and so whether the patients experienced xerostomia as a long-term 
complication was unknown. It was also unknown whether the recording of 
xerostomia was an objective or subjective assessment of the patient.  
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3.8.1.11.3 Other oral complications 
Other oral specific complications for HSCT patients include experience 
of oral candida infections documented for 10 patients in this sample, and 
dysguesia, documented for none of the patients within this sample (Brand et 
al., 2009).  
3.8.1.12 Graft versus Host Disease 
 GvHD presents as a short and long term complication of allogeneic 
HSCT (Filipovich et al., 2005, Imanguli et al., 2008, Duncan et al., 2015). 
Acute GvHD presents in the initial phase following allogeneic HSCT whilst 
chronic GvHD is diagnosed 100 days following transplant, based on the 
presenting signs and symptoms. GvHD presents as a painful mucocutaneous 
rash that can affect multiple organ systems, including the gastrointestinal 
tract, liver and skin (Petti et al., 2013, Scully, 2014, The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018). 
Chronic GvHD can affect the overall mortality of patients following HSCT 
(Mays et al., 2013, Duncan et al., 2015). The presentation of GvHD within the 
oral cavity, in particular the mucosa and salivary glands results in restricted 
mouth opening and xerostomia. Therefore there is an increased risk of dental 
caries for these individuals (Castellarin et al., 2012, Mays et al., 2013).  
 A severe complication of GvHD is its potential for malignant 
transformation. Multiple case reports have highlighted the presentation of oral 
squamous cell carcinoma as a late consequence of allogeneic HSCT (Petti et 
al., 2013, Katz et al., 2014, Torres-Pereira et al., 2014, Tsushima et al., 2015, 
Weng et al., 2017).  
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 The consequences of GvHD, mucosal pain, xerostomia, dental caries 
and its potential malignant transformation, once again highlight the need for 
continued oral and dental surveillance following allogeneic HSCT either in the 
primary of secondary dental setting (Castellarin et al., 2012, Katz et al., 2014, 
Torres-Pereira et al., 2014, Tsushima et al., 2015, Weng et al., 2017, The 
Royal College of Surgeons England / British Society of Disability and Oral 
Health, 2018).  
 There were 20 patients in this sample who experienced acute GvHD 
with both the site and severity being recorded well. Again for cGvHD the 
diagnosis was recorded well but the NIH scoring system was not used 
frequently (Filipovich et al., 2005). This scoring system has been 
recommended by the EBMT (MED A forms) (European Society for Blood and 
Bone Marrow Transplantation, 2017b). With both acute and chronic forms of 
GvHD currently there is no separate score for oral presentation of GvHD and 
it is likely that this is combined with gut as an organ system. 
3.8.1.13 Infections  
 Infections caused by bacterial, fungal or viral organisms are a severe 
and life threatening complication of the HSCT process attributed to the 
neutropenic status of the patient. Neutropenic sepsis is defined as a 
universal complication of HSCT as a result of the low neutrophil counts and 
the high levels of bacteria in the bloodstream. In addition, due to the depleted 
haematological status, fever is often the only sign of infection as the body is 
unable to form pus, abscess or infiltrates. Therefore, prophylactic antibiotic 
treatment is paramount for patients during their inpatient stay (European 
Society for Blood and Bone Marrow Transplantation, 2019d).  
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 As stated previously, dental assessment and treatment is 
recommended prior to transplant to reduce the risk of odontogenic infections 
and potential sepsis in the transplant period. However, the evidence to 
suggest oral causes for sepsis is limited and somewhat contradictory. One 
study reviewed the micro-organisms that had caused sepsis and that it was 
possible that their origin was from the oral cavity including the periodontal 
tissues, however the authors did not find a statistical association between 
poor oral health and septicaemia (Akintoye et al., 2002). A further study 
highlighted that dental extraction sites and periodontitis were the preceding 
causes of sepsis. However, this was only 2 individuals from a cohort of 37 
(Masaya et al., 2013). Soga et al. presented a case of a drug resistant 
bacteria; S.Maltophilia, from the gingivae crevice and again highlighted that 
periodontal tissues were a potential reservoir for infective organisms (Soga et 
al., 2008).  
In contrast, other studies comparing groups of patients receiving pre-
HSCT dental treatment with those that had not found none of the patients 
within the cohorts contracted a systemic infection of odontogenic origin 
(Melkos et al., 2003, Yamagata et al., 2006, Yamagata et al., 2011).    
For the patients within the current study, sepsis was documented for 25 
patients, 6 of whom had detailed documentation of neutropenic sepsis. The 
causal organism was documented, albeit poorly, in only 11 cases, with no 
odontogenic pathogen being clearly identified as the cause of sepsis. 
Pathogens identified included pneumococcus, VRE bacteraemia, candida 
and cytomegalovirus. Antibiotic prophylaxis was documented for 20 of these 
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patients. Patients were also at risk of other infections, alone or in 
combination, with viral infections being the most common.  
3.8.1.14 Overall survival  
Although curative, allogeneic HSCT is associated with multiple life 
threatening long-term complications, including chronic GvHD, with the 
majority of deaths occurring within 2 years of transplant (Wingard et al., 
2011, Shimoni et al., 2016). Survival following HSCT is dependent on 
multiple factors out with the scope of this study, including preliminary 
diagnosis, degree of HLA match, experience of GvHD and relapse (Wingard 
et al., 2011).  
 Following the initial 2 year period, 10 year survival rates have been 
quoted as between 82% - 90% (Wingard et al., 2011). Another study quoted 
10 year survival rates for patients with leukaemia as 71% - 73% after the first 
two years following HSCT, however this decreased significantly if the disease 
relapsed (Shimoni et al., 2016).  
 The survival rate for this cohort of patients is represented well within 
the Kaplan-Meier graph (Figure 3) and highlights the majority of deaths for 
this cohort occurring within the first 2 years.  
  Currently the European Society of Bone Marrow Transplantation 
reviews survival at 100 days post-HSCT and 1 year post-HSCT (European 
Society for Blood and Bone Marrow Transplantation, 2017b). For this group 
of patients in this study, 9 patients had experience of disease relapse within 
(on average) a year of their HSCT. At 100 days post-HSCT, 6 patients had 
died with a further 10 patients dying within a year post transplant. The most 
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common primary reason for death was transplant related, however, sepsis 
was the most common secondary cause of death, again highlighting the high 
risk of infection for this cohort.  
3.8.1.15 Overall outcomes  
Unfortunately, the cohort in this retrospective study was too small to 
compare post-transplant medical complications with dental treatment, as 
there were only 3 patients who did not attend a dental assessment 
appointment and therefore did not receive oral hygiene advice or a dental 
intervention.  
Reviewing the data overall, there did not appear to be any difference 
in complications between those who had good dental health and only 
required oral hygiene instruction, those who had their dental treatment 
completed and those who only had part of their treatment plan completed. In 
a study by Melkos et al. (2003) there was no difference in HSCT outcomes 
for those patients who received dental intervention to those who did not 
(Melkos et al., 2003). In addition, another study evaluated post-transplant 
complications following HSCT in those who were dentate compared to 
edentulous found no difference in complications between the groups (Toro et 
al., 2016).  
3.8.2 Limitations of the study 
 There are a number of limitations to this study, the most pertinent 
being its retrospective nature. Retrospective studies rely upon the relevant 
information being recorded, documented and available. Within this study, 
there were examples of suboptimal record keeping, with data missing from 
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both medical and dental records. In addition, within the medical records, 
there was no standardised scoring system for mucositis and so this was not 
recorded clearly. Likewise, although the MED A form requires a NIH GvHD 
score to be completed this was rarely recorded.  
 Furthermore, much of what was recorded in patient records was 
patient reported and relied upon the patient being open and honest for 
example about their dental attendance and oral hygiene regime. The 
literature suggests that patients will report better oral hygiene than what is 
found clinically (Nuernberg et al., 2017). Likewise in the medical records 
assessment was patient reported and therefore subjective with patients 
recorded as complaining of a sore mouth or a dry mouth but with no record of 
a clinical assessment or formal diagnosis.  
 An additional limitation in regard to record keeping was the change 
within the Stem Cell Transplantation and Cellular Therapy Unit (CCC) paper 
records to electronic patient records. Although the paper records were to be 
available via scanning software, not all of the pages of the paper records had 
been scanned at the time of data collection and therefore this may account 
for the missing data. Furthermore, when the use of PENS commenced there 
was missing electronic data but this decreased with time, as staff were able 
to better navigate the system. In order to attempt to improve data collection, 
data was collected from multiple electronic sources and the information 
compared to try and allow for a more robust data collection. In addition, 20% 
of the patient records were rechecked for errors to validate the data collection 
process of which none were observed. 
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 A further limitation of this study was the sample size. On average 
around 40 allogeneic HSCTs occur within the Stem Cell Transplantation and 
Cellular Therapy Unit (CCC) each year and in 2016, 37 allogeneic HSCT 
were completed. The year 2016 was selected as this was the first year the 
unit was collecting data on the MED A forms. Data collection for 2017 would 
not have been possible as at the time of data collection (July 2018) not all of 
these patients within this cohort would have reached 1 year post transplant. 
Collection of data for subsequent years was not possible within the time 
constraints of this study.  
 The limited sample size meant that only descriptive statistics were 
possible for this sample and therefore no statistical associations were made 
on advice of the Senior Biostatistician (GB).  
Moreover, this study did not evaluate the oral and dental health following 
transplant. Within the literature there are reports that dental pathology is 
often noted post-transplant, due to the complications and side effects of 
medical management, such as xerostomia, mucositis and GvHD. Studies 
have found increases in DMFT and GvHD associated rampant caries within 
this patient cohort (Castellarin et al., 2012, Ertas et al., 2014).  
A recognised long-term oral complication of HSCT is the malignant 
transformation of oral GvHD to squamous cell carcinoma, highlighting the 
increased importance of continued dental surveillance post-HSCT. Current 
guidance recommends that HSCT recipients are seen within the specialist 
dental setting for the first 6 months following transplant however, after which 
if their haematological status is stable, they can be assessed and treated in 
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the primary dental care setting (Bos-den Braber et al., 2015, Barrach et al., 
2015, The Royal College of Surgeons England / British Society of Disability 
and Oral Health, 2018).  
A shared care and multidisciplinary approach to managing this cohort of 
patients would be ideal in reducing barriers such as access to care (Elad et 
al., 2003, de Paula Eduardo et al., 2011, Elad et al., 2015). For example, if a 
patient from the Isle of Man required simple restorations and their 
haematological status was suitable then they could access treatment closer 
to home. However, if more complex dental treatment was required or the 
haematological status was unstable then treatment in a specialist setting 
would be indicated.  
Completion of the study highlighted numerous confounding factors which 
would need to be considered in future studies to highlight the statistical 
association between pre-HSCT dental assessment and post-HSCT medical 
outcomes. For this study the confounding factors have been presented in a 
directed acyclic graph (see section 3.7.10). 
3.8.3 Strengths of the study 
 Although there were multiple limitations to the study, there are also 
merits in its completion. The completion of this study has promoted further 
discussion between the Stem Cell Transplantation and Cellular Therapy Unit 
(CCC) and the Special Care Dentistry Department. More importantly, 
knowledge has been gained as to what would benefit future patients, and so 
service improvements can be developed and implemented, such as 
production of specific information leaflets on the dental component of the 
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HSCT patient pathway and the preventative, dietary and oral hygiene advice 
required throughout the transplant period and beyond.  
 In addition, the study has reassured the dental team that provision of 
care is beneficial to patients and was not causing harm. However, from the 
study it was apparent that there was more time to complete dental treatment 
prior to HSCT than the treating dental team realised. Therefore, more 
effective communication is required with patients and their medical team.  
 Attempts were made to ensure that the data collected was reliable and 
valid, multiple data sources were used in obtaining a robust data set and 
ensured minimal information was missed. In addition, 20% of the patient 
records were rechecked by CW-D to ensure intra-rater reliability and 50% of 
the dental cases notes were checked by a research supervisor (ST), no 
additional data was added to the collection during these checks.  
 An important strength of this study was the creation of a DAG (section 
3.7.10), this will aid future research in adjusting for confounders within this 
cohort of patients to hopefully aid in confirming or rejecting a causal effect 
between dental treatment and HSCT outcome.  
3.8.4 Application to clinical practice 
Currently it would be difficult to generalise these results to the whole 
population of patients receiving allogeneic HSCT given the sample size of 37 
patients. Locally, these results will be used in discussions between the Stem 
Cell Transplantation and Cellular Therapy Unit (CCC). From this research, it 
has become apparent that closer liaison with Haem-oncology team is 
necessary to ensure that the time available prior to transplant is utilised 
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thoroughly with more patients completing the dental treatment required. 
However, increasing the use of the dental service for these patients would 
require a review of the service level agreement between the two 
departments.  
There is evidence to suggest that improvements in periodontal and 
oral health can improve outcomes, namely reducing the severity and duration 
of mucositis, therefore increasing the focus on prevention and periodontal 
health, within the time available prior to transplant, may improve patients 
experience and knowledge around oral complications (Da Silva Santos et al., 
2011, Kashiwazaki et al., 2012, Gürgan et al., 2013).  
The production of patient information leaflets would be helpful to 
highlight why a pre-HSCT dental assessment is advised and what treatments 
a patient might expect prior to and following HSCT. A further information 
leaflet that covers prevention advice would also be helpful in reminding 
patients of the positive impact of good oral hygiene experience on their 
transplant.  
Further discussion between the dental and medical teams is 
necessary to standardise a protocol for antibiotic prophylaxis prior to dental 
extractions. Currently, there is no standardised protocol used however within 
the literature and guidance, the AHA guidance for infective endocarditis is 
cited, prescribing 2g amoxicillin 1 hour prior to treatment with adjustments if 
there is a penicillin allergy (Wilson et al., 2007, The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018). A 
standard protocol would ensure all patients receive the same standard of 
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care, although there is limited evidence to suggest that antibiotic prophylaxis 
prevent infections following extractions.  
 An additional improvement to the patient pathway would be re-referral 
following transplant, particularly within the first 6 to 12 months or if the 
haematological status has not stabilised. This would allow reiteration of diet 
and oral hygiene advice, monitoring of oral GvHD and oral cancer 
surveillance. It would also give the opportunity to discuss where future dental 
treatment could be completed. Again, this would entail a review of the current 
care pathway and the service level agreement between the two departments.  
 With this in mind, education of specialist dentists, General Dental 
Practitioners and the Haem-oncology medical team is important and 
necessary to establish what treatment is safe to provide and for whom in 
primary and secondary care environments. This would potentially ease 
access to dental care for this patient cohort, reducing demands on their time 
and enable them to be treated closer to home with a dentist who is familiar to 
them. In addition, further education of the patient’s Haem-oncology team in 
oral health and hygiene would allow them to encourage patients to continue 
good oral hygiene practices during their HSCT. 
 From a medical perspective, consistent standardised recording of 
mucositis and GvHD, using already recognised proformas, throughout the 
patient journey would ensure correct diagnosis and treatment of these oral 
complications and should be considered for patients going forward.  
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3.8.5 Future research 
 This study has highlighted the difficulties in completing research in this 
patient cohort due to their complex nature. Possible future studies that could 
improve the evidence base for these patients would include: 
1. An initial survey of primary and secondary dental care providers 
(community and hospital) to assess whether they have a standardised 
care pathway for haem-oncology patients and the dental treatment 
provided.  
2. Once centres with a care pathway are identified then a prospective 
longitudinal multicentre study could be completed over a number of 
years to investigate the short- and long-term outcomes of dental 
treatment on HSCT. The DAG developed in this study would be a 
useful tool in highlighting the variables that require adjustment 
(Appendix 10).  
3. A different research approach could involve quality of life 
questionnaires and qualitative work to view what patients regard as 
important during this time and the dental impact prior to HSCT, during 
HSCT and following HSCT.  
4. A further possible future study would be a randomised controlled trial 
whereby one group of patients receives pre-HSCT dental assessment 
and treatment and the other does not. However, this would still be 
limited by the number of confounders and the associated ethical 
dilemmas as in theory dental treatment prior to transplant reduces the 
risk of infection for this patient group.  
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Locally, the results of this study have promoted discussion around this 
care pathway and improvements have been suggested, therefore in the 
future possible re-evaluation of the service would continue to assess if a 
positive impact is being made for patient care. 
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3.9 Conclusion  
Overall, the study highlighted a positive uptake of the care pathway by 
the Stem Cell Transplantation and Cellular Therapy Unit (CCC) with the 
majority of patients being referred for a pre-HSCT dental assessment and 
any necessary treatment. However, issues with communication with the 
medical team were highlighted and overall, there was more time prior to 
transplant to allow patients to have their dental treatment completed than 
understood by the dental team.  
Within this cohort, although most patients experienced sepsis in the 
period directly following HSCT there was no evidence to suggest this was 
due to an organism of odontogenic lineage. Conversely, the number of 
patients who experienced sepsis highlights their high risk of contracting an 
infection due to their immunosuppressive status. Therefore, there remains a 
need to provide necessary dental treatment prior to transplant, removing 
possible areas of pathology and reducing risk of sepsis for this cohort, 
despite the evidence that sepsis is likely to be associated with other 
pathological sources.  
As expected, patients experienced post-HSCT oral complications 
including mucositis and xerostomia. Providing necessary preventative advice, 
including diet advice at assessment is necessary to improve their oral health 
status prior to, during and following transplant to reduce the severity of these 
conditions and maintain good oral health. Furthermore, patients should 
receive the necessary advice and information regarding the experience and 
consequences of oral complications: xerostomia, oral chronic GvHD, 
dysguesia and stomatitis and additionally the associated increased caries 
113 
 
risk and malignant changes of oral GvHD throughout and following the HSCT 
process. From a dental perspective these complications highlight the need 
for continued dental surveillance and preservation of good oral health 
following transplant.  
The study was limited in its retrospective nature, with some elements of 
the data being poorly recorded or missing. Prospective longitudinal 
multicentre studies are required to ascertain the actual impact of dental 
health and provision of pre-HSCT dental assessment for this patient cohort. 
The use of the directed acyclic graph (Appendix 10) within these studies 
would be useful in adjusting for the number of confounding factors that are 
present for this complex cohort of patients.  
Although this study is not able to quantify the impact of dental 
assessment and treatment pre-HSCT for this patient cohort, it does highlight 
that these patients do present with dental pathology and experience post-
HSCT oral complications. Therefore, continuing to provide dental care for 
these individuals is necessary to reduce the infective risk and attempt to 
improve oral symptoms directly following transplant. Improved liaison with the 
patients’ multi-disciplinary team is necessary to ensure opportunity to 
complete dental treatment pre-transplant is maximised, taking into account 
medical status, need for transplant but also their own decisions when 
presented with the dental treatment plan and the risks and benefits of and 
patient choices regarding dental care.  
Further studies for this patient cohort are required to quantify the impact 
of dental treatment on a patient’s medical outcome and quality of life. 
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4 Chapter 4: Describe and explore a patient’s 
outlook on dental care in the context of their 
medical diagnosis and treatment prior to and 
following allogeneic HSCT 
4.1 Introduction 
Chapter 3 evaluated the dental service that is currently being provided 
for patients prior to allogeneic HSCT and the oral and medical complications 
that this cohort of patients face following the treatment.  
Chapter 4 aims to gain a patient’s perspective on both dental treatment 
and medical complications through semi-structured interviews and quality of 
life questionnaires at a point of medical stability following allogeneic HSCT. 
The study had a mixed methods approach with qualitative methods 
being selected to enable an in-depth understanding of the topic area and 
explore human experiences and behaviour (Braun and Clarke, 2006), and 
quality of life questionnaires providing a quantitative snapshot of the patients 
view of their current state and quality of life.  
4.2 Title  
Describe and explore a patient’s outlook on dental care in the context of 
their medical diagnosis and treatment prior to and following allogeneic HSCT. 
4.3 Objectives  
Explore the views of patients that had received an allogeneic stem cell 
transplant and a special care dental assessment, focusing on: 
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1. The dental care pathway. 
2. Oral and dental complications. 
3. Quality of life after allogeneic stem cell transplant. 
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4.4 Methodology 
4.4.1 Study design 
The second part of the research project explored patients’ views of 
their experiences of the care pathway between the Stem Cell Transplantation 
and Cellular Therapy Unit, Clatterbridge Cancer Centre (CCC), Liverpool and 
the Special Care Dentistry Department, Liverpool University Dental Hospital, 
and the physical and emotional complications experienced during and 
following the HSCT process.  
This study involved a mixed methods design, with participants 
completing validated quality of life questionnaires prior to a face-to-face semi-
structured interview.  
The quantitative quality of life questionnaires used in this study were: 
1. Functional Assessment of Cancer Therapy - Bone Marrow 
Transplantation (FACT-BMT) (Appendix 11). This questionnaire 
assesses patients’ views on their physical well-being, social/family 
wellbeing, emotional wellbeing, functional wellbeing and if there are 
any additional concerns (McQuellon et al., 1997, FACTIT, 2010, 
Bassim et al., 2014).  
2. Lee Chronic Graft vs Host Disease Symptom Scale (Appendix 12). 
This self-reported questionnaire requests patients state if they have 
experienced any problems in the last month with their skin, eyes and 
mouth, breathing, eating and digestion, muscles and joints, energy 
and any mental or emotional problems (Lee et al., 2002, Merkel et al., 
2016). 
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3. Oral Health Impact Profile-14 (OHIP-14) (Appendix 13). This 
questionnaire evaluates functional limitations, physical pain, 
psychological discomfort, physical disability, psychological disability 
and social disability in relation to a patient’s teeth, mouth or dentures 
(Slade, 1997, Slade, 1998). 
These questionnaires allowed for a comprehensive evaluation of a 
patient’s quality of life with regards to their experience of the allogeneic bone 
marrow transplant, their experience of cGvHD, and their oral health.  
For both FACT-BMT and Lee cGvHD symptom score permission was 
sought from their publishers. Email correspondence and agreement for its 
use was received from Dr Lee and the study was registered online with 
FACT-IT by the principal investigator (AP).  
4.4.2 Population and sampling 
For this study patients were sampled from a Late Effects Clinic within 
the Stem Cell Transplantation and Cellular Therapy Unit (CCC), Liverpool. 
Patients were considered for inclusion if they were medically stable, had 
received an allogeneic stem cell transplant and had been assessed and/or 
had received treatment in the Special Care Dentistry Department.  
Ideally for qualitative research a purposive sample is used in that the 
research team decides who to include within the study, aiming to recruit a 
variety of participants with different backgrounds, providing a range of views 
and experiences (Ritchie et al., 2014b). A sample framework was developed 
(Appendix 14) to allow monitoring of patient selection and aim to reduce bias. 
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However, due to the low number of patients receiving allogeneic 
HSCT, a convenience sample was used, thus recruiting patients who were 
available to be interviewed and met the recruitment criteria. 
4.4.3 Setting 
An office space in the Stem Cell Transplantation and Cellular Therapy 
Unit (CCC) was used as the setting for this part of the study. This allowed the 
interviews to be completed following the participants review appointment on 
the Late Effects Clinic, and in an environment that was familiar to them. 
Additionally, it ensured the availability of medical staff should participants 
express any additional worries or concerns related to their medical diagnosis 
or treatment.  
Different settings were considered for the interviews prior to agreeing 
on an office space within the Stem Cell Transplantation and Cellular Therapy 
Unit (CCC) including: 
1. Participants own home 
2. Office space within the dental hospital 
Both of these settings had their merits however these were 
outweighed by the lack of specialist support from the Haemato-oncology 
team and the possible effect of a dental setting on patients who were dentally 
anxious or phobic. 
4.4.4 Recruitment  
The timing of recruitment of participants was considered, in order to 
enable the patient to be medically stable, it was decided to recruit patients 
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from the Late Effects Clinics, in the Stem Cell Transplantation and Cellular 
Therapy Unit (CCC), when they are over 100 days post-transplant.  
Recruitment was completed by CW-D who attended the Late Effects 
Clinic to recruit participants and complete the interviews. 
Other possible times of recruitment that were considered included: 
1. Time of the dental assessment in the Special Care Dentistry 
Department  
2. On discharge from the Special Care Dentistry Department 
following assessment and/or treatment  
3. On discharge from the Haemato-oncology ward following HSCT.  
These options were discounted as they are at a time when potential 
participants have increasing amounts of information to consider and retain in 
relation to their diagnosis, the HSCT process, the risks and benefits of 
treatment and the need for other medical interventions. In addition, 
recruitment at the dental assessment would increase the period of time to the 
interview and the medical outcome for the patient would be unknown.  
A particular challenge encountered in recruiting participants was the 
flexible nature of the late effects clinic. Although patients had an appointment 
time they were often required to have bloods or see the nurses on the day 
ward prior to attending the outpatient department. In addition after their 
appointment they may have other appointments, further blood tests or other 
infusions. Therefore, initially it was difficult to arrange a date and time for the 
interview to take place. Following a number of failed attempts, it was decided 
to ask the participant to choose the date and time of the interview. This was 
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usually following their clinic appointment when they had a better idea of the 
demands of their day and the time they would be available for the interview. 
4.4.4.1 Participant selection  
 
Participant selection was dependent on the following criteria: 
 Allogeneic HSCT only  
 Haematological – oncological diagnosis; CLL, CML, ALL, 
lymphoma, myeloma, failed autograft 
 Dental assessment and/or treatment at Liverpool University Dental 
Hospital  
 Dental intervention not completed by CW-D 
 Capacity to consent 
 Ability to speak fluent English 
Appendix 15 shows a flow chart that was used to assess eligibility for 
inclusion. Recruitment took place on the Late Effects Clinic from 1st July 2018 
– 1st September 2018. Potential participants were identified and approached 
by CW-D, the project was discussed briefly and, if they continued to be 
interested, full discussion about the project took place.  
4.4.5 Consent to participate 
Following assessment of eligibility, the purpose and design of the 
study was explained to each potential participant. They received an 
“invitation to participate” letter and time was allowed for them to consider the 
study and ask any questions prior to completion of the consent form 
(Appendices 16 & 17). The participant was offered the option of arranging the 
interview on the day of attending the Late Effects Clinic, to reduce 
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inconvenience to them, or through a telephone interview (telephone 
interviews would have required the quantitative questionnaires to be 
completed and posted to CW-D). No participant requested a telephone 
interview.  
Many participants wished to complete the consent form at the time of 
recruitment, therefore the consent form was completed and then reconfirmed 
at the time of the interview.  
4.4.6 Interview method 
Once recruited participants completed the three quality of life 
questionnaires prior to the face-to-face semi-structured interview. The 
participants were advised that the interview would last as long as they 
wished, however it would be no more than 60 minutes, allowing for a 
thorough discussion around the topic areas.  
The topic guide focused on the following subject areas and additional 
questions were asked dependant on the responses from participants during 
the interviews or due to the analysis of all the previous interviews: 
 Diagnosis and medical treatment to date  
 Views on the care pathway  
 Views on dental service  and /or treatment received  
 Feelings around dental treatment and advice 
 Impact of dental treatment and advice  – change in oral health 
behaviours, speech, function, appearance, quality of life, outcome of 
HSCT 
 Oral complications pre assessment / during / following HSCT process 
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 Future views of dental treatment and oral healthcare  
The topic guide used can be seen in Appendix 18.  
4.4.7 The interviewer 
Charlotte Wilson-Dewhurst (CW-D) was the sole interviewer for this 
study. Interviews occurred on specified sessions around her clinical 
timetable. She is a fully qualified and experienced dentist who has worked on 
the Special Care Dentistry Department at LUDH for 3 years and was in 
specialty training in SCD at the time of the study.  
Potential participants who were assessed or treated by CW-D were 
excluded from this study as this was considered as a potential source of bias. 
Potential participants were made aware of CW-D’s role as a clinician within 
the Special Care Dentistry Department.  
4.4.8 Interview process 
Interviews were recorded on a recording device (M Audio Microtrack 
II). Any additional information regarding difficulties in recruitment, need to 
stop the interview and participants becoming upset was noted in a separate 
field diary.  
Participants were informed the interview could be stopped at any point 
without impacting on their clinical care. If a participant wished to withdraw 
from the study then their information and responses, up to that point, would 
be destroyed. 
4.4.9 Data Analysis 
Following the interviews the recordings were transcribed verbatim by 
CW-D. Thematic analysis was the method of choice for analysis of the 
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transcripts as it is more flexible and allows identification, analysis and informs 
reporting patterns within a data set (Braun and Clarke, 2006, Green and 
Thorogood, 2014a, Ritchie et al., 2014a) 
Analysis occurred continuously throughout the study to allow 
emergence and identification of themes which were then were used as 
discussion points for other participants (Ritchie et al., 2014a).  
Ideally recruitment continues for qualitative research until saturation is 
achieved. Saturation is the point where no new themes are emerging from 
the data (Green and Thorogood, 2014b, Ritchie et al., 2014b). However, 
within qualitative literature, saturation has different definitions depending on 
the author’s own views. Some authors state that saturation is the point where 
no new codes or themes are emerging whereas others state saturation has 
been achieved if the participant has saturated their own narrative. Other 
authors have suggested that saturation is achieved when the theory under 
investigation is represented by the data (Saunders et al., 2018). Therefore, 
guaranteeing saturation has been achieved is arguably difficult and can 
depend on the definition adopted. 
As a guide, a total of 37 allogeneic HSCTs occurred in 2016, therefore 
it was unlikely that the total sample for interviews, within the time available 
would be higher than 20 participants. In addition, Guest et al. found that, for 
in-depth interviews, all of the codes (and therefore themes) were identified 
within the first 12 interviews and so recommended between 6-12 interviews 
as an initial sample size (Guest et al., 2006).  Given the difficulties in 
recruitment, the varied nature of patients receiving allogeneic HSCT and the 
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time constraints on the study it was difficult to be certain that saturation was 
achieved. 
Key codes and themes were identified from the data by CW-D and 
these were subsequently reviewed by other members of the research team.   
 For the quantitative quality of life questionnaires, their individual 
scoring systems were used to quantify the data. Descriptive statistics were 
used to compare the data on advice from a Senior Biostatistician.  
4.4.10 Ethical approval  
Full ethical approval was gained for this study with HRA and Health 
and Care Research Wales (Appendix 1) see section 3.6.11 for further details.  
4.4.11 Data management  
The recorded interviews were uploaded on to hospital password 
protected computers and transcribed verbatim. Each audio file and 
transcription were assigned a unique identification and no patient information 
was included on these files.  
For information regarding archiving see section 3.6.12. 
 
 
 
125 
 
4.5 Results  
4.5.1 Data analysis  
4.5.1.1 Thematic analysis  
Thematic analysis is a widely used, flexible and substantive approach 
to analysing qualitative data, through identifying and reporting patterns or 
themes. It is often used within other qualitative analysis methods, however, it 
is argued that it can stand alone as an analysis tool presenting rich and 
detailed accounts of the data (Braun and Clarke, 2006, Ritchie et al., 2014a). 
For this project a deductive semantic approach was undertaken 
(Braun and Clarke, 2006). The topic guide and the researcher’s prior 
knowledge were developed from literary evidence, current expert opinion and 
practice. This in turn influenced the methodology and questioning during the 
interviews. Although, ideally an interpretive approach is suggested for 
analysis, the prior knowledge and professional status of the research team 
would have influenced the analysis and tailored participant responses to prior 
knowledge. The participants views and opinions allowed more meaning and 
context to be given to existing knowledge on this subject area (Green and 
Thorogood, 2014a). 
Thematic analysis seeks initially to find codes, important words or 
fragments of text (fragment coding) of interest to the researcher, similar 
codes are then grouped into categories, allowing themes to be generated. A 
theme is an important element of the data in relation to the research question 
or participants’ responses (Braun and Clarke, 2006, Green and Thorogood, 
2014a, Ritchie et al., 2014a).  
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As stated by Braun and Clarke in 2006 there are six main stages to 
thematic analysis (Braun and Clarke, 2006): 
1. Familiarising yourself with the data  
2. Generating initial codes 
3. Searching for themes  
4. Reviewing themes 
5. Defining and naming themes  
6. Producing the report  
4.5.2 Recruitment 
Recruitment of this patient cohort was challenging as each patient had 
individual conflicting demands on their time. In addition, approximately 40 
allogeneic HSCTs are completed by the Stem Cell Transplantation and 
Cellular Therapy Unit (CCC) each year, with some patients not surviving, 
presenting a small sample from which to recruit.  
The Late Effects clinic within the Stem Cell Transplantation and 
Cellular Therapy Unit (CCC) is an outpatient clinic where adult patients who 
are 100 days post-transplant are reviewed. The clinic reviews patients who 
have had autologous or allogeneic HSCT in addition to those patients who 
have received other treatments for their haemato-oncology malignancy such 
as chemotherapy. The patients attending this clinic may have received their 
transplant within the last 100 days, or their transplant may have occurred 
over 2 years ago, but they still require follow up due to their haemato-
oncology diagnosis or treatment history. Thus, the clinic presented a broad 
sample of patients of varying complexity and differing experiences.  
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Recruitment occurred over 8 clinical sessions, with 15 patients 
meeting the inclusion criteria for the study, 12 of these participants were 
interested in the study, with 7 confirming they wanted to take part and the 
other 5 patients wished to consider the study further in their own time.  
A further difficulty experienced in recruiting participants to the study 
was arranging a suitable time to complete the interview. Although the 
patients had a booked appointment time, there was a fluidity to the 
appointment journey, which may involve additional procedures such as blood 
tests or treatments such as transfusion, therefore it was difficult for patients 
to anticipate at what point they would arrive on clinic or how long their 
consultation would be. For some patients, the interview was rearranged on 
three occasions because their consultant requested more tests, they didn’t 
have a family member with them, or because they had other arrangements 
outside of the hospital. Given the number of appointments that they were 
required to attend, participants were reluctant to attend on a separate day. In 
the end, a more relaxed approach was taken and it was agreed with the 
participants that they would decide when the interview would occur.   
4.5.3 Initial analysis  
A total of 7 semi-structured interviews were completed within the time 
frame of this study. Data saturation is used within qualitative research to 
define the point at which no new themes are emerging from the data.  
From the analysis of the 7 interviews no new themes were emerging 
at the last interview. Given the variety of individuals, treatment history, 
haemato-oncological diagnoses, patient experience, and difficulties in 
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recruitment, it was unclear whether data saturation had been fully achieved 
for this cohort of patients.  
Four female and three male participants, were interviewed over a 
range of 13 minutes to 45 minutes. The average age of the participants 
interviewed was 44.3 years (range 27 years – 63 years) and their haemato-
oncological diagnoses were that of Hodgkin’s lymphoma (n = 1), acute 
myeloid leukaemia (AML) (n = 4) and myelodysplastic syndrome (MDS) (n = 
2). During the interviews, the interviewer made minimal field notes of any 
further information stated outside of the interview.  
Following completion of the interviews, the recordings were 
transcribed verbatim by CW-D. The transcriptions were completed by CW-D 
allowing her to be fully immersed within the data to aid in its analysis. It was 
also felt that transcribing the recordings was an effective method for CW-D to 
debrief, given that some of the interviews were difficult in their emotional 
impact on the interviewer. The transcriptions were then confirmed against the 
recordings as being accurate, by re-listening to the recording at a different 
period of time. An example of a transcribed recording can be seen in 
Appendix 19.  
The transcripts were read prior to analysis to increase the depth of 
understanding of the data. The data was then read initially line by line and 
coded. Fragments of the data were also coded if it was felt that this allowed 
the code to be more robust. The transcripts were analysed, where possible, 
prior to completing the next interview to allow the concepts to be considered 
in the interviews as they progressed.  
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The initial codes and categories were reviewed and discussed with 
supervisors and qualitative researchers involved in the project (ST, RH and 
LL) to ensure there was agreement prior to formulating themes.  
Once coded, the codes were grouped into categories and then into 
themes. This was completed initially on a Microsoft PowerPoint® document 
(see example in Appendix 20) and then as a paper-based exercise. Nvivo® 
computer software (QSR International) was trialled, however, the researcher 
did not feel, personally that this allowed for a good visual representation of 
the data. The data was then presented in tables to allow collation of the 
codes, categories and themes.  
The data analysis process and tables can be seen in Appendix 21 
(posters created and tables). 
4.5.4 Identification of themes  
Four main themes emerged from the data: 
 Preventing transplant related complications  
 Patient experience of the care received 
 Consequences of medical management  
 Psychological impact of treatment 
A schematic diagram of the main themes identified can be seen in Figure 4. 
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Figure 5: Schematic representation of the main themes identified through 
thematic analysis of the data 
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4.5.5 Preventing transplant related complications  
Participants alluded to the fact that a dental assessment and 
necessary treatment was required to prevent complications during and 
following the HSCT process.  
4.5.5.1 Dental referral  
The need for dental referral was discussed during the interviews. The 
participants appeared to have been informed by their specialist medical team 
about the referral and the reasons for it. Some of the participants had 
previously had medical interventions such as chemotherapy for breast cancer 
or a hip replacement and so had an understanding and previous experience 
of dental assessment and intervention prior to medical treatment.  
Prevention and the need for good oral hygiene was highlighted 
together with the provision of dental interventions as two of the reasons for 
dental referral.  
“…I had to have good dental hygiene, in case I needed any 
teeth removing or if there was any problems that could, they could see 
before…” P2 Female  
“…errrm and then obviously for preventative care during the 
transplant.” P3 Female 
 “…I thought it might have been in case any of my teeth or 
fillings came out during any procedures…” P5 Male  
In addition to provision of treatment and delivery of prevention advice, 
participants were aware of the impact of the conditioning and transplant on 
their immune system and therefore the need to avoid or treat potential 
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sources of infection in order to reduce the risk of complications. Some of 
participants identified the mouth, teeth and gums as a potential source of 
infection and the impact an infection would have during transplant and so this 
highlighted the importance of the dental assessment.  
“…but no it was explained to me that I would lose my immune 
system so basically I was open to to anything and one of the last 
things they wanted was any hidden germs or anything lurking in my 
body and obviously the mouth is one the places that things can lurk 
and go undetected” P5 male  
“…just to just to check off another box in case that you know I 
had the infection in my gum you know maybe I had a dodgy tooth for 
instance and could of easily got an infection in there once me immune 
system was down so that's what I assume is you’re just covering all 
the corners” P6 male 
“…obviously they’re checking for any infections or problems 
before the transplant so that can be avoided errrm coz obviously 
you've got no immune system when you're having your transplant so 
having something that bad with no immune system must be awful and 
then obviously all the medications and treatment you've had can affect 
your teeth…” P7 female  
4.5.5.2 Patient motivation regarding oral hygiene  
There is evidence within the literature that good oral hygiene can 
reduce the oral complications faced by patients undergoing HSCT, 
particularly the duration and severity of mucositis (Gürgan et al., 2013). 
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Participants identified the need for good oral hygiene to reduce the severity 
and complications particularly presentation of ulcers.  
“…people who've had really really bad problems with ulcers, so 
I was quite lucky, but I was quite methodical at keeping my mouth 
clean. So I think that I help myself so yeh.” P1 female  
“…when I'd had my breast cancer and me chemo, it really 
affected me mouth then, I had a lot of mouth ulcers, so I knew what 
was coming like this time, so I was a bit paranoid over, straight away I 
asked for mouth wash and I was using it probably about 5 or 6 times a 
day, just to keep my mouth clean.” P2 female   
“…no do everything, they the nurses and doctors tell you you 
know they do tell you to do as you know oral hygiene is a big thing and 
it certainly helped me with not having as many blisters and pain I 
suppose than other patients that were admitted at the same time” P6 
male  
In addition, participants highlighted the importance of trying to 
continue oral hygiene regimes as normal during the transplant process, 
however highlighted the fact that on some days they felt too tired or unwell to 
brush their teeth. 
 “…brushed them in the morning but at night but I you know I 
was trying to do it in the middle of the… and I just couldn't be bothered 
but I think you should force yourself really to do what you'd normally 
do…” P4 male  
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“…pain wise no... errm no I was probably, I took me time I got a 
baby brush a baby toothbrush... so it was I brushed quite gently as I 
say took my time and had no problems.” P6 male  
“No issues with brushing my teeth...errrm I think a couple of 
days I probably didn't brush em in the morning because I just couldn't 
physically couldn't get out of bed… But as soon as when my mouth 
was hurting I’d probably like make the effort to swig some mouthwash 
or something yeh” P7 female  
However, other participants felt that during the post-transplant period 
their priorities changed and therefore maintaining their oral hygiene regime 
became less important to them.  
“…you're given advice about your teeth and all of a sudden 
you’re in intensive care and you think you're going to die so throwing 
some toothpaste on your pearly whites doesn't sort of... it's not up 
there really is it?” P5 male  
“I felt I was going to die and that's before I had me bad spells, 
that was just me that was just the way I felt I just thought I’m not going 
to pull through this and I was aware that err I was aware the dental 
hygiene wasn't being done I was aware that I wasn't cleaning my teeth 
but I didn't get like any bad breath or anything it was strange. I didn't, 
my mouth didn't feel yacky.” P5 male  
“…there are going to be parts of transplant like when you've 
melphalan, you physically can't brush your teeth because your skin 
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falls off like it... (Laughs) like you're going to end up with a toothbrush 
full of gum.” P3 female 
Although the some participants felt that the oral hygiene advice was 
adequate, others felt that changes to provision of oral hygiene advice were 
necessary, as patients undergoing HSCT become saturated with information 
with regards to their condition and treatment. Suggestions around provision 
of written advice, a personalised prevention plan that could be made 
available on the ward and involvement of relatives in providing oral hygiene, 
along with highlighting any issues with the mouth to nursing staff were made 
to improve the service.  
“…actually write it down, like a treatment plan for each person, 
even if you could just speak to them and say look focus on this, this 
and this… if they could write it down maybe do a note sheet for in 
each of the transplant rooms because your head is that muddled by 
everything that your being told in the run up to transplant you can't 
remember ANYTHING” P3 female  
“…just sort of saying there are going to be times when you can't 
do it but just in the days afterwards make sure you're really careful, 
and make sure you notify the nurses if you think there is anything 
amiss.” P3 female  
 “I’d advise anybody to certainly try even if it comes down to 
something I didn't do if you can get your partner or one of your family 
to clean your teeth for you.” P5 male  
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4.5.5.3 Theme summary 
Generally, participants were aware of the importance of the dental 
referral, assessment and treatment in order to prevent infection. Additionally, 
participants recognised how good oral hygiene can prevent oral 
complications, namely ulcers, through the transplant process. Trying to 
continue normal regimes was important to these transplant patients, and was 
highlighted in the efforts made by participants in attempting to carry out their 
oral hygiene regime, despite feeling tired or unwell as a result of the 
transplant. Participants also recognised how their priorities changed during 
the transplant process and, therefore oral hygiene may not be the most 
important factor in recovery. Further developments to the service in the 
provision of written oral hygiene advice would be helpful to both patients and 
their relatives along with ward staff.  
4.5.6 Patient experience of the care received  
In all healthcare settings, understanding a patient’s experience of a 
service is necessary in order to improve patient satisfaction and to implement 
changes (Batalden and Davidoff, 2007). There are often differences seen in 
the service provided and the expectations of the patients who access that 
service. For these participants, their experience of the care pathway and their 
expectations of treatment were explored.  
4.5.6.1 Beliefs around dental management  
The care pathway between the Stem Cell Transplantation and Cellular 
Therapy Unit (CCC) and the Special Care Dentistry Department was 
established in 2013 to enable patients to have a dental assessment and any 
necessary treatment prior to their HSCT, for emergency situations during the 
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transplant process, and for further dental review following transplant and 
recommendation regarding ongoing oral care and oral care provider.  
There was a general feeling amongst the participants that being 
referred to the dental hospital meant seeing a dentist with increased 
specialist knowledge and experience. They felt that their diagnosis and its 
impact, along with the medical treatment they had received, was understood 
by the dental team with regard to the complications they might face, such as 
risk of infection and bleeding tendency.  
“…fine it was erm good really when if you go to your own 
dentist you got to do all the explaining of I’ve had this I’ve had that, 
whereas going to the Dental they know all the case notes and they 
know what you've been through .. and ... what's happening so it’s 
much much better.” P1 female  
 “…even my regular dentist didn't really understand what a 
stem cell transplant was and you’re kinda sat there going... I’ve got to 
explain all this and then he's going to go digging about in my mouth 
unless I I I wanna feel comfortable that he knows just as well as I 
know, what it entails and how easy it is to get a nasty infection and 
that sort of thing...” P3 female  
“…It was helpful to see the Special Care Dentistry to be honest 
I think more than anything, as a transplant patient... I personally was 
terrified of going anywhere that might not... understand my condition 
and might not understand how clean it needs to be and how careful 
they need to be.” P3 female 
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Participants viewed seeing a specialist dental team for a dental 
assessment prior to transplant as reassuring and also found the attitude of 
the staff who saw them likewise as reassuring. They appreciated that in the 
early days of diagnosis and treatment having this link meant that the service 
was more direct in terms of communication and referral.  
“I remember being quite happy because... (Cough)... somebody 
that I’d like gone through my journey with, who's no longer with us 
now. I remember him, bless him, he was terrified of the dentist and he 
had to go and have a load of teeth out before... we both like came 
here. So, and I was like breathing a sigh of relief because I didn't have 
to have anything done.” P2 female  
“...it’s been relax...fairly relaxed in there and errr been seen to 
quickly and that and err no I haven't had any sort of problem you 
know... you know and everyone's sort of nice just... talking and joking 
away with you but I suppose to relax you like which you want (laughs) 
don't you, when you’re feeling a bit worried about it” P4 male  
“I think the link between the Dental Hospital and here I think 
that link might be more direct and stronger than when it goes outside. 
So, every patient in the early stages is coming from one place not like 
there’s a dentist in the Isle of Man, there’s a dentist in Wales, 
Manchester, Wallasey it’s all coming from one place that would be the 
benefit in the early days.” P5 male  
Amongst the participants, there was a variety of expectations of the 
dental treatment provided. The dentist’s aim of treatment prior to transplant is 
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to allow the patient to be as dentally fit as possible in the time available, 
therefore the treatment plans prior to transplant include extractions, basic 
restorations, plus periodontal treatment aiming to see the patients following 
transplant to complete the more advanced work. Aesthetic concerns were 
highlighted by participants, with the provision of composite restorations, 
whitening treatments and provision of dentures being important to them. 
Expectations of treatment modality were explored particularly with 
participants who had dental anxiety. These participants attended expecting 
dental treatment under general anaesthetic but received their treatment 
under local anaesthetic.  
“I had this idea in my head that after me transplant that I would 
go back to the dental hospital and I would have some like magic... 
treatment (laughter) on me teeth, and it would make them sparkling 
white, but that never happened…” P2 female  
“…some that would have to come out but probably the worst 
thing is, you know errr I think well what I thought was like there not 
coming out straight away and that and and I was hoping I would be 
knocked out…” P4 male  
A contrary view was that the dental treatment received was not a 
priority during the transplant process, however, they could see its importance 
in being a part of the process in the work up to HSCT. 
“I think visiting a dentist to get your mouth checked out doesn't 
come very high on the scale of when you're having chemotherapy 
although looking back... err it is an important part of the procedure, at 
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the time when you're putting it I don't think it comes in the top three but 
it is like I say an important part.” P5 male  
Together with the dental treatment received, there was a range of 
expectations as to where participants should receive their dental care post-
HSCT. Current guidelines suggest that, for 1 year following HSCT, patients 
should be reviewed either within a secondary care setting or within primary 
care with close liaison with specialist dental services. However, this decision 
would be governed by the patient’s medical stability and haematological 
status (British Society of Disability and Oral Health, 2012). Some participants 
were happy to be seen at the Dental Hospital but were accepting of the fact 
that they would be discharged in the future.  
“I'd like to think they'd carry on seeing seeing me but errrm we'll 
just have to wait and see.” P1 female  
 “Well... I think in a few ways it would be a lot better if I could 
just go to somebody in Southport, but I’m quite happy at the moment 
coming to the Dental Hospital.” P4 male   
“it all goes hand in hand with my condition like when my 
platelets are low I quite understand that I’ve got to stay away from 
things that are sharp and dentists tend to use a lot of sharp things... 
err but I think once I think once your platelets are back ok, I personally 
don't see why your own dentist can't treat you… I really can't see the 
difference between your own NHS dentist treating you and coming to 
a Dental Hospital, I see that the err tooling is the same, the 
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procedures are the same the only thing that changes is me is my 
platelet level” P5 male  
4.5.6.2 Competing demands and expectations 
Participants highlighted that patients who were receiving treatment for 
Haemato-oncological diseases often needed to attend multiple appointments, 
including chemotherapy and radiotherapy treatments, regular appointments 
for blood tests and in-hospital stays prior to, during and following transplant. 
This often meant that they had conflicting demands on their time.  
“had a course of radiotherapy.... it came back... so i had a 
transplant, using my own cells...erm stem cell transplant in between 
having chemotherapy stuff... i relapsed and it come back in other 
parts... erm... so they decided that it would be best if i had a donor 
transplant.... so errm I had months and months of chemotherapy” P1 
female  
“yeh so it's it's my second anniversary of being diagnosed 
tomorrow so I’ve spent 53 weeks in hospital that was up to May so it's 
still luckily only 53 weeks now but that's if you take the anniversary 
tomorrow that's over half of my time I’ve spent in hospital very very ill.” 
P5 male  
“the 8th 9th 10th and 11th was radiotherapy, total body 
irradication errm twice a day, on the 11th I came back to the Royal 
and errrm on the 12th I had err I think two doses of chemotherapy and 
then the 13th I had errrm I think I had fluids and then I think the 14th I 
had the stem cell transplant.” P6 male  
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As well as attending their regular treatment appointments, the patients 
were also required to attend specialist appointments to assess their cardiac 
and respiratory function, for psychological support and for a dental 
intervention.  
“…coz obviously they wanted to harvest my eggs before I went 
into transplant and what have you and... They wanted to do lung and 
liver and all your like different function tests.” P3 female  
“I think it was only the ones really all the other were sort of 
connected you know one way, you know like counsellors even or there 
was this one, I don't know whether she was a psychiatrist or that I saw 
a few times.” P4 male  
“…you know for your breathing for your lung, I had to have like 
a breathing test and then a errrm heart monitor as well... yeh before 
my transplant” P7 female  
In addition to attending appointments, these participants felt saturated 
with information, regarding their diagnosis and treatment.  
“…what people have said to you is just unreal you’re learning 
stuff about your condition, you’re learning stuff about your diagnosis, 
about your treatment every minute that you're in this hospital.” P3 
female  
Participants highlighted the struggle they faced to attend appointments 
or to remember the reason for the appointment. In certain cases, it was not 
possible to complete the dental treatment prior to the HSCT as the need for 
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the HSCT was more urgent than the dental treatment itself, or if the dental 
assessment appointment was too close to the transplant date. 
“…Errr to be honest there was that much going on at the time it 
wasn't sort of... it was just... there were that many different 
appointments I think you kinda lose track of what you're going to 
appointments” P3 female  
“I think I should have had some stuff.. some work done before 
me transplant but I always thought for some reason, someone said the 
dentist had broke her leg and then it just got too close to having me 
transplant” P4 male  
“It was just before my transplant, so I went I think it was a week 
before I had my transplant yeh…” P7 female  
Participants highlighted they felt they had a lack of knowledge 
regarding what dental treatment they required or when it should take place, 
this was both in regard to dental treatment prior to and following HSCT. 
“…oh no we're taking your wisdom teeth out today and I was 
like, well I haven't booked any time off work coz I didn't know you were 
going to do that, so can we not (laughter)... and... They’re still in there 
but they've done alright” P3 female  
“I needed a errrm a filling. Errm it's like coated but he said he 
could like do a filling for it when I after my transplant, but I’ve not heard 
anything back yet. I've not had another appointment to do that” P7 
female  
144 
 
In addition, following HSCT, participants felt that it was unclear as to 
how they accessed returning to the Special Care Dentistry Department for a 
review or to complete treatment, leading to delays in their accessing dental 
care.  
“I think the only improvement would be with the follow up that I 
had to, I did have to chase that errm, coz I asked a few times at errm... 
I think I asked in clinic upstairs and I asked a few times at my 
appointments, like my consultants appointments, and it was months 
before it was sorted and like in the end I sort of had to push for it” P2 
female  
“No I should have came back a lot sooner but I don't know what 
happened, I don't know whether it was my fault not following it up with 
yourselves probably I think it was my fault for not phoning coz I think I 
had a we arranged err a filling I got an appointment letter in the post 
but I was having me transplant at that time” P6 male  
4.5.6.3 Theme summary 
Overall, participants felt reassured by the link between the Special 
Care Dentistry Department and the Stem Cell Transplantation and Cellular 
Therapy Unit (CCC), as they felt the dental clinicians they saw had specialist 
knowledge and experience of treatment for patients with Haemato-
oncological diagnoses. However, many patients understood that once their 
haematological values were stable following transplant then they could be 
seen by their own GDP, closer to home, whom they may have known for 
years and in whom they had developed trust and rapport. 
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Participants highlighted that more information was required, in 
different formats, to explain the dental treatment that could be provided and 
the process of accessing dental care following transplant in order to manage 
expectations and prevent delays to treatment. In addition, careful liaison is 
required with the Stem Cell Transplantation and Cellular Therapy Unit (CCC) 
to allow ample time for patients to have an oral assessment and ideally have 
any necessary dental treatment prior to transplant.  
4.5.7 Consequences of medical management  
Following HSCT patients are likely to develop complications that can 
impact on their recovery and survival. The complications can occur directly 
following transplant or have a delayed presentation.  
4.5.7.1 Medical complications  
The treatments required to manage or cure haematological 
malignancies; chemotherapy, radiotherapy and transplant results in patients 
becoming immunosuppressed and thus increasing their susceptibility to 
infections. Participants within this study eluded to the infections they 
experienced following treatment, resulting in further hospital stays and 
additional treatment for the infection.  
“…then in the October so 10months later I got sepsis and 
pneumonia, errm and ended up in intensive care at the Royal and 
nearly died.” P2 female  
“…I was only out for a month and had to go to Arrowe Park for 
a week err I picked up an infection so unfortunately that's the way I 
and other patients are.” P5 male  
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The infections experienced by participants were a combination of viral, 
bacterial and fungal organisms. 
“…prothioconazole stuff like that which, that's not nice, errrm 
but that was for a fungal lesion on my lung, and then I got a virus and 
was on... Ribavirin errrm so I’ve had that in tablet form and in... the 
nebulising form, which is really really unpleasant” P3 female  
Graft versus Host Disease (GvHD) is an early and late complication of 
an allogeneic HSCT. Presentation of GvHD after 100 days being classified as 
chronic GvHD. Participants within the study described how the GvHD 
affected their skin, bowels and mouth. One participant experienced a 
particularly severe form of GvHD affecting his bowel which impacted on his 
nutrition and required an extended stay in hospital following his transplant.  
“…I had the most horrific rash from here right up and all over 
my head and it was just like really really itchy, so that's when they 
started me on the steroids.... and then I had it in my.... tut... bowel as 
well... erm so that was probably connected to why I was not eating 
very much and had no appetite” P2 female  
“I remember it started inside me mouth a bit milky looking, me 
lip was a bit purple and milky looking just the bottom one the top one 
seemed alright” P4 male  
“GvH of the mouth, GvH of the skin, GvH of the eyes, although 
horrible and uncomfortable won't kill us, it's the GvH of the gut that 
apparently is the killer…” P5 male  
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Receiving good nutrition directly following HSCT has been shown to 
improve recovery (Espinoza et al., 2016). Patients are encouraged to eat as 
normal, however, some require supplemental nutrition including nasogastric 
feeds, total parenteral nutrition (TPN) and build-up drinks. Participants 
discussed the issues of having a lack of appetite as a consequence of feeling 
depressed, others explained that having a sore mouth and lack of taste 
reduced their appetite.  
“…the smell of the food was just knocking me sick and I don't, I 
don't know whether, thinking about it now whether I was just a bit 
depressed about it all and that was my way of dealing with it, by not 
eating...” P2 female  
“Oh I didn't eat for 2 weeks, they wanted to put a tube in and all 
sorts but I think that was infection and the fact that my mouth was red 
raw...” P3 female  
“…errrm I could eat quite a lot at the start of it all while my taste 
was gone but towards the end… I err couldn't eat much” P6 male  
The majority of participants were accepting of the need for 
supplemental nutrition, however, some found the thought of having a 
nasogastric tube distressing.  
“…so... .... I know it sounds really strange of all the things 
they've done to me the one thing that really really puts me off more 
than anything is them putting a tube down my nose, I just can't deal 
with it” P3 female  
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 “…you've got to get nutrients in if you don't say you go off your 
food and errr if you haven't got the tube up your nose you’re not 
getting any nutrients you'll be in longer and as soon as they said that 
you know I just wanted to get out so I say I agreed to it then” P4 male  
“I had numerous NG feeds yeh, err there came a point where I 
was that bad with the graft versus host of the gut that I was stopped 
fed by NG… I was fed with what they called errm TPN… fed direct into 
the vein because my gut was that affected they didn't want to pass 
anything through” P5 male  
“…they did try and give me that several times and I I said I said 
no but every time, I just tried to force down which I did yeh...  it's just 
something that I didn't like the the look of really it seemed quite 
uncomfortable errrm so yeh I was quite happy trying to force it down 
me” P6 male  
4.5.7.2 Oral complications  
Oral complications are frequently associated with HSCT. This has 
been explained by sensory changes caused from the Haemato-oncological 
malignancy itself, a reduction in the number of taste receptors, and the use of 
chemotherapy drugs resulting in neurotoxicity and xerostomia, leading 
patients to experience dysguesia, mucositis, ulceration and xerostomia 
(British Society of Disability and Oral Health, 2012, Meirelles and Diez-
Garcia, 2018). In addition, the susceptibility to infections results in 
opportunistic organisms, particularly candida, presenting in the mouth (British 
Society of Disability and Oral Health, 2012).  
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Participants within the study had insight into the oral complications 
that they had experienced. They were aware that they would be likely to have 
a sore mouth and taste disturbances and this information was discussed prior 
to transplant and they were able to place their experience of oral 
complications into perspective in the context of the rest of their treatment.  
“If you’re outside of transplant and your mouth was that bad, 
then yeh that would really suck but I think in the greater scheme of 
things when you're in transplant you kinda have bigger fish to fry…” 
P3 female  
“Awful, it wasn't as bad as I expected because people had told 
me like the doctors the dentist as well, that like you're going to get a 
really sore mouth, so it wasn't as bad as I thought” P7 female  
Dysguesia, or taste disturbances, was a complication that many of the 
participants experienced, and this, along with the difficulties in eating, was a 
lasting memory of that period.  
“…the weird thing, I’d lost all taste in my mouth for the best part 
of 2 weeks... errm... I couldn't taste anything, like I had a 
relentless...and that stuffs just pure fizz but I was like, it’s got a fairly 
strong taste... nothing. The only think I could taste was Rubicon 
Mango and I hate that stuff.” P3 female  
“…me taste buds must of went for maybe, I think a good month, 
good month or so errrm all I could taste was MacDonald’s cheese that 
was the that was everything, everything tasted like MacDonald’s 
cheese believe it or not so ummm very strange…” P6 male 
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A participant described how he was advised by other patients on the 
ward how to combat the problems with taste that he was experiencing.  
“…somebody said to me if you drink oxo or Bovril you don’t get 
the metallic taste and another one apparently is pineapple” P5 male  
Participants’ experience of mucositis was not as clear, as they mainly 
described having a sore mouth or their experience of ulceration. Again, 
mucositis experience was a further factor that impacted on nutrition and 
ability to eat, throughout the transplant process resulting, in certain cases in 
nasogastric feeding.  
“…then of course on top of that you've got the soft tissue break 
up... the skin splitting in the mouth and everything yeh... no not a good 
time that” P5 male  
“…errrm I can't remember what it was called now, but you get 
like a horrible like foam on your mouth and yeh a really sore mouth, it 
was I couldn't eat a lot really no.” P7 female 
Another participant described experiencing a candida infection, 
however, considering the other complications she experienced, she was not 
surprised to contract an oral infection. 
“... no I got oral thrush I think twice and had to have nys... 
nystatin, errm but that's pretty sort of common coz it's... I mean I got 
fungal infections in my lungs so... it would kinda come hand in hand 
that you might get one in your mouth... so... but worse things have 
happened so...” P3 female  
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4.5.7.3 Impact on normal routine  
Participants discussed, in addition to the medical complications they 
experienced, how the HSCT process impacted on their daily life. In particular, 
patients highlighted the change to their appearance through weight loss and 
hair loss, as impacting on their mood.  
“…went down to that weight I just would look at myself and it 
was just awful, you could just like feel my bones and yeh...” P2 female  
“…me hair as well errm emotionally I think it was quite... quite 
depressing errm having no hair whilst being wheeled through the 
hospital and people starring at you errrm that was quite quite upsetting 
actually especially when everyone's looking at you err in that your 
feeling quite quite sick so for everybody to see” P6 male  
Their increased risk of bleeding and susceptibility to infection impacted 
on normal routines such as shaving. Participants were advised to use electric 
shavers to negate this risk.  
 “…and I used an electric shaver if I needed to shave” P6 male  
In addition, a participant explained how her fear of contracting an 
infection influenced her interaction with customers at work.  
“ …haven't been facing patients, up until recently because of 
the infection risk, obviously my boss didn't want me, getting an 
infection either so they've been really careful about not wanting to put 
me on the shop floor…now I can face some patients that come in, I’m 
just fairly picky about who.” P3 female  
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The emotional impact that the HSCT had on patients both during the 
transplant process and after was described. It was explained that the impact 
was not only on themselves as the patients, but other members of the family 
if the patient was unwell.  
“…three possibly four occasions where they've nearly lost me, 
err you know it's not just me it's the family as well you know the wife 
getting phone calls at 2.30 in the morning saying you need to come 
over as soon as possible.” P5 male  
The feelings of friendship formed with other patients undertaking the 
transplant process was described and how patients may feel guilty for 
surviving when others have not.  
“…you're then hospitalised for seven months and you come into 
clinic and you start asking about people who you haven't seen and 
then you find out that they've passed away whilst you've been in 
hospital. Errm it makes me feel guilty, I feel very emotional, and I think 
why me, why how have I survived, and these other people haven't 
survived and it’s a real err I say eye opener it makes me feel like I say 
sometimes guilty that I’m still here” P5 male  
4.5.7.4 Theme summary 
Participants are generally aware of the medical consequences of the 
HSCT and accepting of them as an outcome. An interesting finding from 
participants was the reluctance to have NG feeding, even though the 
evidence suggests that supplemental feeds improve recovery and decrease 
the duration of the initial hospitalisation (Espinoza et al., 2016). There was 
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only one participant in this cohort who had severe cGvHD which affected his 
bowel and significantly impacted on his recovery due to the issues of 
malnutrition. Taste disturbances were the most frequent oral complication 
described and the majority of the participants could remember their taste 
changing and the impact that had on how they felt about eating. There is a 
continued emotional impact of the treatment following transplant with 
participants reporting anxiety with regards to contracting infections or having 
guilt around surviving.  
4.5.8 Psychological impact of treatment 
Patients are confronted with numerous stressors throughout their 
HSCT journey which can have a significant psychological and emotional 
impact. In this study, participants described their feelings and emotions with 
regard to their medical treatment, and the dental treatment they received.  
4.5.8.1 Medical fears  
Throughout the interviews participants described their anxieties 
around their diagnosis, the treatment they received, and the appointments 
they needed to attend.  
“So, you're kind of scared of your own shadow…” P3 female  
“Anxious, I get anxious with everything though, every 
appointment yeh” P7 female  
A participant explained that even now, 6 years post-transplant, she is 
still conscious about infection risk in her day to day life, including seeing 
clients at work.  
“…I’m still like OCD about clean stuff (laughs)” P3 female  
154 
 
In addition, participants explained their concerns regarding the often 
lengthy wait for a suitable donor to be identified. They explained how this 
often led to them having further chemotherapy treatment which resulted in 
experience of infections and other side effects alongside prolonged hospital 
stays.  
 “Waited on the register again, couldn't really find anything.... 
got to October really started to panic coz I’d had some really nasty 
infections and been in hospital pretty much 90% of the time” P3 
female 
Another patient explained how he wished he had been given more 
information about the transplant process and the possible complications, 
prior to transplant, to help reduce his anxiety. He eluded that this information 
would be helpful from a patient’s perspective.  
“…more advice prior to the transplant would have been better 
for peace of mind, obviously it's quite nervous for anybody to have 
such a erm such a treatment for something like that a transplant err I 
think any advice would have been great, something to settle the 
nerves so yeh” P6 male  
Many of the participants had experienced multiple different treatments 
prior to their HSCT and, for most, having a HSCT was the only option for 
recovery. Participants described how some chemotherapy treatments made 
no impact on their disease whilst others explained that they has been in 
remission but relapsed.  
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“…I been on lots of different chemotherapies, coz each one 
from the beginning of this didn’t work... wasn't making any difference.” 
P1 female  
“…then I was told that I had no option other than the stem cell 
transplant, otherwise.... I wouldn't get better.” P2 female  
“…when I was in remission for about a year and a half, then it 
comeback and I relapsed in June 2017 which then meant that I had to 
have a bone marrow errrm transplant” P7 female  
One participant described his fear of relapse, now that he is post-
transplant as he does not feel he could undergo the necessary treatment for 
a second time.  
“I’ve... really been through the mill and at times I’ve thought you 
know I wasn't going to pull through. And I’ll be honest now I’ve said to 
a couple of people I honestly don't think I could go through that again, 
I don't think my body could go through that again, if I was to have a 
relapse I don't think I’d pull through it, I honestly don't think I could go 
through what I’ve been through” P5 male  
4.5.8.2 Dental anxiety 
Further to the anxiety regarding their medical care, this cohort of 
participants reported feelings of anxiety in regard to attending for their dental 
assessment appointment, its impact on their medical care, and their feelings 
around the dental treatment required.  
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“…yeh I mean no saying that I’m never I’ve never been 
comfortable with dentists err its needles I suppose it’s not the best are 
they so no” P6 male  
“…touch wood I’ve always had quite good teeth anyway, I don't 
like going the dentist obviously who does but errr I was ok yeh. Bit 
nervous had to have like an x-ray and stuff but yeh fine…” P7 female  
A participant described how his dental phobia had developed since his 
wife passed away. Since this time he had not accessed dental care and so 
felt anxious regarding his assessment appointment in Special Care Dentistry 
as he knew that dental treatment was required.  
“Like from 2006, I just never went the dentist, and I knew things 
were getting more, were getting worse, there was times where I said 
about forcing myself to go” P4 male  
“Oh he'll have to be referred to the Dental Hospital... and I was 
a bit nervous at times about going but because everything they've 
done to me in here I’ve never had a problem with at all.” P4 male  
Other participants explained their dislike of dental treatment, however, 
understood why a dental assessment and treatment was required prior to 
transplant and therefore viewed the dental aspects of care as part of the 
process.  
“Well I don’t love them (laughter) but no it’s fine.” P1 female  
“No the hospital have done worse to me so... I'm not too keen 
on that drill but other than that... it's alright” P3 female  
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“It didn't bothered me to be honest because I saw it as part of 
the process… It's like building the house you have to have the 
foundations in place before you lay the bricks and I just saw it as part 
of the process” P5 male  
Some participants did not receive their dental treatment until after the 
HSCT, however, felt that their views on dental treatment had changed due to 
the experience throughout the transplant process. 
“…like I say bone marrow things done and all that you just 
realise your teeth is just the same really you know it should be nothing 
really like… I always think I’d be fighting with the dentist, you know 
struggling with him like and err but like I say I was relaxed when I got 
in the other week and I think it's probably better for me being about 
another year, you know you can set your mind to it and you just realise 
it’s nothing should be nothing really.” P4 male  
“…it’s changed from my experience with the stem cell and the 
amount of needles that you go through having that experience, so I 
think coz I had a bit of a phobia before this with needles, I think that's 
maybe helped me going the dentist a bit more” P6 male  
Alongside dental anxiety around dental treatment, participants 
expressed future concerns about their dental health and dental appearance 
from the effects of the medical treatment they have received.  
“I do worry about me teeth, because you know my gums are 
receding so I you know I worry about all that…” P1 female  
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“…that was one of me main worries I don't want sorta like gaps 
in me teeth” P4 male  
“errm I was just worried a bit about you know in the past I’ve 
used the mouthwashes and my teeth’s gone a bit yellow” P7 female  
4.5.8.3 Theme summary 
Unsurprisingly, participants expressed feelings of concern and anxiety 
around their medical diagnosis, treatment and ongoing management. For 
many participants, the treatment required is complex and not always 
successful at inducing remission; necessitating the need for further 
interventions such as further infusions of stem cells, treatment for infections 
and treatment for GvHD. Such complications result in prolonged hospital 
stays and continued high frequency of medical appointments. Within the 
general population, dental anxiety is common and therefore the requirement 
of a dental assessment in the medical management for these patients could 
be seen to be overwhelming (National Health Service, 2009). However, many 
of the participants in this study demonstrated a realistic mind-set towards 
dental treatment, as it was not comparable to the medical management they 
had experienced.  
4.5.9 Quality of life  
Prior to the semi-structured interview participants were asked to complete 
three quality of life questionnaires. A full description of the quality of life 
questionnaires (Appendices 9, 10, and 11) used can be found within the 
methodology in Section 14.4: 
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1. FACT-BMT (Functional Assessment of Cancer Therapy – Bone 
marrow transplantation) (Appendix 11) 
2. Lee cGvHD symptom scale (Appendix 12) 
3. OHIP-14 (Oral Health Impact Profile – 14) (Appendix 13) 
The questionnaires were scored at the time of the interview and, if 
relevant, were used within the interviews to allow for an increased depth of 
information.  
Table 41 shows the demographics of the participants included in this 
study along with the overall results of the quality of life questionnaires.  
 
Gender Age Diagnosis Year of 
transplant 
FACT-
BMT 
score 
OHIP-
14 
score 
Lee 
cGVHD 
score 
1 Female 55.0 Hodgkin's 
lymphoma 
2017 85.0 8.0 31.0 
2 Female 44.0 AML 2016 88.0 11.0 14.0 
3 Female 27.0 MDS 2012 108.0 24.0 34.6 
4 Male 60.0 AML 2017 120.9 22.0 7.1 
5 Male 63.0 AML 2017 76.0 13.0 34.3 
6 Male 34.0 MDS 2017 100.0 21.0 19.9 
7 Female 27.0 AML 2017 93.3 9.0 18.2 
Average 
 
44.3 
 
 95.9 15.4 22.7 
Table 41: Overall results of the quality of life questionnaires 
 
4.5.9.1 Fact-BMT quality of life questionnaire 
Fact-BMT is a quality of life questionnaire used for to assess quality of 
life for patients undergoing bone marrow transplantation (McQuellon et al., 
1997, FACTIT, 2010).  
Since its development it has been used to assess quality of life across 5 
domains:  
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 Physical wellbeing (PWB) 
 Social and family wellbeing (SWB) 
 Emotional wellbeing (EWB) 
 Functional wellbeing (FWB) 
 Bone marrow transplant subscale (BMTS) 
The results of each question are scored individually on a scale of 0 – 4. 
Each section is then scored as per the FACT-BMT scoring guidance 
(available when a study is registered with FACT-IT). A total score is then 
derived by adding the scores of each section, providing a FACT-BMT total 
score. The higher the score the better the quality of life. The total score 
possible for the questionnaire is 148.  
For these participants, the scores for each section and their total score 
are shown in Table 42. 
 
PWB 
score 
(28) 
SWB 
score 
(28) 
EWB 
score 
(24) 
FWB 
score 
(28) 
BMTS 
score 
(40) 
Total 
1 18.0 24.0 14.0 11.0 18.0 85.0 
2 24.0 21.0 14.0 18.0 25.0 88.0 
3 14.0 25.0 19.0 25.0 25.0 108.0 
4 25.6 23.3 20.0 20.0 32.0 120.9 
5 8.0 21.0 16.0 11.0 20.0 76.0 
6 18.0 17.0 23.0 22.0 20.0 100.0 
7 21.0 23.3 9.0 16.0 24.0 93.3 
Average 18.4 22.1 16.4 17.6 23.4 95.9 
Range 8.0 – 
25.6 
17.0 – 
25.0 
9.0 – 
23.0 
11.0 – 
25.0 
18.0 – 
32.0 
76.0 – 
120.9 
Table 42: Results of the FACT-BMT quality of life questionnaire 
 
From the results it appeared that, on average, participants scored highest 
(higher quality of life) in terms of social wellbeing and emotional wellbeing. 
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On average, the lower scores were seen within the bone marrow transplant 
subscale which explored the additional concerns faced by participants. As 
can be seen from the results the wide range of responses confirming that the 
bone marrow transplant experience is different for each individual patient.  
4.5.9.2 OHIP-14 quality of life questionnaire  
The Oral Health Impact Profile – 14 is an adapted version of the Oral 
Health Impact Profile – 49 exploring the dimensions of oral health as first 
proposed by Locker in 1994, these include (Slade, 1997, Slade, 1998): 
 Functional limitation 
 Physical pain  
 Psychological discomfort 
 Physical disability 
 Psychological disability 
 Social disability  
 Handicap 
OHIP-14 uses these dimensions to evaluate the impact of the 
participants’ mouth, teeth, and dentures on their daily life, including function, 
aesthetics, pain and emotional status. The questionnaire is scored from 0 – 
4, where 0 refers to never having the experience of the issue to 4 where the 
issue is experienced very often. A high score suggests a worse oral health 
related quality of life. The total score of the questionnaire is 48.  
The results for these participants can be seen in Table 43.  
Generally, the participants had low scores in relation to their Oral Health 
Impact Profile indicating an overall better oral health related quality of life with 
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an average score for this cohort of 15.4 out of a possible 48. However, the 
range of responses varied amongst participants and this questionnaire was 
completed at one point in time thus no comparisons can be made. With 
regard to the question responses, the questions that received higher scores 
(thus indicating a poorer oral health impact profile) were question 5 and 
question 10. Both of these questions focused on respondents’ feelings of 
self-consciousness and embarrassment in regard to their teeth.  
 
Q 
1 
Q 
2 
Q 
3 
Q 
4 
Q 
5 
Q 
6 
Q 
7 
Q 
8 
Q 
9 
Q 
10 
Q 
11 
Q 
12 
Q 
13 
Q 
14 
Total 
1 0 0 2 0 0 0 0 2 2 0 0 0 2 0 8 
2 0 2 0 1 1 1 0 0 0 2 0 2 2 0 11 
3 0 0 0 2 4 3 1 1 2 4 3 2 2 0 24 
4 0 3 2 2 3 2 0 1 2 2 0 2 3 0 22 
5 0 3 0 2 2 0 2 0 0 2 0 0 2 0 13 
6 0 0 0 0 4 4 0 0 2 4 1 1 3 2 21 
7 0 2 1 0 2 2 0 0 0 2 0 0 0 0 9 
Q. 
Total  
0 1.4 0.7 1 2.3 1.7 0.4 0.6 1.1 2.3 0.6 1 2 0.3 
 
           
Total average  15.4 
Table 43: Results of OHIP-14 quality of life questionnaire 
 
4.5.9.3 Lee cGvHD symptom scale 
The Lee cGvHD symptom scale is used to assess the impact of the multi-
organ manifestations of cGvHD on quality of life (Lee et al., 2002, Merkel et 
al., 2016). The questionnaire evaluates the impact of cGvHD across seven 
different domains consisting of thirty items: 
1. Skin 
2. Eyes and mouth 
3. Breathing  
4. Eating and digestion  
5. Muscles and joints 
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6. Energy  
7. Mental and emotional.  
The participants were asked to limit their responses as to how they had 
felt within the last month at the time of the questionnaires being completed. 
The responses were scored from 0 (not affected at all), to 4 (extremely 
affected).  The totals of each subscale were calculated and then linearly 
transformed to a 0 to 100 scale where 0 indicates that all answers were a 0 
and 100 indicates all answers were a 4.  
The results for this patient cohort are displayed in Table 44. 
A summary of the total scores for each subset of questions can be seen 
in Table 45.  For this questionnaire, higher scores represent a poorer quality 
of life with regards to cGvHD. Table 44 shows the total scores for each 
participant and the average score for each subset. As can be seen in Table 
45, the total scores for each participant were quite low, ranging from 7.1 to 
34.6.The average scores for each subset were low with the poorest quality of 
life in regards to cGvHD being seen in the subsets of “Energy” and “Mental 
and Emotional” where both subsets scored 39.3. 
Overall, on viewing the results, it was apparent that the participants within 
this study generally reported having a good quality of life with regard to their 
bone marrow transplant, oral health and cGvHD symptoms.  
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Participant P1 P2 P3 P4 P5 P6 P7 
Skin 
       
a 1.0 0.0 1.0 0.0 1.0 0.0 0.0 
b 3.0 1.0 1.0 0.0 2.0 0.0 1.0 
c 0.0 0.0 2.0 0.0 0.0 0.0 0.0 
d 0.0 1.0 2.0 0.0 0.0 0.0 0.0 
e 0.0 1.0 3.0 1.0 1.0 3.0 1.0 
Total for subset  4.0 3.0 9.0 5.0 4.0 3.0 2.0 
Linear transformation  20.0 15.0 45.0 5.0 20.0 15.0 10.0 
Eyes/mouth 
       
f 3.0 1.0 0.0 3.0 1.0 1.0 2.0 
g 3.0 0.0 0.0 3.0 0.0 0.0 0.0 
h 0.0 0.0 0.0 0.0 1.0 1.0 2.0 
i 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
j 1.0 0.0 0.0 0.0 1.0 0.0 0.0 
k 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Total for subset  7.0 1.0 0.0 6.0 3.0 2.0 4.0 
Linear transformation  29.2 4.2 0.0 25.0 12.5 8.3 16.7 
Breathing 
       
l 0.0 0.0 2.0 1.0 2.0 1.0 1.0 
m 1.0 0.0 1.0 0.0 2.0 0.0 1.0 
n 4.0 0.0 1.0 0.0 4.0 1.0 1.0 
o 1.0 0.0 0.0 0.0 1.0 0.0 0.0 
p 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Total for subset 6.0 0.0 4.0 1.0 9.0 2.0 3.0 
Linear transformation  30.0 0.0 20.0 5.0 45.0 10.0 15.0 
Eating 
       
q 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
r 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
s 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
t 0.0 0.0 0.0 1.0 0.0 1.0 0.0 
Total for subset 0.0 0.0 0.0 1.0 0.0 1.0 0.0 
Linear transformation 0.0 0.0 0.0 6.3 0.0 6.3 0.0 
Muscles/joints 
       
u 0.0 1.0 2.0 0.0 3.0 0.0 1.0 
v 0.0 0.0 2.0 0.0 2.0 0.0 0.0 
w 3.0 0.0 1.0 0.0 1.0 0.0 1.0 
x 3.0 1.0 2.0 0.0 4.0 4.0 1.0 
Total for subset 6.0 2.0 7.0 0.0 10.0 4.0 3.0 
Linear transformation  37.5 12.5 43.8 0.0 62.5 25.0 18.8 
 
 
 
165 
 
Participant P1 P2 P3 P4 P5 P6 P7 
Energy 
       
y 4.0 1.0 4.0 0.0 4.0 1.0 1.0 
z 2.0 1.0 4.0 0.0 4.0 3.0 1.0 
aa 0.0 0.0 3.0 0.0 0.0 0.0 0.0 
Total for subset 6.0 2.0 11.0 0.0 8.0 4.0 2.0 
Linear transformation  50.0 16.7 91.7 0.0 66.7 33.3 16.7 
Mental/emotional 
       
bb 2.0 2.0 2.0 0.0 1.0 2 0 
cc 2.0 2.0 2.0 1.0 1.0 3 4 
dd 2.0 2.0 1.0 0.0 2.0 0 2 
Total for subset 6.0 6.0 5.0 1.0 4.0 5 6 
Linear transformation  50.0 50.0 41.7 8.3 33.3 41.7 50 
Table 44: Results of Lee cGvHD symptom scale quality of life questionnaire 
 
 
P1 P2 P3 P4 P5 P6 P7 Average 
Skin 20.0 15.0 45.0 5.0 20.0 15.0 10.0 18.6 
Eyes/Mouth 29.2 4.2 0.0 25.0 12.5 8.3 16.7 13.7 
Breathing 30.0 0.0 20.0 5.0 45.0 10.0 15.0 17.9 
Eating 0.0 0.0 0.0 6.3 0.0 6.3 0.0 1.8 
Muscles/joints 37.5 12.5 43.8 0.0 62.5 25.0 18.8 28.6 
Energy 50.0 16.7 91.7 0.0 66.7 33.3 16.7 39.3 
Mental/emotional 50.0 50.0 41.7 8.3 33.3 41.7 50.0 39.3          
Total score 31.0 14.0 34.6 7.1 34.3 19.9 18.2 22.7 
Table 45: Summary of Lee cGvHD symtom scale quality of life questionnaire 
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4.6 Discussion 
4.6.1 Interpretation of the results 
Overall, the individuals within the study understood the reasoning 
behind a pre-HSCT dental assessment and the need to complete any 
necessary dental treatment prior to transplant. There was an awareness of 
the importance of good oral hygiene and how this needed to be continued 
throughout and following the transplant process. From the interviews, insight 
was gained into the challenges facing this cohort of patients, for example the 
need to attend multiple hospital appointments, difficulties carrying out their 
normal daily routines and the emotional impact of their transplant journey. 
4.6.1.1 Preventing transplant related complications  
In keeping with national guidance, all patients who are receiving a 
haematopoietic stem cell transplant, chemotherapy or radiotherapy for 
cancer treatment should receive a pre-interventive dental assessment, 
provision of dental treatment and preventative advice (The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018).  
The participants within this cohort were, on the whole, informed by 
their medical team (doctors and specialist nurses) as to the reason for 
attending the dental assessment and so viewed the dental assessment as 
part of the HSCT process. The individuals interviewed were informed that the 
mouth was a potential source of infection during the period of 
immunosuppression and understood that any dental pathology required 
treatment to reduce the risk of infection. A further qualitative study, 
completed in Brazil, also found that patients tended to only attend the dental 
assessment appointment as the request was made by the medical 
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practitioner thus it was seen as part of the HSCT process (Mendes et al., 
2018).   
However, one of the individuals within the cohort of the current study 
gained her knowledge from previous health care interventions. The individual 
had received a dental assessment prior to chemotherapy to treat breast 
cancer in 2011. During this episode of chemotherapy she experienced 
severe oral ulceration and was therefore aware, ahead of her HSCT, of the 
importance of good oral hygiene and maintaining a normal oral hygiene 
regime throughout transplant.  
Receiving preventative advice and the need to avoid or treat potential 
sources of infection, of which the oral environment is a potential source, were 
the two main reasons highlighted by this cohort for attending the dental 
assessment appointment.  
Participants saw good oral hygiene as a way of combating oral 
ulceration and mucositis following HSCT, in keeping with the evidence which 
suggests improvements in oral hygiene and periodontal health can reduce 
the severity and duration of mucositis (Da Silva Santos et al., 2011, 
Kashiwazaki et al., 2012, Gürgan et al., 2013).  
The individuals in this cohort discussed the difficulties in maintaining 
their normal oral hygiene regime whilst in hospital during the transplant 
period. They highlighted that their priorities changed, in particular, if admitted 
to intensive care or due to fatigue or illness. Additionally, experiencing 
mucositis, and the associated pain or bleeding from the oral cavity, reduced 
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the frequency of toothbrushing. Hence other techniques such as 
mouthwashes were advised to cleanse the oral cavity.  
The individuals within this study felt that an increased awareness of 
oral hygiene on the ward, such as posters and personalised preventative 
plans, would have been a useful aid to remind them to brush their teeth or 
use mouthwash.  
4.6.1.2 Patient experience of the care received  
The individuals who were interviewed within this study were grateful to 
be seen within a specialist dental setting either because of the enhanced 
knowledge and understanding that the dental specialists or specialty trainees 
had about their cancer diagnosis and treatment or because all of the patients 
are referred to one place and so everyone was presumed to be receiving the 
same standard of care. It was felt that having a single dental unit would 
improve the communication with the Haem-oncology team as opposed to 
patients seeing multiple general dental practitioners.  
The study highlighted that further information was required for patients 
receiving HSCT regarding the types of dental treatment available together 
with the different treatment modality options. The treatment plan was often 
dictated by the time available prior to transplant, with the priority being 
treatment of teeth of poor prognosis and associated signs of infection. 
Although conscious sedation was a possible treatment modality for the 
majority of patients, its availability is more limited than treatment with local 
anaesthetic. One individual within this study highlighted his dental anxieties 
and preference for sedation, unfortunately his treatment was not provided 
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due to the limited time prior to transplant and cancelled appointments, 
however, following his HSCT, he felt more confident in managing treatment 
with local anaesthetic alone.  
Many studies within the literature highlight time limitations prior to 
transplant as a particular challenge in treating this cohort of patients, in 
addition to their medical status, including thrombocytopenia and neutropenia, 
impacting on the ability to arrange suitable appointments to complete the 
necessary dental treatment (Elad et al., 2003, Yamagata et al., 2006, Bos-
den Braber et al., 2015, Bogusławska-Kapała et al., 2017, Mendes et al., 
2018).  
Additionally, individuals within this study highlighted the difficulties and 
challenges in attending further appointments for dental treatment due to the 
pressures of attending haem-oncology review appointments, treatment 
appointments for chemotherapy and radiotherapy, additional medical 
appointments and being a hospital inpatient within the hospital for prolonged 
periods of time. These conflicting demands on a patients’ time further limited 
the time available to provide the necessary dental treatment and so perhaps, 
closer liaison with the medical team or earlier referral would relieve some of 
this time pressure.    
This cohort had mixed views regarding future dental care provision 
following HSCT, with some individuals seeing themselves as “transplant 
patients” and so presumed that care would be continued in a specialist 
setting whereas others would prefer to see their own dentist due to the 
rapport that they have with them, the normalisation of seeing a dentist in 
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community, and care being available closer to home. The literature 
highlighted that, while patients preferred to be seen by their own GDPs, they 
also wanted reassurance of treatment in a specialist centre. Reasons given 
by the patients in 2 studies for specialist dental care included refusal of GDPs 
to treat them due to their medical status and a lack of patient trust in their 
own GDP to be able to provide treatment outside of a hospital setting 
(Nuernberg et al., 2016, Mendes et al., 2018). A further study suggested a 
shared care approach to providing dental treatment for this patient cohort, 
with more invasive treatment being provided within the hospital but with 
simple treatment provision at a dental practice closer to the patient’s home, 
thus reducing the impact on their daily routine (Elad et al., 2003).  
To ensure effective shared dental care for this patient cohort, 
education of specialist dental staff, general dental practitioners and the 
patients’ medical team is required to ensure that everyone is aware of the 
suitability of the dental treatment and the appropriate safe haematological 
reference ranges for each setting.  
This present study suggests there were difficulties in arranging a 
follow up appointment post-HSCT. Some of the individuals interviewed had 
outstanding dental treatment and were delayed in being re-referred to the 
Special Care Dentistry Department following their transplant. This again 
highlights the need for more effective communication with both the medical 
and dental team and an update to the current care pathway with patient 
specific information regarding follow up appointments, which may be useful in 
improving access to care post-transplant. If the patient was well and 
haematologically stable then the review and treatment could take place with 
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the patient’s own GDP. However, national guidance suggests ongoing dental 
care in a specialist setting for a year following HSCT (The Royal College of 
Surgeons England / British Society of Disability and Oral Health, 2018).  
In addition, long term complications of HSCT such as xerostomia and 
GvHD highlight the need for further dental surveillance following transplant 
since patients with these complications are at increased risk of dental caries 
and/or of malignant change with oral GvHD. The literature suggests the 
dental reviews would be appropriate within the primary care setting (Petti et 
al., 2013, Torres-Pereira et al., 2014, Santos-Silva et al., 2015, Tsushima et 
al., 2015, Weng et al., 2017).  
4.6.1.3 Consequence of medical management  
There are numerous complications following HSCT that can affect 
patients in the early or late stages following transplant.  
Infections are a severe risk following HSCT due to the 
immunosuppressive nature of patients during the immediate post-transplant 
period. Within this cohort, participants described the variety of infections that 
they had experienced and the side-effects of the drugs used to treat them. 
Many of the individuals experienced multiple admissions to hospital following 
chemotherapy or HSCT for infections of a bacterial and viral nature including 
pneumonia. In addition, they described fungal infections of the mouth and 
other organs including the lungs.  
The immunosuppressed nature of individuals during transplant is the 
rationale for a pre-HSCT dental assessment and treatment of any dental 
pathology (Epstein et al., 2009, The Royal College of Surgeons England / 
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British Society of Disability and Oral Health, 2018). There is limited evidence 
to support this with some studies finding no difference in odontogenic 
infections in patients who have received dental treatment compared to those 
that have not (Melkos et al., 2003, Yamagata et al., 2006, Yamagata et al., 
2011, Barrach et al., 2015). In contrast, other studies describe odontogenic 
infections causing septicaemia or organisms present in the oral cavity being 
identified as the likely cause of sepsis (Akintoye et al., 2002, Soga et al., 
2008, Masaya et al., 2013), with one study highlighting two cases of sepsis 
as a consequence of oral mucositis (Yamagata et al., 2011). All of these 
studies describe sepsis as a consequence of HSCT and therefore the 
management of dental pathology and improvement in oral hygiene would 
theoretically lower the risk of sepsis associated with the oral cavity.   
Graft versus Host disease (GvHD) is a well-documented acute and 
chronic complication of allogeneic HSCT affecting between 30-60% of HSCT 
survivors (Filipovich et al., 2005). Individuals within this study highlighted the 
varying nature of GvHD presentation and severity, from some describing a 
skin rash and changes in appearance to their oral cavity to others describing 
a severe impact of GvHD of the gut causing malnutrition and need for 
prolonged hospital stays.  
GvHD impacts significantly on overall mortality. Within the literature, 
GvHD is the cause of death in 32% to 70% of cases. However, the studies 
are over a 10 year and 5 year period respectively (Mays et al., 2013, Duncan 
et al., 2015).  
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In addition, for patients surviving with chronic GvHD, there is an 
impact on their quality of life. One study compared the quality of life of those 
who had both extra-oral and oral presentation of GvHD to that of those who 
had extra-oral or oral presentations alone. They found no meaningful 
difference between the groups, however the authors found that the disease 
severity was worse in the groups where there was extra-oral presentation of 
the disease (DePalo et al., 2015). 
Oral complications were experienced by the individuals within this 
study, they described having a sore mouth (mucositis) with associated 
difficulties in toothbrushing, changes in tastes (dyguesia) and experience of 
candida infections. However, as a cohort they were able to contextualise 
these complications in regard to the rest of their transplant. Disturbances in 
taste was discussed at length by multiple individuals within this study and 
although self-limiting, caused a lasting impression on these participants 
during their transplant period.  
One study within the literature highlighted that altered taste was more 
prevalent in patients who receive total body irradiation as part of their 
allogeneic HSCT (Brand et al., 2009). 
A common oral complication which was not described by this cohort 
was that of xerostomia. Xerostomia is again a self-limiting complication of 
HSCT and has been found in the literature to improve within 1 year following 
HSCT (Laaksonen et al., 2011, Mauramo et al., 2017). However, the dental 
consequence of hyposalivation is that of dental caries and again warrants 
dental review and necessary intervention, in particular prevention advice 
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following HSCT (Castellarin et al., 2012, Ertas et al., 2014, The Royal 
College of Surgeons England / British Society of Disability and Oral Health, 
2018).  
Oral complications can impact on difficulties in eating and the 
evidence suggests that good nutrition during HSCT can improve recovery 
and reduce length of hospital stay (Espinoza et al., 2016, European Society 
for Blood and Bone Marrow Transplantation, 2019e). The individuals within 
this study highlighted difficulties in eating either as a consequence of a sore 
mouth, change in taste, or a reduced appetite due to the emotional impact of 
transplant. To combat these difficulties adjuncts to feeding were 
implemented, such as supplemental nutrition or nasogastric tubes and in 
some cases total parenteral nutrition was required. Within this cohort, some 
participants accepted any additional nutrition that was suggested as a way of 
recovering quicker and reducing the inpatient stay, whereas others 
highlighted their reluctance to have a nasogastric tube as they saw it as 
uncomfortable and distressing.  
Individuals within this study also highlighted the other effects of their 
treatment, particularly the overall impact on their life. They described 
changes in their appearance, particularly the impact of hair loss, needing to 
use an electric razor due to the risk of bleeding and also the amount of time 
spent in hospital with one participant spending their 21st birthday as an 
inpatient. They also described continued anxiety regarding infection risk and 
also the guilt associated with surviving.  
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4.6.1.4 Psychological impact of treatment  
The diagnosis of a haematological malignancy and its treatment 
(chemotherapy, HSCT) present a challenging and life-threatening period for a 
patient with subsequent psychological impact.  
Individuals within this cohort described the anxiety experienced in 
regard to the period prior to transplant but also the continued anxiety 
following transplant with regard to their longer term survival. Before 
transplant, individuals described periods of relapse and time spent on the 
donor waiting list awaiting a match. In addition following transplant, patients 
described the effect of their experience on their daily life, such as continued 
awareness of infection. The biggest worry for participants was the fear of 
relapse of the disease and the need for further medical intervention. One 
participant highlighted his feelings that he wouldn’t be able to go through the 
HSCT process again.  
Within the literature, disease relapse, concerns regarding medical 
status, and appearance are prevalent as post-HSCT trepidations (Mosher et 
al., 2011). In addition, the effect on family life and employment status feature 
highly (Mosher et al., 2011). One study found that those who find 
employment with higher incomes have a better functional status and have a 
better quality of life following transplant (Mosher et al., 2011). Other studies 
have found that an optimistic attitude towards the future together with a good 
social support network were related to a better ability to cope post-transplant 
(Beeken et al., 2011, Rueda-Lara and Lopez-Patton, 2014). In addition 
mental health issues, such as depression, post-traumatic stress disorder and 
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delirium feature highly with patients following HSCT (Rueda-Lara and Lopez-
Patton, 2014). 
Within the Stem Cell Transplantation and Cellular Therapy Unit (CCC), 
counsellors were available to help patients through the process of HSCT. 
This service, although limited, was also available following HSCT. A specific 
long term service for these patients may be helpful in negating some of the 
emotional and mental consequences of this distressing period within a 
patient’s life.  
In addition to general anxiety, specific dental anxiety is prevalent 
within the population. The most recent Adult Dental Health survey in 2009 
highlighting that 48% of the adult population have moderate to severe dental 
anxiety. It is therefore unsurprising that individuals within this patient cohort 
were anxious of both dental treatment and pre-HSCT dental assessment 
(National Health Service, 2009). Some of the participants within the cohort 
who were unable to have their dental treatment prior to transplant felt that 
having experienced the transplant process, their dental anxieties had been 
alleviated somewhat and they felt more relaxed about attending dental 
appointments in the future.  
Other participants highlighted anxieties around future dental treatment 
and the appearance of their teeth and were unsure who would provide the 
necessary dental treatment in the long term. This again highlights the need to 
improve delivery of information to patients on the service that is provided as 
part of their care pathway.  
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4.6.1.5 Quality of Life  
The second element of this study was to review the participants’ 
quality of life in reference to their bone marrow transplant, oral health and 
experience of GvHD through three separate quality of life questionnaires (see 
Methodology section 14.4 for full description of each questionnaire).  
On reflection, the use of these questionnaires as a part of this study 
was not fit for purpose as they were only used at one point in time and 
therefore did not allow pre-/post- HSCT comparisons. Thus, they provided 
information of limited value within the current study.  
Overall, the quality of life of these 7 individuals was good in terms of 
their post-BMT experience, experience of GvHD and oral health. However, 
there were elements of each questionnaire that showed where quality of life 
was deemed lower.  
4.6.1.5.1 OHIP-14 
From an oral health perspective some participants highlighted 
concerns with the appearance of their teeth and feelings of embarrassment in 
relation to their teeth. This links with the qualitative results where participants 
highlighted concerns related to dental follow up, anxieties around missing 
teeth subsequent to extractions, and also a concern regarding staining of 
their teeth following medical treatment, including prolonged use of 
chlorhexidine mouth wash.  
There has been limited use of oral health related quality of life 
(OHRQoL) questionnaires for haematopoietic stem cell transplant recipients. 
However, one study conducted in Brazil in 2015 compared OHIP-14 of 
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patients prior to HSCT to a group of healthy individuals. Although there was a 
weak correlation of oral health related quality of life between the groups, they 
found that patients awaiting HSCT with a severely neglected dentition 
reported poorer oral health related quality of life. However, their study did not 
compare results post-HSCT and therefore the impact of the HSCT process 
on OHRQoL was unknown (Tinoco-Araujo et al., 2015). 
The OHIP-14 questionnaire has also been used in two studies 
evaluating the use of low-level laser therapy (LLLT) in the treatment of 
mucositis for HSCT recipients. One study found that the use of LLLT had no 
impact on quality of life between those receiving LLLT and those who did not 
(Silva et al., 2015). The other study found the QoL for those treated with 
LLLT improved with time; however as mucositis resolves within 14-21 days 
the QoL would be expected to improve with time without interventive 
treatment (Bezinelli et al., 2016). 
4.6.1.6 FACT BMT 
The FACT-BMT quality of life questionnaire has been designed 
specifically for patients undergoing bone marrow transplantation, and is 
usually used prior to and following HSCT (FACTIT, 2010).  
Given the limited sample size within the current study, it was difficult to 
draw conclusions from these results. In general, participants reported having 
a higher quality of life with regards to their bone marrow transplant 
particularly with regard to their emotional and social well-being. In addition, 
participants only completed the questionnaire following their transplant and 
so comparisons could not be made to their quality of life prior to HSCT.  
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4.6.1.7 Lee GvHD symptom score 
The Lee GvHD symptom score reviews the impact of the multi-organ 
effect of GvHD on patients’ quality of life (Lee et al., 2002, Merkel et al., 
2016). The use of this questionnaire has been recommended since 2005 by 
the NIH to capture the GvHD symptoms and their effects (Merkel et al., 
2016).  
From the questionnaire the participants within this current study 
reported a positive outlook on their quality of life in regards to chronic GvHD. 
The areas where they reported poor quality of life were around the amount of 
energy they had and also their mental and emotional wellbeing.  
As the questionnaire was only completed at one point in time, the time 
of transplant was different for each individual, it was not possible to compare 
the results. Participants were asked to consider the questionnaire with regard 
to the last month, and therefore, as they had their transplant at various times, 
the symptoms would have been different for each individual. Some may have 
been on long-term treatment for GvHD (although this was not investigated as 
part of the study) and they may have adapted and learned to cope with and 
manage their GvHD symptoms reducing the impact on quality of life.  
Within the literature, the Lee GvHD symptom score is ideally used in 
combination with other quality of life questionnaires. Lee recommends the 
use of the questionnaire along with the FACT-BMT quality of life 
questionnaire and the Short Form health survey (SF-36) to ensure a full 
robust assessment of a patients’ quality of life (Lee et al., 2002). Although the 
current study also used the FACT-BMT questionnaire, the results overall 
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were limited as the participants were at different stages post-transplant and 
only completed the questionnaire at a single point in time.  
The impact of GvHD on quality of life has been assessed with other 
quality of life questionnaires. Depalo et al. utilised the SF-36 and FACT-BMT 
to assess if there was any differences in quality of life when comparing extra-
oral GvHD, oral GvHD and those experiencing both. They found that quality 
of life was lower, if there was an extra-oral component of the disease 
(DePalo et al., 2015).  
The Lee GvHD symptom score is a validated specific questionnaire that 
would give valuable results if utilised correctly within the framework of a 
potential future prospective study (Lee et al., 2002, Merkel et al., 2016). 
4.6.2 Limitations of the study  
There were a number of limitations of this study. Firstly the sample 
size was small with only 7 participants being interviewed. The length of the 
interviews ranged from 15 minutes to 45 minutes which could be a reflection 
of the limited experience of qualitative research of CW-D or reflective of the 
fact that some participants felt more comfortable to discuss their experiences 
in depth, whereas others were more withdrawn. In addition, although no new 
themes appeared to be emerging, achievement of data saturation is unclear 
due to the difficulties discussed previously in Section 4.4.9 and Section 4.5.3. 
Unfortunately it was not possible within the time constraints of the study to 
conduct further interviews.  
On reflection only a select number of patients have an allogeneic 
HSCT within the Clatterbridge Cancer Centre each year, hence the variety of 
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individuals was broad, with HSCT being the recommended treatment for 
multiple diseases, and these diseases affecting patients of any age and both 
genders. There is therefore the possibility that saturation could never be 
reached. Furthermore, the topic guide for this study was again rather broad, 
looking at both the pre-HSCT assessment and dental treatment but also the 
post-HSCT complications and the journey as a whole. This gave a broad 
variety of responses and perhaps, for future research a more niche topic 
guide would be required to increase the quality of the responses.   
A further challenge of this study was the recruitment process. As 
mentioned throughout the study the participants had multiple conflicting 
demands on their time, with their appointments being flexible in regard to 
timings. This made it difficult to arrange a suitable time for participants to 
attend for interview. Participants were also reluctant to attend the hospital on 
a different day to their appointments, therefore for future studies, a neutral 
environment away from the hospital and closer to the patients’ home may be 
preferable but would take away the availability of the medical team should 
any issues arise.  
Additionally, the recruitment process only captured the views of 
participants who wished to be engaged with medical research. There were 
patients who were approached who declined to take part in the research 
project, one of whom was not happy that he had not had a denture 
constructed as part of his dental treatment. His views of the service would 
have been extremely valuable in this study. For future studies the use of a 
gate-keeper, e.g. a specialist research nurse, to recruit participants and 
facilitate initial rapport with the research may increase recruitment rates.  
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The next limitation of this study was the fact that given the small 
number of patients available for recruitment, the time since the patients’ 
transplant was varied, with some having their transplant in the last year, to 
others having had their transplant a number of years ago. This raised the 
issue of recall bias and whether what they are reporting was accurate (Green 
and Thorogood, 2014b). For future studies it would be preferable to interview 
participants within a defined timespan following transplant to ensure more 
accurate information and perhaps information that was more in depth and 
valuable.    
As mentioned previously this was CW-D’s initial experience of 
qualitative research and so, with experience and guidance, the interview and 
analysis techniques would be improved upon.  
Unfortunately, the use of the quality of life questionnaires within this 
project added limited additional value to the study. The sample size was 
small and all of the participants were at a different stage post-HSCT and 
given the difficulties in recruitment it was not possible for this to be 
standardised. In addition, the questionnaires only captured one point in time 
and there were no results to which to compare them to. In future, prospective 
studies could be devised to address the need for standardisation of the 
timing of the questionnaire for each individual. In addition, completion of the 
questionnaire at different stages of the transplant process and recovery 
would be necessary to evaluate changes in quality of life and may increase 
the validity of the results. 
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4.6.3 Reflexivity 
Reflexivity is a necessary part of qualitative research whereby the 
impact of the researcher on the interview, analysis and reporting process is 
explored. Ideally within qualitative research the researcher is invisible, 
however this is unlikely to be possible in most projects (Green and 
Thorogood, 2014a, Ritchie et al., 2014c).  
There were multiple potential areas of bias with regards to reflexivity in 
this study. The researcher, CW-D, worked as a Speciality Registrar within the 
Special Care Dentistry Department and participants were made aware of this 
at the time of the study. The knowledge that the person conducting the 
interview was a dentist is likely to have had an effect on the participants’ 
responses. Also the researcher herself had preconceived knowledge and 
experience of treating this patient cohort which may have influenced not only 
the interview process but the analysis.  
In addition, it was difficult for CW-D to detach from the emotive side of 
the participants’ experiences and not to provide reassurance throughout the 
interview. Becoming a researcher as opposed to a clinician was a difficult 
achievement, but became easier with the later interviews.  
As the interviews were emotive in their content, and in some cases 
distressing, the process of transcribing all of the interviews provided an 
effective method of debrief for CW-D. In addition, discussion around the main 
themes of each interview with clinical colleagues, along with supervisors, 
helped gain perspective on the research project.   
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For future studies the use of a gate keeper in recruiting patients and 
forming the initial introduction between the potential participant and the 
researcher may improve recruitment. Additionally, if the researcher was 
someone non-specific to the patients’ medical or dental team, then the 
participant responses may be more open.  
4.6.4 Strengths of the study 
There were also a number of strengths of this study. Conducting 
qualitative research allowed for an in-depth perspective directly from the 
patients using this service.  
The study did not look solely at the dental service and oral health 
perspective but also the medical management and therefore improvements 
to both services could be implemented in the future to provide a positive 
impact on patient care.   
In order to make the study more reliable, supervisors reviewed some 
of the transcripts and all of the themes and results were reviewed by ST and 
RH.  
Importantly, conducting this qualitative research has highlighted that it 
is possible to recruit from this hard to reach and vulnerable patient cohort. 
However, for future research a more specific patient population and topic 
guide would be required.  
Although the quality of life questionnaires did not add value to this 
project, they were all validated questionnaires and so if used correctly and in 
combination would be able to show changes in quality of life in regard to the 
experience of bone marrow transplant, effects of GvHD and oral health.  
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4.6.5 Application to clinical practice 
With the views of the individuals within this study in mind, a number of 
improvements to the service could be implemented.  
Participants highlighted the need for more information on the reasons 
for a dental assessment and follow up dental care. There was the suggestion 
made for personalised prevention plans and reminders to be placed on wards 
with regards to oral hygiene. It would be possible to produce posters or 
infographics to provide oral hygiene information and prompts, individual 
preventive plans to be given to each patient at assessment. The production 
of information leaflets to describe the care pathway, what to expect, the 
dental care received and also the importance of follow up dental care would 
also help to meet the patient information need.   
The care pathway requires modification as many participants 
highlighted the delay in attending for dental treatment following HSCT. 
Education for the dental team in the Special Care Dentistry Department, the 
patients’ medical team and also General Dental Practitioners is necessary to 
ensure that the patient is being referred to the correct service at the right 
time. A shared care approach would be ideal, allowing patients to have 
simple and aesthetic treatment closer to home with their own GDP and more 
interventive dental care provided in the secondary care setting, again 
dependant on the severity and stability of the individuals’ haematological 
status.  
A further application to practice involves the psychological aspect of 
the HSCT process, as many participants in this study highlighted prior or 
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current anxieties with regards to their medical status. The current counselling 
service available for HSCT patients it is limited however, an increased 
availability throughout the transplant process would be helpful to better 
support patients’ psychological needs. In addition, one participant in this 
study highlighted that patient advocates would be helpful in order to describe 
the transplant journey and provide reassurance as they are the ones who 
have experienced it first-hand.  
4.6.6 Future research  
Future research of both a qualitative and quantitative nature is 
required for this patient cohort in order to evaluate the impact of dental 
treatment on patients undergoing HSCT. Overall the participants within this 
study found that having a dental assessment prior to transplant was useful 
and reassuring. However, the sample size of the study was small and it is 
unclear if saturation was reached.  
A mixed methods approach involving a prospective longitudinal study 
would allow for dental and medical data collection and semi-structured 
interviews regarding pre-HSCT dental care to be completed at the time of 
dental assessment and then at 100 days post-HSCT to explore patient views 
on dental treatment and oral complications. Limiting recruitment to a specific 
disease process, e.g. AML or myeloma, may aid in achieving saturation, as 
the participants may have more in common such as their chemotherapy 
regimens, ages and gender.  
A study using the quality of life questionnaires OHIP-14, FACT-BMT 
and the Lee GvHD symptom score would be valuable to assess the changes 
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in quality of life and experience of GvHD for these individuals (Slade, 1997, 
Lee et al., 2002, FACTIT, 2010). The questionnaires would need to be 
completed prior to transplant and then at standardised intervals following 
transplant to allow comparisons to be made.  
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4.6.7 Conclusion 
Completion of this study provided insight into a patient’s views of dental 
treatment and oral health within the context of their transplant journey.  
From the interviews completed, four key themes materialised allowing 
exploration of the impact of dental treatment prior to and directly following 
HSCT and also participants’ future concerns with regards to oral health.  
Overall, participants had an understanding of the importance of a pre-
HSCT dental assessment regarding increased risk of infections during their 
period of immunosuppression with the oral environment providing a potential 
source of infection. The majority felt reassured by having their dental 
treatment completed in a specialist setting as they felt the clinicians had an 
increased understanding of their medical conditions.  
Participants had insight into the importance of maintaining good oral 
hygiene throughout transplant. However, they also alluded to the change in 
priorities with regards to daily routines due to the resulting fatigue and 
malaise of the transplant process and the reduction in the ability of 
participants to complete normal oral hygiene practices. 
There was confusion regarding ongoing dental care and the dental 
treatment available to them following transplant.  
The quality of life questionnaires had limited value within this study, 
however, it was positive that each of the seven participants reported a good 
level of quality of life.  
Future work is required on the quality of life of this HSCT patient group 
particularly with reference to oral health. To aid in establishing the impact of 
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dental treatment on HSCT, the use of a mixed methods design would be 
useful in providing a rich data set.  
To conclude, completion of this study will enable changes to the 
current care pathway for patients including provision of more written 
information as to the reason for dental assessment, importance of continued 
oral hygiene and follow up dental care post-HSCT. It also provides a base for 
future research to build upon with regards to improving the oral health care 
for this patient group.  
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5 Chapter 5: Overall conclusion  
In conclusion, the results of this study are consistent with the available 
literature and this study provides an initial insight and overview to the effects 
of dental treatment on patients’ outcomes following allogeneic HSCT.  
From the first project it can be seen that for this cohort of patients, there 
were no detrimental effects of dental treatment following transplant, with no 
patients experiencing neutropenic sepsis as a result of an odontogenic 
infection. In addition, the vast majority of patients received prevention advice 
that impacts on oral complications following transplant. Within the cohort 
there was evidence of patients experiencing oral complications including 
mucositis, xerostomia and stomatitis, highlighting the need for prevention 
advice but also ongoing dental surveillance following transplant.  
From the second project, the qualitative views of participants highlighted 
their appreciation of the dental review prior to transplant and reassurance in 
seeing a specialist dental unit team who were knowledgeable of their medical 
condition and could communicate easily with the medical professionals 
involved in their care. However, participants also highlighted their confusion, 
post-transplant, as to how their continuing dental care would be managed. 
Further efforts to inform and educate both medical and dental professionals 
regarding the dental management of post-HSCT patients would be beneficial 
to patients.  
Further specific research is required as to the impact of oral health and 
HSCT on a patient’s quality of life which was not possible within the time 
limitations of this study. In addition, further prospective longitudinal research 
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is required to determine the clinical effects and outcomes of dental treatment 
on HSCT recipients. Future studies would need to involve multiple centres to 
ensure that a sufficient cohort of patients is recruited. The use of the directed 
acyclic graph within future research would allow for minimal adjustments of 
the variables within the statistical analysis.  
From a service perspective positive improvements can be made to the 
established care pathway as a result of this research. Improving the 
communication with both the medical team and patients with regards to the 
initial referral and treatment could ensure a more predictable completion of 
dental treatment prior to transplant. The production of information leaflets is 
required for patients to improve their knowledge of the service, act as 
prompts during the transplant period, and to clarify the re-referral post-
transplant. From a medical perspective standardising the record keeping for 
both mucositis and GvHD would allow for consistent recording and provision 
of the most appropriate management of these oral complications.  
Introduction, embedment and review of these improvements to the 
service would hopefully prove helpful for patients at a particularly challenging 
and vulnerable stage in their lives.  
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7.4 Appendix 4: Key search terms  
 
 
 
 
 
 
Search 
Number 
Key terms (MEDLINE, Scopus, EBSCO, PsycInfo) 
1 haematopoietic stem cell transplant AND dental treatment  
2 haematopoietic stem cell transplant OR bone marrow 
transplant AND dental care OR comprehensive dental 
care OR dental treatment 
3 haematopoietic stem cell transplant AND dental treatment 
AND “quality of life” 
4 haematopoietic stem cell transplant OR bone marrow 
transplant AND dental care OR comprehensive dental 
care OR dental treatment AND “quality of life”  
5 haematopoietic stem cell transplant OR bone marrow 
transplant AND osteonecrosis OR bisphosphonate 
associated osteonecrosis of the jaws  
6 haematopoietic stem cell transplant AND dental treatment 
AND “graft vs host disease” 
7 haematopoietic stem cell transplant AND dental treatment 
AND mucositis  
8 haematopoietic stem cell transplant AND dental treatment 
AND xerostomia OR “dry mouth” 
9 haematopoietic stem cell transplant AND dental treatment 
AND “neutropenic sepsis” 
10 haematopoietic stem cell transplant AND dental treatment 
AND mortality 
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7.5 Appendix 5: Example search strategy 
 
Search terms: 
HSCT OR haematopoietic stem cell transplant OR transplant conditioning  
AND  
Comprehensive dental care OR dental care OR oral health  
 
 
 
  
Medline = 43 articles Scopus = 98 articles 
Total = 197 articles 
Abstracts reviewed + 
included = 93
Included for full review 
= 64
Duplicates removed = 
29
Excluded = 104
(irrelevant, not 
English, unable to 
access) 
Ebsco = 56 articles 
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7.6 Appendix 6: Literature summary 
 
Dental Assessment  
Author/ Title /Level of 
Evidence 
Sample Characteristics Study Design  Summary of Findings  
 
 
(Abed et al. 2019)  
Oral and dental 
management for 
people with lymphoma  
4 
 
No sample described – 
review article/expert 
opinion 
Review article/expert opinion 
No structured literature 
review described 
Describes treatment for lymphoma 
including HSCT. Describes pre HSCT 
dental assessment, haematological 
values and post-HSCT review  
Describes GvHD as a complication of 
allogeneic HSCT.  
 
(Boguslawska-Kapala. 
A. et al. 2017) 
Oral health of adult 
patients undergoing 
hematopoietic 
cell transplantation. 
Pre-transplant 
assessment and care 
4 
No sample described – 
review article  
Review article/expert opinion 
No structured literature 
review described 
Described development of 
their local protocol for 
treatment pre-HSCT 
Gives a well-balanced argument for the 
provision of dental care prior to HSCT – 
discussed radical vs minimalistic 
treatment plans  
Discusses limitations in providing 
treatment – medical status, timing of 
appointments  
Highlights risk of providing treatment 
pre-HSCT – thrombocytopenia, 
neutropenia  
Discusses importance of providing oral 
hygiene due to post-transplant 
complications – xerostomia, mucositis.  
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(Burke et al. 2014) 
Dental management 
during 
stem cell 
transplantation 
4 
No sample described – 
review article  
Review article/expert opinion 
No structured literature 
review described. 
Describes stages of HSCT – harvest, 
conditioning, infusion 
Describes complications of 
chemotherapy  
Describes post-HSCT complications – 
graft rejection, GVHD 
Describes the role of the dentist and the 
dental team. 
Describes the importance of timing 
dental treatment  
 
(Durey. K. et al. 2009) 
Dental assessment 
prior to stem cell 
transplant: treatment 
need and barriers to 
care 
3 
94/116 complete dental 
records for patients 
undergoing HSCT were 
reviewed  
M:F = 52:42 
Average age:49years (18 
– 67years) 
Transplant type: unknown  
 
Subject dental records were 
reviewed data on subject 
demographics, presenting 
conditions and dental 
treatments along with any 
complications were collected  
Referral for subject was on average 
31.5days prior to HSCT, subjects were 
seen on average within 8days of 
referral. 
79.5% had periodontal disease but often 
unable to perform BPE due to lack of 
information about haematological 
values. 
93.6% of subjects had oral disease 
94.7% of subjects required dental 
treatment – 74.5% active treatment and 
20.2% OHI alone. 
Those subjects who were regular dental 
attenders (29.8%) required fewer 
extractions  
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(De Paula Eduardo. F. 
et al. 2011) 
Oral care in Brazilian 
bone marrow 
transplant centres  
3 
12/36 bone marrow 
transplant centres 
responded to the 
questionnaire 
These centres account 
for 47% of BMT 
completed in Brazil 
 
Questionnaire involving open 
and closed questions was 
sent to 36 BMT centres in 
Brazil. 
Questionnaire looked at who 
was part of the MDT, if dental 
assessment and treatment is 
provided prior to BMT, if 
delays have been caused to 
BMT due to oral conditions, 
use of an oral care protocol, 
use of sodium bicarbonate 
mouthwash, use of laser 
therapy for mucositis, use of 
antibiotic cover and protocols 
for GVHD.  
33.3% response rate 
100% of centres had a dentist as part of 
the MDT 
100% of centres provided an oral health 
assessment prior to BMT 
75% reported delaying BMT due to 
dental pathology 
41.7% of centres thought OHI was the 
most important recommendation 
41.7% of centres recommended the use 
of sodium bicarbonate mouthwash, with 
75% recommending chlorhexidine 
mouth rinse.  
75% of centres used laser therapy in the 
treatment of mucositis either routinely or 
sporadically 
33.3% of centres had a protocol for 
GVHD but use was variable.  
 
(Elad. S. et al. 2003) 
Time limitations and 
the challenge 
of providing infection-
preventing dental care 
to hematopoietic stem-
cell transplantation 
patients 
3 
 
46/86 consecutive HSCT 
patient’s notes were 
reviewed.  
46 patients examined by 
hospital staff 
July 1997 – October 1998 
M:F = 25:21 
Average age – 37years 
 
Retrospective examination of 
case notes 
Patient demographics, 
planned HSCT, details of 
dental assessment, details of 
dental treatment and length 
of time prior to HSCT were 
recorded.  
 
Calculus most common dental finding 
(54.3%) 
Caries was diagnosed in 50% of cases 
 
Dental treatment included scaling and 
OHI (47.8%), simple restorations 
(39.1%), dental extractions (19.5%) and 
were often multiple (10.8%) 
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Average time from assessment to HSCT 
was 20.65 days 
Complex MH of patient cohort makes 
scheduling difficult 
 
Queried need for involving community 
dental service in treating these patients.  
 
(Elad. S. et al. 2015) 
Basic oral care for 
haematology-oncology 
stem cell transplant 
recipients: a position 
paper paper from the 
joint task force of the 
Multinational 
Association 
of Supportive Care in 
Cancer/International 
Society of Oral 
Oncology 
(MASCC/ISOO) and 
the European Society 
for Blood 
and Marrow 
Transplantation 
(EBMT). 
4 
Review paper 
To develop a protocol to 
aid practitioners in 
treating patients with 
haematological 
malignancies  
Review paper/ expert opinion 
paper 
No clear methodology to 
literature review  
 
Recommends dental treatment pre- and 
post- HSCT – provides a basis for 
consensus.  
Multidisciplinary team approach.  
Further research is required within this 
area.  
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(Epstein. J et al. 2009) 
Advances in 
hematologic stem cell 
transplant: An update 
for 
oral health care 
providers 
¾ 
No sample described – 
review article  
 
Review article/expert opinion 
No structured literature 
review described. 
Provision of background information of 
HSCT in the treatment of malignancies, 
recent progresses and appropriate 
advice for oral care providers.  
Highlights complications affecting the 
oral cavity; mucositis, infection, 
bleeding, GVHD, xerostomia, 
dysgeusia, secondary malignancies.  
Describes the oral care involvement 
required at each stage of HSCT.  
 
(Mawardi. H. et al. 
2014) 
Cost analysis of dental 
services needed prior 
to hematopoietic cell 
transplantation 
3 
423 subjects 
M:F= 243:162 
Age range: 18-72 
January 2005 – June 
2007 
Subjects had had a 
dental assessment prior 
to HSCT 
Retrospective study 
From patients dental records 
cost of dental treatment were 
estimated along with the 
reimbursement by insurance 
companies.  
Caries prevalence = 23% 
45.6% of subjects required restorations 
20.5% required 1 or more extractions 
Average cost $275 or $384 dependant 
on insurer  
Dental assessment is assumed to 
reduce overall costs for patients 
undergoing HSCT, than increased stay 
in hospital if the patient acquires 
septicaemia 
(Mendes et al. 2018) 
What haematopoietic 
stem cell transplant 
patients think about 
health and oral care: A 
qualitative study in a 
Brazilian health 
service 
17 participants recruited, 
16 participants 
interviewed  
 
M:F = 9:7 
 
Age = 46 (26-66 years) 
 
Qualitative study  
 
Semi-structured interviews 
were conducted with a topic 
guide that was adjusted 
following the first 5 interviews 
 
Following analysis 3 main themes were 
highlighted: 
1. What is oral health 
Oral hygiene, diet, aesthetics, lack of 
pathology  
2. Dental treatment as required for 
haematopoietic transplant  
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3 
 
Transplant type 
Autologous: Allogeneic = 
4:12  
 
No control group 
 
Topic areas – perceptions on 
oral health, dental treatment 
prior to HSCT, Importance of 
dental treatment prior to 
HSCT 
 
Analysis – content thematic 
analysis  
 
?single interviewer  
 
Interviews conducted on day 
of dental assessment 
following transplant  
Consent completed on the 
day of transplant  
 
Dental referral at request of medical 
staff, preference for treatment with 
own dentist, difficulties in receiving 
treatment – medical barriers. 
3. The importance of dental 
treatment to perform transplants 
Reduce infection risk prior to 
transplant, oral complications post-
transplant, success of transplant  
 
(Morimoto. Y. et al. 
2004) 
Dental Management 
Prior to Hematopoetic 
Stem Cell Transplant  
3 
38 subjects undergoing 
HSCT 
15 subjects for BMT. 
M:F= 9:6. Average age: 
35.9 +/- 11.3 years 
23 subjects for PBSCT. 
M:F 14:9. Average age: 
43.3 +/- 15.1 years 
 
1997-2001  
Retrospective 
Review of subjects 
medical/dental records 
Recorded background 
factors, time from dental 
assessment to HSCT, 
haematological findings, 
dental treatments and 
complications  
Patients with platelet counts <50x109 or 
<30x109 safe to provide XLAs and S+P 
with platelet transfusions. 
Patients with neutrophil counts 1-
1.5x109 can carry out XLAs and S+P 
with antibiotic cover.  
Dental treatment can be problematic 
due to reduced platelet count and 
immunosuppression. 
Need to allow a 2 week healing period 
prior to transplantation 
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(Nuernberg. M. et al. 
2016) 
Access to oral care 
before stem cell 
transplantation: 
understand to improve 
3 
110 subjects who had a 
allogeneic stem cell 
transplant 
M:F= 69:41 
Children: 39 subjects 
aged 4-11years 
Adolescents: 23 subjects 
aged 12-18years 
Adults: 48subjects 
>18years 
March 2014 – March 
2015 
Non-malignant disease = 
most frequent conditions  
Questionnaire sent to 
subjects looking at: 
Patient demographics 
Diagnosis  
Access to dental service and 
history of dental treatment  
Patients preferences – where 
they’d like to receive dental 
treatment  
Knowledge – oral health prior 
to HSCT 
74% of subjects had received oral care 
in the previous year.  
66% said they did not receive guidance 
as to oral care prior to HSCT 
Time limitation is a barrier for accessing 
dental care for subjects undergoing 
HSCT 
17% of subjects were refused dental 
treatment by their own dentist due to 
their medical complexities 
Subjects would prefer to receive dental 
treatment at the transplant centre. 29% 
said they wouldn’t trust a dentist to 
provide treatment outside of a hospital. 
Use of an outside dental service was 
statistically associated with income 
(Nuernberg. M. et al. 
2017) 
Periodontal status of 
candidates for 
allogeneic 
hematopoietic stem 
cell 
transplantation 
2- 
62 subjects recruited, 26 
excluded due to timing of 
HSCT therefore 36 
included.  
 
M:F= 22:14 
Age = 25.5 (14-67years) 
 
Allogeneic only  
Prospective cross-sectional 
study – survey regarding 
patients oral health followed 
by periodontal assessment 
 
Single interviewer and 
examiner – intra and inter-
rater reliability calculated. 
 
Evaluated visible plaque, 
bleeding on probing, pocket 
depths and attachment loss 
on 6 teeth upper and lower.  
There 21/36 participants who had seen 
a dentist in the last year, with 81% 
brushing teeth more than 1 x day.  
 
78% of participants denied receiving 
oral health advice prior to HSCT. 
 
Diagnosis of periodontal disease in this 
cohort was high with 58% having pocket 
depths >4mm and inflammatory 
changes.  
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Excluded platelet counts 
<50x109 or those who were 
uncooperative for 
examination 
 
There was no correlation with bleeding 
on probing and platelet counts or 
diagnosis of periodontal disease and 
neutrophil counts. 
 
Highlighted that although patients self 
reported to have good oral health the 
majority actually had clinically poor oral 
health.  
 
(Pelinsari. C.M. et al. 
2014) 
Dental extractions in 
patients prior to stem 
cell transplant  
3 
33 participants 
 
M:F = unknown 
Age = unknown  
 
Transplant type = 
unknown 
 
All received at least 1 
extraction  
 
Retrospective cohort study 
 
Reviewed bleeding 
complications following 
extraction on patients prior to 
HSCT 
At the time of extraction 7 patients had 
platelet levels <100x109. Those with 
platelet counts <50x109 received platelet 
transfusion (2 cases).  
Fibrillar absorbable sponges were used 
in 2 patients.  
No infectious complications despite no 
antibiotic cover.  
 
Extractions prior to HSCT are safe with 
a recent blood count and assessment of 
platelet levels.  
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Dental effect on HSCT outcome 
Author/ Title /Level of 
Evidence 
Sample Characteristics Study Design  Summary of Findings  
 
 
(Akintoye.S. et al. 
2002) 
A Retrospective 
Investigation of 
advanced periodontal 
disease as a risk factor 
for septicaemia in 
haematopoetic stem 
cell and bone marrow 
transplant 
2- 
77/141 patients who 
received HSCT fulfilled 
inclusion criteria 
January 1996 – 
September 1999 
M:F = unknown 
Average age: 37.3 +/- 
11.9years 
 
2 groups - <20% periodontal 
bone loss and >20% 
periodontal bone loss  
Retrospective review of 
medical and dental notes  
Dental examination 1-3weeks 
before transplant and dental 
treatment  
Periodontal diagnoses were 
drawn from radiographs using 
Schei ruler due to difficulties 
in recording periodontal 
probing depth due to lack of 
haematological values. 
Blood cultures were drawn if 
patients exhibited signs of 
septicaemia 
 
66% of cohort received dental 
treatment prior to HSCT. 
18.2% of sample had >20% horizontal 
bone loss  
72.7% survival rate 
63.6% of sample had positive blood 
culture for septicaemia from which 81 
isolates were recovered 
20 subjects had blood cultures likely of 
subgingival/periodontal origin, 23 
subjects were positive for microbes 
from the oral cavity and 49 with 
organisms from body sites.  
No statistical significant associations 
between radiographic bone loss and 
incidence of septicaemia.  
Patient cohort are at high risk for 
infections.  
(Bos-den Braber. J. et 
al. 2015) 
Oral complaints and 
dental care of 
haematopoietic stem 
cell transplant patients: 
160 adults had HSCT 
2010 and 2011 
101 survived to start of 
survey 2012 
96 responded to survey 
M:F unknown 
Questionnaire to patients 
included 20 questions asking 
them to recall the short and 
long term oral complications 
following HSCT 
 
8/96 patients had not had a dental 
assessment prior to HSCT 
59% had short term oral complaints the 
main one being altered taste 
28% had long term oral complaints the 
main one being dry mouth 
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a qualitative survey of 
patients and their 
dentists 
3 
Average age: unknown 
 
52/88 dentists responded 
to their questionnaire 
 
 
 
Questionnaire to dentists 
(following patient permission) 
asking them to report on 
dental assessment and 
treatment for these patients 
and why it is important 
 
No interview schedule or 
example questionnaire 
provided  
 
Allogeneic transplant – 72% short term 
oral complaints, 47% long term oral 
complaints  
Autologous transplant – 52% short 
term oral complaints, 17% long term 
oral complaints.  
Pre and post transplant 52% visited 
dentist to ensure mouth was fine 
49% were aware of professional 
cleaning and 31% wanted OHI prior to 
hospitalisation 
54% of dentists stated the patient’s 
medical condition made treatment 
more difficult. 
Visiting a dentist (73% before, 77% 
after), how to brush teeth (77% before 
and 60% after) and using a fluoride 
rinse (50% before and after) were the 3 
most important recommendations 
given by dentists.  
 
(Braga-Diniz. J. et al. 
2017) 
The need for 
endodontic treatment 
and 
systemic 
characteristics of 
hematopoietic 
188 participants  
 
M:F = 114:74 
 
Age: unknown 
 
Pre HSCT = 103 
 
Retrospective study  
 
Medical records reviewed 
March 2011 – March 2016 
 
Review the characteristics of 
HSCT and the need for 
endodontic treatment  
The majority of participants were 
having HSCT for leukaemia.  
Potential for dental infections to have a 
negative impact on HSCT success 
 
24.3% of participants required 
endodontic treatment pre-HSCT, 
24.7% required endodontic treatment 
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stem cell 
transplantation 
patients  
2- 
 
Transplant type 
Autologous:Allogeneic = 
13:175 
 
 
 
post-HSCT. Highlighting the need for 
dental assessment pre-HSCT and 
post-HSCT. 
 
Doesn’t discuss reason for endodontic 
treatment as opposed to extraction  
(Elad. S. et al. 2008) 
A decision analysis: 
The dental 
management 
of patients prior to 
hematology cytotoxic 
therapy 
or hematopoietic stem 
cell transplantation 
2- 
Decision analysis looking 
at 40year old patients 
undergoing conditioning 
+/- HSCT 
Included patient with 
haem-oncology 
malignancies 
Decision analysis – 
comparing met and unmet 
dental needs  
 
Literature review – 2 
databases with multiple 
MESH headings. Literature 
was reviewed and outcomes 
placed in the decision tree.  
 
Decision tree is used to estimate the 
likelihood of each outcome 
Choosing no dental evaluation 
increased the probability of 1.8 in every 
1000 HSCT patients dying of dental 
infection 
Differences between the 2 groups were 
small, however decision tree showed 
that dental assessment and treatment 
are the preferred method.  
Didn’t examine cost or quality of life for 
these patients 
 
(Ertas. E.T. et al. 
2014) 
Comparison of 
chemotherapy and 
hematopoietic 
stem cell 
transplantation pre and 
postterm DMFT 
scores: A preliminary 
study 
36 subjects 
M:F = 27:6  
Average age: 31.8 +/- 
12.4 
 
Allogeneic transplant: 34 
Autologous transplant: 2 
 
Pre HSCT subjects attended 
for dental assessment and 
treatment  
Post HSCT (6months) 
subjects were re-referred for 
a review 
DMFT – pre and post HSCT 
were recorded 
 
Mean DMFT score was 7.0 pre-
transplant and 8.3 post-transplant 
Pre HSCT 34/36 subjects and post-
HSCT 29/36 subjects showed signs of 
dental pathology 
Percentage of decayed teeth was 7.9% 
pre HSCT rose to 8.9% post HSCT 
Significant increase in DMFT scores 
following HSCT – including increase in 
decayed teeth 
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2- Highlights important of post-HSCT 
follow up.  
 
(Gurgan. C.A et al. 
2013) 
Periodontal status and 
posttransplantation 
complications 
following intensive 
periodontal 
treatment in patients 
who underwent 
allogeneic 
hematopoietic stem 
cell 
transplantation 
conditioned with 
myeloablative regimen 
2- 
 
February 2004 – 
September 2010 – 202 
subjects had a HSCT 
All these subjects had a 
pre-HSCT dental 
assessment and 
treatment. 
3 months following HSCT 
subjects were invited 
back for review only 29 
attended and were 
included in the study. 
(85.6% drop out rate) 
M:F =12:17 
Average age: 32.45 +/- 
8.44years 
PBSCT =14 subjects 
BMT =15 subjects 
 
No controls  
Compared periodontal health 
pre-HSCT and post-HSCT 
Intervention = dental 
treatment including OHI, 
scaling, NSPT, restorations 
and extractions  
Periodontal values were 
recorded pre-HSCT, 3-
4weeks after treatment and at 
3 months post-HSCT 
including: plaque indices, 
gingival indices, pocket 
depths and bleeding on 
probing. 
Presence of acute GVHD, 
duration and severity of 
mucositis were also recorded.  
 
Significant improvement in periodontal 
health post periodontal treatment and 
this was maintained 3months after 
HSCT 
Significant decreases in plaque and 
gingival indices along with BOP scores 
and pocket depths 
15 subjects had acute GVHD, 12 
subjects had mucositis. 
Alterations/decreases in bleeding on 
probing reversely related to presence 
of OM – the more BOP values 
improved = lower frequency of OM 
(Masaya, A. et al. 
2013) 
Myelosuppression 
grading of 
chemotherapies 
37 subjects receiving 
treatment for 
haematological 
malignancies.  
M:F = 23:14. 
Age range = 23-70 
Retrospective observational 
study 
Classified different 
chemotherapy regimens into 
groups based on the level of 
myelosuppression: 
Grade A = mild 
No delays or alterations to the 
scheduled chemotherapy regimen 
2 subjects experienced severe 
odontogenic infections 
1 subject experienced sepsis 
associated with a dental extraction site.  
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for hematologic 
malignancies to 
facilitate 
communication 
between medical and 
dental 
staff: lessons from two 
cases experienced 
odontogenic 
septicaemia. 
2- 
January 2009 – 
December 2010 
Transplant = 14 subjects 
Chemotherapy alone = 
23 subjects 
Autologous transplant = 
4subjects 
Allogeneic transplant = 
10 subjects 
 
 
Grade B = moderate 
Grade C = severe 
Grade D = persistent 
myelosuppression 
 
Dental examination 
completed and removal of all 
unsalvageable teeth. 
 
Noted any odontogenic 
infections that occurred 
during chemotherapy or 
transplant period.  
 
1 subject experienced sepsis due to 
advanced marginal periodontitis. 
Found that the grading used for 
chemotherapy regimens was a useful 
tool. 
Chemotherapy regimens of either 
grade B or C put patients at increased 
risk. 
Need for a prospective study with a 
larger sample size. 
 
(Mawardi. H. et al. 
2016) 
Hematopoietic Cell 
Transplantation in 
Patients with 
Medication-Related 
Osteonecrosis of the 
Jaws 
3 
 
11 subjects 
M:F= 8:3 
Age range: 46-71years 
December 2005 – 
December 2014 
Retrospective  
Review of medical and dental 
records for patients 
undergoing HCT for MM with 
diagnosed MRONJ 
Record of Post HCT 
complications. 
The incidence of post HCT 
complications – fever, positive blood 
cultures, length of hospital stay were 
comparable to Non-MRONJ patients 
MRONJ stage was not worsened by 
HCT 
(Melkos. A.B. et al. 
2003) 
Dental treatment prior 
to stem cell 
transplantation 
58 subjects 
M:F= 36:22 
Average age: 39.7years 
Allogeneic transplant: 52 
subjects 
Prospective study 
Control: no dental treatment 
Dental examination and 
treatment was carried out and 
then patients were followed 
Post op complications in 48 subjects 
(27 group 1 and 21 group 2) 
19 post op infections in 16 subjects 
(group 1 = 9, group 2 =7) 
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and its influence on the 
posttransplantation 
outcome 
2+ 
Autologous transplant: 2 
subjects 
January – December 
2000 
2 groups 
1. No treatment 
need/treatment 
complete (36 
subjects) 
2. No dental 
treatment provided 
(22 subjects) 
 
up for complications 
(infection, mucositis, relapse, 
GVHD) for an average of 
50.45weeks.  
Comparisons between both 
groups  
No statistical association between 
dental foci impact and post-HSCT 
complications. 
Survival rate was unaffected between 
the groups  
(Soga . Y. et al. 2008) 
Appearance of multi-
drug resistant 
opportunistic bacteria 
on the gingiva during 
leukaemia treatment  
3 
1 case presentation 
53year old female  
AML  
Allogeneic: Umbilical cord 
stem cell transplant  
Case report – 53year old 
female with AML. Pre-HSCT 
dental assessment identified 
mild generalised periodontitis 
with gingival hypertrophy 
however due to platelet and 
neutrophil count scaling of 
pockets could not be 
performed.  
Pocket irrigation with 0.2% 
povidone iodine daily and 2% 
minocycline gel was applied 
weekly.  
The patient had an elevated 
CRP pre- and during HSCT 
with elevated temperature. 
No other systemic infection other than 
periodontitis was diagnosed in this 
patient before conditioning. 
Scaling and root planning prior to 
chemotherapy can reduce gingival 
inflammation 
Gingivae in patients undergoing HSCT 
can act as a reservoir for multi-drug 
resistant bacteria. 
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7 days post HSCT white 
smears appeared on gingivae 
= S.Maltophilia.  
Patient died 14days post 
HSCT 
 
(Toro. J.J. et al. 2016) 
Edentulism and 
transplant-associated 
complications in 
patients 
with multiple myeloma 
undergoing autologous 
hematopoietic 
stem cell 
transplantation 
2+ 
254 subjects  
100% males 
Age range: 42-75years 
45 subjects were 
edentulous 
90 subjects were dentate  
100% autologous 
transplant  
January 2003 – 
September 2012 
Control: dentate subjects 
Retrospective 
Subject records were 
reviewed 
All subjects underwent a pre-
HSCT dental assessment 
and treatment  
Recorded: age, gender, 
ethnicity, MM stage, time 
from diagnosis – HSCT, 
performance status, 
conditioning regime, 
complications during 
transplant (fever, oral 
mucositis, bacteraemia, 
diarrhoea, nausea/vomiting), 
neutrophil engraftment and 
duration of hospitalisation 
 
No significant differences between the 
groups with regards to post-HSCT 
complications  
(Yamagata. K. et al. 
2006) 
A prospective study to 
evaluate a new dental 
41 subjects 
M:F= 22:19 
Average age: 41.3years 
1998-2004 
Prospective evaluation to 
develop new protocol 
Dental examination and 
treatments were recorded 
38 subjects had dental pathology 
36 subjects had dental treatment 
completed  
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management protocol 
before 
hematopoietic stem 
cell transplantation 
3 
BMT = 28 subjects 
PBSCT = 13 subjects  
along with post HSCT 
complications 
Aim of new dental protocol 
was to preserve teeth where 
possible. 
Only extracted retained roots, 
teeth with PA pathology 
where limited treatment time, 
teeth with severe periodontal 
involvement, P/E third molars 
with pericoronitis/suppuration 
 
No subjects experienced odontogenic 
infections during HSCT 
Time limitations affect clinical decisions 
and completed dental treatment  
Intensive dental treatment is not 
necessary 
Treatment modality matched against 
severity of disease – only extract 
severely disease teeth.  
Early dental screening is essential and 
patients should be reassessed 1 month 
before if seen early.  
Suggestion that it is safe to observe 
periapical lesions <5mm 
(Yamagata. K. et al. 
2011) 
Prospective study 
establishing a 
management plan for 
impacted 
third molar in patients 
undergoing 
hematopoietic stem 
cell 
transplantation 
2- 
84 subjects referred 
35/84 had 1 or more 
impacted third molars 
enrolled 
M:F= 18:17 
Average age: 32.1years  
BMT – 51 subjects 
PBSCT – 30 subjects 
Umbilical cord – 
3subjects  
 
2 groups  
Non ITM group 
ITM group 
2000-2008 
Prospective evaluation to 
develop new protocol 
All subjects had a dental 
assessment and appropriate 
dental treatment as 
necessary pre-HSCT 
Frequency of oral complaints 
and complications during the 
HSCT period were recorded  
7/35 ITMs on 6 subjects were 
extracted due to symptoms (all 
mandibular) 
No subject showed signs of 
odontogenic infection during the HSCT 
period 
No significant difference between 
groups and duration of fever or number 
of days where WBC were <1000µL. 
Sepsis from oral mucositis – 2 in ITM 
group + 4 in non-ITM group 
No difference in median survival 
periods between the 2 groups however 
median number of days where WBC 
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<1000µL for patients who died or 
survived was significant. 
Protocol to not to remove 
asymptomatic ITM appears not to 
increase risk of odontogenic infections 
during HSCT. 
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Post-HSCT complications 
Author/ Title /Level of 
Evidence 
Sample Characteristics Study Design  Summary of Findings  
 
 
(Barrach. R. et al. 
2017) 
Oral changes in 
individuals undergoing 
hematopoietic stem 
cell transplantation 
2- 
65 subjects  
Gender – unknown 
Age – unknown 
 
Transplant type: 
Autologous: Allogeneic= 
31:34 
 
Prospective longitudinal 
cohort study  
 
Patients were reviewed with 
regards to their oral health 
status – 20 days prior to 
HSCT, 7 days following 
HSCT and at 100 days post-
HSCT  
 
Reviewed and quantatively 
scored with regards to caries, 
periodontal health, retained 
roots, mobile teeth, 
prosthesis and orthodontics, 
mucositis, infection 
experience  
 
Highlight potential for retained roots, 
carious teeth, periapical pathology, 
periodontally involved teeth being 
reservoirs for infections.  
 
All patients had experience of 
mucositis at 7 days post-transplant. 
 
No patients experienced infections that 
were odontogenic in origin despite the 
fact that no evidence of dental 
treatment being provided prior to 
HSCT.  
(Borbasi.S et al. 2002) 
5 themes described 
the experiences of 
patients with 
chemotherapy induced 
oral mucositis 
6 subjects 
M:F = 2:4 
Age range = 38-63years  
 
Inclusion: autologous 
stem cell transplant 
Qualitative Study 
Interpretive descriptive 
phenomenological study. 
Subjects underwent weekly 
indepth interviews (45mins-
1hour) over 4weeks, then 
Key themes that emerged: 
1. Presence of nurses  
2. Therapeutic interventions 
3. Manifestations of mucositis  
4. Distress of eating (and not eating) 
5. Was the treatment worthwhile?  
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3 Exclusion: non-english 
speak, expected survival 
<3months  
week 8 and week 12 or when 
their mucositis had resolved.  
Total of 19 interviews – 
recorded and transcribed 
verbatim   
Interviews explored subjects 
experiences of mucositis  
 
 
 
Highlights the need for nurses to 
prepare the patients for the 
consequences of HSCT. 
(Brand.H.S et al. 2009) 
Xerostomia and 
chronic oral 
complications among 
patients treated with 
haematopoietic stem 
cell transplant 
2+ 
48 subjects 
M:F = 19:29 
Average age: 53.0 +/- 
9.4years  
Autologous transplant – 
11 subjects 
Allogeneic transplant – 
33 subjects 
Autologous followed by 
Allogeneic transplant – 4 
subjects  
 
Comparison group – 41 
subjects 
M:F = 14:27 
Average age: 51.1 +/- 
9.1years  
 
Control: partners of HSCT 
subjects  
 
All subjects completed the 
Dutch translation of the 
xerostomia inventory and an 
oral health questionnaire  
The results were then 
compared between the 2 
groups 
 
There were significant differences 
between all items explored in the 
xerostomia inventory between the 
HSCT group and the control. 
Greater severity of oral problems was 
found in the HSCT group 
No significant difference between 
HSCT group and control with regards 
to tooth sensitivity, broken/painful teeth 
or gingival bleeding.  
No significant difference between 
patients in the HSCT group receiving 
TBI than those who didn’t. 
Those in HSCT who had received TBI 
reported increased altered taste 
86% of allogeneic transplant reported 
GVHD affecting oral cavity and for 
these subjects mucosal pain was more 
severe 
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(Castellarin. P. et al. 
2012) 
Extensive Dental 
Caries in Patients with 
Oral Chronic 
Graft-versus-Host 
Disease  
2- 
21 participants with a 
diagnosis of cGvHD 
following HSCT 
 
M:F = 15:6 
Average age = 45 (13-67 
years) 
 
All allogeneic HSCT 
recipients  
 
Retrospective case note 
review 
 
All patients had pre-HSCT 
dental assessment and 
definitive treatment  
Assessed post-HSCT with 
diagnosis of cGvHD and 
caries  
19/21 diagnosed with oral cGvHD 
Review post-transplant occurred on 
average at 22 months  
20/21 shows signs of salivary gland 
cGvHD 
Rampant caries was noted in 10 
participants requiring extractions – this 
was higher than what was required 
pre-transplant 
 
Highlights the need for continued 
dental review and advice following allo-
HSCT. The participants in this study 
had worse caries experiences post-
HSCT with diagnosis of cGvHD and 
xerostomia.  
  
(Da Silva Santos. P.S. 
et al. 2010) 
Impact of oral care 
prior to HSCT on the 
severity and clinical 
outcomes of oral 
mucositis 
2+ 
70 patients receiving 
HSCT for CML from 2 
hospital sites 
SG – 35 patients who 
received dental treatment 
prior to HSCT 
CG – 35 patients who did 
not receive dental 
treatment prior to HSCT 
M:F unknown  
Average age unknown 
Transplant type unknown 
Control: 35 patients who did 
not receive dental treatment 
prior to HSCT 
Following hospital admission 
all subjects were reviewed 
with regards to incidence, 
severity and time elapsed for 
oral mucositis  
No statistical difference for incidence 
or severity of mucositis however SG 
had a shorter duration of mucositis 
than CG who did not receive oral care.  
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Conditioning regimes 
were similar  
 
(Duncan. C. et al. 
2015) 
Long-Term Survival 
and Late Effects 
among One-Year 
Survivors 
of Second Allogeneic 
Hematopoietic Cell 
Transplantation for 
Relapsed Acute 
Leukemia and 
Myelodysplastic 
Syndromes 
2+ 
325 subjects 
146 children M:F= 92:54 
179 adults M:F= 99:80  
Average ages: unknown 
 
January 1980 – 
December 2009 
Retrospective analysis of 
data contained in CIBMTR 
database of subjects who 
were alive and in remission a 
year following their second 
allogeneic transplant due to 
disease relapse.  
Data collected over 10 year 
period looking at late effects 
and complications  
2 – 10year survival rates: 
Children = 83% - 55% 
Adults = 75% - 39% 
Disease progression or relapse = 
major cause of death 
Overall mortality due to GVHD 32%, 
organ failure 25%, infection 16% and 
secondary malignancy 5%.  
Acute grade 2-4 GVHD late effect in 
46% adults and chronic GVHD late 
effect 75% adults 
Over 10years for adults late effects 
most common 13% avascular necrosis, 
20% cataracts.  
 
(Elad. S et al. 2011) 
A randomized 
controlled trial of 
visible-light therapy for 
the prevention 
of oral mucositis 
1- 
June 2007- February 
2009 
20 subjects undergoing 
HSCT 
Group A (10 subjects) 
Exposed to visible light 
therapy (BB-VLT) and 
standard preventative 
prophylaxis  
M:F = 6:4 
Age = 49.1 +/-16.91 
Prospective randomised 
double-blinded study 
Group A – exposed to visible 
light therapy  
Group B – exposed to a 
placebo light device of a 
similar design.  
All light therapy was 
administered 5 times a week 
for 28days (or 21 days if no 
mucositis) 
There was only a statistical significant 
difference in mucositis presentation on 
visit 3. 
A reduction of mucositis related pain 
was also significant at visit 3. 
No difference in patient satisfaction 
with the treatment.  
BB-VLT is a safe and effective device 
to use in the prevention of mucositis 
post-HSCT 
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Group B (10subjects) 
1 subject excluded (died) 
Exposed to placebo light 
and standard 
preventative prophylaxis 
M:F = 4:5 
Age = 35.33 +/- 10.82 
 
Patients and oral care 
provided were blinded to 
treatment groups 
Patients examined daily by a 
physician and weekly by a 
member of research team.  
Mucositis scores using WHO 
and OMAS grading  
Subjects graded pain using 
visual analog scale. 
Adverse events were 
recorded.  
Patient satisfaction survey 
was completed about the 
treatment.  
 
Further studies are needed with a 
larger sample size.  
 
 
(Elad. S. et al. 2008) 
Oral effects of non-
myeloablative stem 
cell transplantation: A 
prospective 
observational study. 
2+ 
 
34 subjects  
 
Transplant type:  
Autologous = 9 (group 1) 
MAC allogeneic = 9 
(group 2) 
RIC allogeneic = 16 
(group 3) 
 
M:F / Average age 
Group 1: 8:1 / 39.2yrs 
Group 2: 5:4 / 35.0yrs 
Group 3: 8:8 / 35.4yrs 
Prospective longitudinal 
observational study 
 
Recruitment period – 
September 2000 – June 2001 
 
Patients oral mucosa was 
review every 2 weeks from 14 
days post-HSCT to 100days 
 
aGvHD oral lesion was 
defined as oral ulceration 
No statistical difference between 
prevalence of non-GvHD oral lesions 
between MAC and RIC regimes 
 
Prevalence of aGvHD oral lesions was 
statistically more in patients who 
received MAC  
 
There was no difference in the 
prevalence of opportunistic infections 
e.g candida.  
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following the engraftment 
period.  
 
(Epstein. J. et al. 2008) 
Doxepin rinse for the 
management of 
mucositis pain in 
patients with cancer: 
one week follow up of 
topical therapy. 
2- 
9 subjects 
M:F = 6:3 
Age range: 25-61years 
Subjects having 
treatment for cancer 
including head and neck 
radiotherapy (6subjects), 
chemotherapy or HSCT 
(3subjects) 
No controls  
Assess the impact of using 
doxepin over 1 week  
Subjects visited twice – at the 
start of the trial and the 
following week  
Doxepin (5mg/ml) suspension 
mixed with 1% alcohol and 
sorbitol 
Rinse 5ml for 1min – 3-
6times per day as required 
(started from initial visit) 
Patients usual management 
of mucositis pain continued  
Level of mucositis was 
scored at each visit. 
VAS scores for oral pain were 
scored pre-rinse, then 5mins, 
15mins, the hourly (to 
4hours) following rinse. 
 
Significant reduction of oral pain at 
5mins and 15mins following the rinse  
Statistically significant reduction of pain 
on eating from after the rinse was 
administered at initial up visit and 
follow up visit 
Doxepin gives an extended duration of 
pain reduction  
Severity of mucositis, reduction of 
baseline pain over the week and 
reported side effects showed no 
statistical difference from baseline 
recordings. 
 
(Filipovich. A. et al. 
2005) 
National Institutes of 
Health consensus 
development project 
No sample – 
report/review article  
Expert opinion and review 
article  
No methodology described  
Report has 3 main outcomes: 
1. Standardises the criteria for 
diagnosis cGvHD 
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on criteria for clinical 
trials in chronic graft-
versus-host disease: I. 
Diagnosis and staging 
working groups report. 
4 
 
2. Proposal of a new clinical scoring 
system to describe the severity of 
cGvHD 
3. New guidelines on how to assess 
cGvHD 
 
(Imanguli. MM. et al. 
2008) 
Oral graft-vs-host 
disease 
3 
No sample – review 
article.  
Literature review 
Searches limited to 
MEDLINE/Pubmed 
databases.  
Limited to English language, 
peer reviewed journals.  
Searches looking at – GVHD 
patho-biology, salivary gland 
disease after HSCT, 
treatments for GVHD.  
Describes patho-biology, oral 
presentation, histopathology and 
treatment.  
Describes difference between aGCHD 
and cGVHD – presentation as opposed 
to time.  
cGVHD difficult long-term challenge in 
allogeneic HSCT.  
Still need to develop effective 
therapeutic strategies.  
Similarity of cGVHD and other 
autoimmune disorders.  
Need further research in this field.  
 
(Kashiwazaki. H. et al. 
2012) 
Professional oral 
health care reduces 
oral mucositis and 
febrile neutropenia in 
patients treated with 
140 subjects seen 
between February 2002 – 
December 2009, who 
underwent allogeneic 
bone marrow transplant 
2 groups: 
Non-POHC (2002-2005) 
– 62 subjects – age 
Retrospective analysis  
Recorded: 
Conditioning regimes 
Grade of mucositis – WHO 
classification 
Febrile neutropenia – where 
temperature >37.5’ and 
neutrophils <0.5x109/L 
Incidence of mucositis in POHC group 
was 66.7% compared to 93.5% in non-
POHC group.  
Incidence of febrile neutropenia and 
CRP levels were also lower in POHC 
group. 
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allogeneic bone 
marrow transplant  
2+ 
 
range: 15-66years. M:F = 
32:30 
POHC (2006-2009) – 78 
subjects – age range: 18-
77years. M:F = 44:34  
 
Professional oral health care 
(POHC) was only given from 
2006 onwards; included 
toothbrushing, interdental 
cleaning, and use of a wet 
sponge when complained of 
dry mouth.  
 
Multivariate analysis showed POHC 
was significantly associated with 
mucositis incidence.  
(Katz. J. et al. 2014) 
Oral squamous cell 
carcinoma positive for 
p16/human papilloma 
virus in post allogeneic 
stem cell 
transplantation: 2 
cases and review of 
the literature  
3 
2 cases 
 
Both male  
 
Case 1 – 68yrs, allo-
HSCT for B cell 
lymphoma 22 yrs 
previous  
 
Case 2 – 18yrs, allo-
HSCT for AML 9 yrs 
previous.  
 
2 case reports presenting a 
number of years after allo-
HSCT with SCC. Following 
histopathology both 
specimens were strongly 
reactive for p16/HPV 
Recommend long-term surveillance for 
allo-HSCT recipients particularly with a 
diagnosis of cGvHD. Question whether 
HPV screening is indicated.  
(Khouri.V. et al. 2009) 
Use of therapeutic 
laser for the prevention 
and treatment of oral 
mucositis 
2+ 
 
22 subjects 
March 2004 – September 
2006 
Ethics achieved  
Allogeneic HSCT 
 
Group 1 (12) (treatment):  
Randomised control trial  
 
Randomisation according to 
hospitalisation. 
Differing conditioning regimes 
amongst subjects however all 
myeloablative.  
Group 1 had a lower frequency and 
severity of OM – statistically significant 
No clinical difference in the presence 
of erythema between the groups 
Size of the lesions present were 
greater in group 2  
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M:F = 10:2 
Age = 32.7 
 
Group 2 (10) (control) 
M:F = 7:3 
Age = 27.5 
 
Inclusion: >12yrs, 
haematological/haem-
oncological disease, 
myeloablative 
conditioning regime, 
allogeneic HSCT. 
 
Both groups underwent the 
same prevention protocol for 
mucositis  
 
Group 1 = treatment group. 
“Mucositis Formula” 
mouthrinse, oral hygiene 
protocol and laser treatment. 
2 lasers used on alternate 
days once a day. 
Questionnaire about the laser 
completed at the end of 
treatment.  
Group 2 = control group. 
Conventional mouthwash and 
oral hygiene protocol only. 
 
Study was not blinded as 
group 2 were not “treated” 
with a sham laser.  
 
Interventions were continued 
until day 15 post-transplant or 
if engraftment was observed 
prior to this the interventions 
were stopped.  
 
OMAS and WHO scale to 
measure mucositis present. 
Laser treatment can be an effective 
option in the treatment and prevention 
of oral mucositis  
Further research is required.  
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(Laaksonen. M. et al. 
2011) 
Longitudinal 
assessment of 
haematopoietic stem 
cell transplant and 
hyposalivation 
2+ 
228 allogeneic HSCT 
recipients (2002-2009) 
M:F = 134:94 
Average age: 43years 
 
Control group = 141 
healthy individuals (no 
medications)  
M:F = 69:75 
Average age: 46years  
 
Control = healthy individuals 
CG – stimulated saliva flow 
measured on one occasion 
 
HSCT group – grouped due 
to diagnosis, dose of TBI (no-
TBI, low dose TBI, high dose 
TBI) and conditioning regime  
stimulated saliva flow 
measured pre-HSCT, 6 (109 
subjects),12(99 subjects), 24 
months (76 subjects) 
following HSCT 
 
Stimulated saliva – first to 
chew on wax for 1min whilst 
swallowing saliva then to 
chew on wax for 5mins whilst 
saliva collected.  
  
Hyposalivation was common amongst 
HSCT group – 40% pre HSCT, 53% 
6months, 31% at 12months and 26% 
at 12months. CG 16% had 
hyposalivation 
Pre-HSCT females demonstrated 
increased frequency of hyposalivation 
than males 
Severe hyposalivation was seen 
particularly at 6months – 18% HSCT 
group 
40% of subjects died during this period 
in whom hyposalivation was more 
common. 
Patients having TBI showed increased 
hyposalivation pre-HSCT and at 
6months 
Recovery of stimulated saliva with 
time.  
 
(Legert K.G. et al. 
2014) 
Reduced intensity 
conditioning and oral 
care measures prevent 
oral mucositis and 
reduces days of 
hospitalisation in 
171 subjects undergoing 
allogeneic HSCT (161 
subjects treated for 
malignant disease) 
 
October 2007- May 2011 
Age range: 12-71years  
MAC = 72 subjects, M:F= 
36:36 
Comparative between MAC 
and RIC regimes 
Baseline dental examination 
and treatment  
During observation period; 
nursing staff examined for 
oral mucositis (OM) from 
3days prior to 25day post 
HSCT – WHO criteria. 
86% of subjects developed OM 
MAC significantly higher total OM 
score from days 9-12 than RIC  
Use of Bulsulfan increased WHO OM 
score on days 9-12 
TBI didn’t influence severity or 
incidence of OM 
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allogeneic stem cell 
transplant participants.  
2- 
RIC = 99 subjects, M:F= 
55:44 
3xweekly dentist/hygienist 
examined oral cavity for OM 
using OMAS  
VAS and NCI-CTCAE used to 
record pain in the oral cavity 
Oral function and salivation 
was discussed with the 
patient daily  
 
Year of HSCT had an effect on severity 
of OM, introduction of oral care 
protocol in 2011 
Significant correlation between higher 
OM score on days 13-24 and length of 
hospitalisation 
 
(Lew. J. et al. 2007) 
Mucosal graft-versus-
host disease  
4 
 
Review paper  No sample – review article  Discusses – pathophysiology and 
types of GvHD along with its treatment.  
(Mauramo. M et al. 
2017) 
Determinants of 
stimulated salivary flow 
among haematopoietic 
stem cell 
transplantation 
recipients 
2- 
118 subjects 
M:F = 66:52 
Age = 49.3 (22-74) 
Autologous HSCT: 27 
subjects 
Allogeneic HSCT: 91 
subjects 
TBI: 59 subjects 
Myeloablative 
conditioning: 66 subjects 
 
Control group = 247 
subjects 
M:F = 106:141 
Age = 43 (22-74) 
Prospective longitudinal study 
– case control 
Patients receiving HSCT had 
stimulated salivary flow 
measured: 
 Post-conditioning (Pre-
HSCT) (118) 
 6months post HSCT (102) 
 12months post HSCT (95) 
Any changes to medications 
were noted.  
 
Control group – healthy 
volunteers with no 
medications. Stimulated 
Hyposalivation was more frequent at 
each interval among the HSCT group 
compared the controls  
Females had slightly lower stimulated 
salivary flow rates than males 
Stimulated salivary flow rates improved 
with time and were higher 12months 
post-HSCT 
Antivirals, antifungals, antacids, 
antineoplastics and 
immunosuppressants, antibacterials, 
corticosteroids, cardiovascular drugs, 
antiemetics, anxiolytics and 
antidepressants were the most 
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 salivary flow rate measured 
once. 
 
Stimulated salivary flow rate 
<0.7ml/min = hyposalivation 
 
common drugs post HSCT but did not 
significantly impact on SWSFR 
Hyposalivation is a multicausal 
phenomenon 
All subjects receiving HSCT should be 
considered high risk of hyposalivation.  
 
(Mays. J.W et al. 2013) 
Oral chronic graft 
versus host disease: 
current pathogenesis, 
therapy, and research  
4 
Review article – no 
sample 
Review article based on 
literature review and expert 
opinion  
No methodology of literature 
review stated.  
Keywords stated.  
Highlights general and systemic 
features of general and oral GVHD 
50% of patients who survive 1year 
post-HSCT develop the disease.  
5year mortality rate for cGVHD 
patients = 70% 
Oral cavity = second most common 
organ involved – mucosal lesions, 
salivary gland disease, restricted 
mouth opening, secondary 
malignancies  
Increased risk of oral pain, dental 
caries 
Negative impact on speech, nutrition, 
eating and QoL 
NIH consensus report – clinical scoring 
Importance of early detection, 
diagnosis, management and regular 
follow up.  
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(Meier.J. et al. 2011) 
Oral chronic graft 
versus host disease: 
report from the 
International 
Consensus 
Conference on clinical 
practice in cGVHD 
4 
No sample – review 
article with expert opinion 
Review article  
No methodology for literature 
review 
Literature and guidance were 
graded as to the publication 
by the expert panel and then 
reviewed.  
Expert panel consisted of an 
oral medicine specialist, a 
dentist, 2 haematologists and 
an epidemiologist  
Symptoms of cGVHD present within 
2years post-HSCT. Usually preceded 
by aGVHD.  
Presentation of oral lesions, 
hyposalivation and secondary 
malignancies.  
Describes NIH clinical scoring scale 
Need for regular dental assessment, 
importance of good oral hygiene, 
possible restriction of mouth opening 
due to fibrosis.  
Risk of BRONJ in patients receiving 
bisphosphonates for multiple myeloma 
Need for interdisciplinary working  
 
(Nappalli. D. et al. 
2015) 
Oral manifestations in 
transplant patients  
4 
Review article – no 
sample 
Review article  
No method stated for 
literature review  
Key words stated  
Oral cavity is a potential source of 
sepsis in immunocompromised 
patients  
Infections in the oral cavity may be 
suppressed or exaggerated due to 
decreased inflammatory response  
Recipients of matched 
unrelated/mismatched allogeneic 
transplants are at increased risk of 
infections.  
Increased risk of gingival overgrowth 
due to immunosuppressive drugs 
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Presentation of oral mucositis, GVHD, 
xerostomia and secondary 
malignancies.  
 
(Patussi. C. et al. 
2014) 
Clinical assessment of 
oral mucositis and 
candidiasis compare to 
chemotherapeutic 
nadir in transplanted 
patients  
3 
Subjects attending for 
HSCT January – 
December 2012 
31 subjects 
M:F = 15:16 
Age = 43.8 (19-66years) 
Autologous: 28 subjects 
Allogeneic: 3 subjects  
 
 
Observational study 
Prospective 
Ethics and informed consent 
achieved  
Blood tests were performed 
daily on all subjects 
Mucositis was evaluated with 
the WHO scoring system  
Low frequency laser 
application was used at least 
twice weekly on all subjects 
All subjects used 
chlorhexidine mouthwash 
0.12% to support oral 
hygiene  
Comparisons were made 
between tobacco use, 
diagnosis, type of transplant, 
use of oral prosthesis  
Chemotherapeutic nadir is the period 
where following chemotherapy the cell 
count decreases rapidly.  
Prescence of mucositis was no 
associated with the counting of 
leukocytes  
Decrease in leukocytes found between 
day 2 -8  
No difference in presence of mucositis 
between allogeneic and autologous 
transplants  
No patients presented with candidiasis  
Patients who reported low tobacco 
consumption presented with more 
severe mucositis 
Low frequency laser treatment can be 
effective in treating and preventing 
mucositis  
 
 
(Petti.S. et al. 2013) 
Orofacial diseases in 
solid organ and 
haematopoietic stem 
Review article - No 
sample  
Review article  
Searches limited to MEDLINE 
– observational studies and 
cases series were assessed.  
Keywords listed.  
Oropharyngeal cancer is the most 
common in HSCT recipients  
Oral cancer is significantly associated 
with cGVHD 
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cell transplant 
recipients.  
4 
Strength of association 
between the literature was 
agreed by the four authors  
cGVHD is the leading cause of 
mortality in HSCT recipients  
Definition of aGVHD and cGVHD 
GVHD is associated with the HLA 
mismatch of donor and recipient  
Mucositis is a frequent toxicity in 
myeloablative or TBI conditioning 
regimes  
Oral infections in HSCT recipients – 
bacteraemia, fungal infections 
(candida, aspergillous), HSV, CMV, 
VZV. 
Oral infections are often proceeded by 
mucositis 
Need for pre- and post- HSCT dental 
review.  
(Santos-Silva. A.R et 
al. 2015) 
cGVHD-Related 
Caries and Its Shared 
Features with Other 
‘Dry-Mouth’-Related 
Caries 
3 
 
5 cases 
M:F= 3:2 
Age range: 14-47years 
All subjects underwent 
allogeneic transplant 
Series of case reports 
All subjects underwent pre-
dental assessment prior to 
HSCT. However developed 
chronic GVHD as a 
consequence. Dentally they 
suffered with extensive caries 
as a consequence 
Importance of continuing review of 
patients who have undergone a HSCT 
particularly if they have cGVHD 
Links of GVHD and xerostomia leading 
to rampant caries 
 
(Sonis. S.T. et al. 
2001) 
Oral mucositis and the 
clinical and economic 
92 subjects 
 
M:F = 40:60 (%) 
 
Piolet observational 
prospective study 
 
Found that the severity of OMAS is 
significantly correlated with: 
 Days of injectable narcotics, TPN 
and injectable antibiotics 
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outcomes of 
hematopoietic stem 
cell transplantation 
3 
Age = 44.5 (+/- 10.6) 
 
Transplant type: 
Allogeneic = 50 
Autologous = 42 
 
Subjects were assessed for 
oral mucositis (OMAS score) 
from day 1 of conditioning 
and continuing for 28 days.  
 
OMAS score was compared 
against other outcomes: 
1. No. febrile days 
2. Incidence of infection  
3. No. days received TPN 
4. No. days received 
injectable narcotics 
5. No. days spent in hospital 
within 60 days from 1st 
day of conditioning 
6. Total hospital charges 
7. Mortality within 100 days 
 Risk of significant infection 
 Increased hospital days and 
therefore charges 
 Increased risk of mortality 
 
Peak mucositis scores were higher in 
allograft patients.  
 
However mucositis was found to be a 
more important risk factor for autograft 
patients.  
 
 
 
(Sonis. S.T. 2009) 
Efficacy of palifermin 
(keratinocyte growth 
factor-1) in the 
amelioration of oral 
mucositis  
3 
 
No sample – review 
article  
Systematic review article 
Key word search of 2 
databases  
Reviewed 100 papers and 4 
abstracts – only 12 papers 
and 3 abstracts were 
included for analysis  
Patients receiving myeloablative 
conditioning particularly TBI are at 
>50% risk of mucositis.  
Level 3 evidence supports the use of 
palifermin in treating mucositis in 
allograft recipients. 
Level 2 evidence supports the use of 
palifermin in treating mucositis in 
autograft recipients. 
 
(Stoopler. E. 2013) 1 case presentation 
50year old female  
Patient presented with painful 
mucosal lesions 8 months 
Topical corticosteroids can be helpful 
in the treatment of cGVHD.  
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Management of oral 
chronic graft-versus-
host disease 
3 
Unspecified leukaemia  
Allogeneic HSCT 
post-HSCT. Diagnosed with 
vaginal GVHD by 
gynaecologist.  
Diagnosis of cGVHD made.  
Treatment with: topical 
dexamethasone rinse, topical 
betamethasone gel and 
nystatin oral suspension. 
At 1 month review lesions, 
had resolved and masticatory 
function returned.  
 
(Torres-Pereira. C.C. 
et al. 2014)  
Oral squamous cell 
carcinoma in two 
siblings with Fanconi 
anemia after 
allogeneic bone 
transplant  
4 
2 cases  
M:F = 0:2 
 
Case 1 – 18year old 
female with Fanconi 
anemia and treatment 
with allogeneic HSCT. 
 
Case 2 – sibling of case 1 
(donor for case 1). 28 
year old female with 
Fanconi anemia, 
treatment with allogeneic 
HSCT 
 
Both cases developed 
cGVHD following allogeneic 
HSCT.  
They then preceded to 
present with squamous cell 
carcinomas in the oral cavity 
which required treatment.  
Consideration to long term oral 
surveillance following allogeneic HSCT 
especially in patients who develop 
cGvHD or have an initial diagnosis of 
Fanconi anemia.  
(Tsushima. F. et al. 
2015) 
1 case 
Male 
Case report  Recognition of long term complications 
of HSCT. 
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A case of upper 
gingiva carcinoma with 
chronic graft versus 
host disease after 
allogeneic bone 
marrow transplant  
3 
 
51years  
Allogeneic stem cell 
transplant 22years ago 
for AML 
Subject developed cGVHD 
following HSCT  
22years following HSCT 
developed squamous cell 
carcinoma left palatal 
gingivae.  
 
Solid tumors are a consequence of 
GVHD 
(Villa. A. et al. 2015) 
Mucositis: 
pathobiology and 
management  
4 
Review article  Review article  
No structured methodology 
stated.  
Describes pathobiology and 
management of mucositis  
60-85% of patients receiving HSCT will 
experience mucositis. 
Following HSCT mucositis tends to 
present at day 3 or 4 and peaks at 
days 7-14 then proceeds to resolve.  
Describes current drugs that can 
reduce the severity and duration of 
mucositis.  
Advises future studies should be 
around the effect of drug therapies on 
patients who are genetically 
predisposed. 
 
(Yuan. A. et al. 2016) 
Oral chronic GVHD 
outcomes and 
resource utilization: a 
subanalysis from the 
79 patients across 5 oral 
medicine or transplant 
centres (2 oral medicine 
centres) 
March 2012 
M:F = unknown 
Retrospective data analysis 
(as part of the GVHD cohort 
study 2007) 
To compare current practice 
of diagnosis and treatment 
with NIH consensus guidance 
Ancillary topical therapies were 
prescribed to over half of patients  
Additional ancillary topical therapies 
were prescribed more often at oral 
medicine centres (52%) 
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chronic GVHD 
consortium  
3 
Age = 50years (11-71) 
Diagnosis of chronic 
GVHD 
Clinical or histological 
diagnosis of GVHD was 
accepted 
Both patient and clinician 
measures of severity and 
impact of oral cavity changes 
were assessed.  
Study member at each site 
collected the data 
Data collected at each visit = 
date, provider type, systemic 
immunosuppressive 
medications, and ancillary 
therapies  
 
 
Patients treated with topical therapies 
were 5 times more likely to have NIH 
mouth pain = oral cavity score >1.  
A positive score on pain or function 
prompted management more than 
clinical assessment of lesions 
Data was consistent with current 
guidance  
(Weng. X. et al. 2017) 
Multiple and recurrent 
squamous cell 
carcinoma of the oral 
cavity after graft-
versus-host disease 
3  
1 case  
42 year old male patient 
– allo-HSCT for AML  
Diagnosed with cGvHD 
 
Presented with multiple 
SCCs 5 years post HSCT 
 
Case report  Importance of continued surveillance 
post-HSCT and GvHD diagnosis  
Need for multi-disciplinary team 
involvement in their diagnosis and 
treatment.  
  
 
 
251 
 
HSCT and oral health related quality of life  
Author/ Title /Level of 
Evidence 
Sample Characteristics Study Design  Summary of Findings  
 
 
(Bezinelli. L. et al. 
2016) 
Quality of life related to 
oral mucositis of 
patients undergoing 
haematopoietic stem 
cell transplantation and 
receiving specialised 
oral care with low-level 
laser therapy: a 
prospective 
observational study) 
3 
 
69 subjects over a 2 year 
period  
 
M:F = 46:23 
 
Type of transplant  
Autologous = 35 
Allogeneic relative donor 
= 14 
Allogeneic unrelated 
donor = 20  
 
No control group 
Observational prospective 
study  
 
WHO grading system used to 
grade the severity of 
mucositis 
 
OHIP-14 and PROMS scales 
used to assess the patient 
reported QoL 
 
All patients received 
treatment with LLLT for their 
mucositis from day 1 post-
HSCT.  
 
QoL was measured at: 
1. Prior to HSCT 
2. 5th day for autologous and 
8th day for allogeneic post-
HSCT 
3. At bone marrow 
integration 
4. 30 days post-discharge.  
 
All patients scored the worst on OHIP 
and PROMS at time 2 (5/8 days post 
HSCT).  
 
QoL improves over time in patients 
receiving LLLT for treatment of 
mucositis.  
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(Depalo, J. et al. 2015) 
Assessing the 
relationship between 
oral graft-versus-host 
disease and global 
measures of quality of 
life.  
2+ 
569 subjects from 9 
participating study 
centres.  
 
M:F = 329:240 
 
Age = unknown 
 
Diagnosis = incident 
GvHD (diagnosed 
<3months post HSCT) or 
prevalent GvHD 
(diagnosed >3 months 
but <3 years post-HSCT) 
340:229 
 
Prospective multicentre 
observational study. 
 
QoL assessment using 
FACT-BMT and SF-36. 
 
Subjects were classified into 
three groups depending on 
their presentation of GvHD 
1. Isolated oral involvement  
2. Concomitant extra-oral 
involvement  
3. Only extra-oral 
involvement  
Differences in QoL were 
assessed between the 
groups.  
No meaningful difference in QoL 
scores between the three groups 
 
Overall disease severity was higher in 
the concomitant extra-oral involvement 
and the only extra-oral involvement 
groups.  
 
Further work is required on the impact 
of oral health related quality of life in 
patients with oral GvHD. 
(Silva. L. C. et al. 
2015) 
The impact of low-level 
laser therapy on oral 
mucositis and quality 
of life in patients 
undergoing 
hematopoietic stem 
cell transplantation 
using the oral health 
impact profile and 
functional assessment 
39 subjects 
M:F = 17:22 
Age = 39 (14-63years) 
 
Transplant type  
Autologous: Allogeneic = 
24:15 
 
Control group = 19 
subjects 
 
Randomised, controlled and 
double blinded clinical trial – 
a pilot study.  
 
Comparing the quality of life 
of subjects with mucositis 
who have LLLT compared to 
those who do not.  
 
QoL questionnaires – FACT-
BMT and OHIP-14 
 
QoL between the two groups was at its 
lowest at day 7 post-HSCT 
 
There was no difference in reported 
QoL scores between the control group 
and the study group.  
 
LLLT can improve the clinical 
presentation and severity of oral 
mucositis.  
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of cancer therapy – 
bone marrow 
transplantation 
questionnaires.  
1- 
 
Study group = 20 
subjects  
 
Study group received LLLT 
from day 1 post-HSCT to day 
7 post-HSCT at 10 points 
around the mouth.  
 
QoL was assessed at 
admission, day 7 post-HSCT 
and at discharge.  
 
(Tinoco-Araujo. J. et 
al. 2015) 
Oral health-related 
quality of life before 
hematopoietic stem 
cell transplantation. 
2- 
200 subjects  
Control group (CG) = 100 
subjects 
Study group (SG) = 100 
subjects 
 
CG = healthy volunteers 
SG = subjects having 
autologous or allogeneic 
HSCT 
 
CG: 
M:F = 62:38 
 
SG:  
M:F = 61:39 
Transplant type: unknown 
 
Prospective observational 
cohort study 
 
CG and SG underwent dental 
assessment – underlying 
disease, dental and 
periodontal conditions  
 
OHIP-14 questionnaire was 
completed to assess oral 
health-related quality of life.  
 
 
There was found to be a weak impact 
of oral health on QoL in both groups.  
 
A significant impact of oral health on 
QoL was seen in patients with severely 
compromised teeth – in the domains of 
discomfort, psychological disability and 
deficiency.  
 
Recommends pre-HSCT dental 
assessment.  
 
 
 
254 
 
7.7 Appendix 7: SIGN levels of evidence  
 
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs 
with a very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a 
low risk of bias 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case control or cohort or studies 
High quality case control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is 
causal 
2+ Well-conducted case control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relationship 
is causal 
2- Case control or cohort studies with a high risk of confounding or 
bias and a significant risk that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
 
(Scottish Intercollegiate Guidelines Network, 1999-2012) 
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7.8 Appendix 8: Study groups 
 
The types of patients who will be included in each different study 
group defined by the type of dental intervention received. 
 
Dental intervention received 
Group 1 
 Patients who received comprehensive dental care – provision of all 
dental treatment required. Patient is dentally fit at time of transplant. 
Group 2  
 Patients who received solely extractions and dressings (temporary 
restorations).  
Group 3 
 Patients where no dental treatment was advised pre-transplant other 
than prevention advice  
 
Group 4 
 Patients who refused the dental treatment offered and received 
preventative advice.  
 
No dental intervention received (control group) 
Group 5  
 Patients who were not referred for dental assessment due to time 
constraints, prognosis or refusal to be referred. 
 Patients who had a dental assessment but refused the dental 
treatment offered, and did not receive preventative advice.   
 Patients who are edentulous (these patients are not currently 
referred). 
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7.9 Appendix 9: Data collection form 
 
 
Unique ID  
Gender  Postcode 
(first part of 
code MAX 
4 digits) 
 
Age  Occupation  
Comorbidities   
 
 
 
Medications  
 
 
Social History 
 
 
Smoker  
Y / N 
 
No. 
______ 
Alcohol  
Y / N  
 
Units 
_____ 
Other   
 BMI: Weight pre HSCT: 
Date of initial diagnosis   
Haematological Diagnosis  
Disease Classification  
(including genetic 
abnormalities) 
 
Haematological treatment to 
date 
 
 
 
 
 
 
 
Predisposing Condition  
 
 
Previous HSCT: Yes No 
Proposed date of transplant   
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Date of dental referral   
Date of Dental Assessment   
GDP Yes / No 
Previous attendance Regular / Irregular  
Dental Findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral Hygiene  
 
 
Mobile teeth 
 
 
Carious teeth 
 
 
Retained roots 
 
 
BPE score: 
 
Recorded 
 
Not Recorded 
 
   
   
Other pathology  
 
 
Dental Treatment 
completed  
 
 
Date of appointments: 
Oral Hygiene 
advice  
 
 
Prescription 
 
 
Extractions  
 
 
 
 
 
Restorations  
 
 
 
 
 
Periodontal 
treatment  
 
 
Other treatment  
 
 
Outstanding Dental 
Treatment  
Yes 
No 
Refused 
treatment  
 
Review of healing   
Y / N 
 
Date(s) 
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Date of transplant   
Delayed Yes No 
Reason: 
 
Status at HSCT Primary induction 
failure 
Complete 
haematological 
remission 
Relapse 
___ /___ / 
____ 
Preparative regimen Yes No  
 
 
Myeloablative: 
Yes  No (reason) 
 
 
Drugs: 
Unknown No  Yes (list) 
 
 
 
 
 
 
TBI: 
No Yes 
Total dose ______Gy 
No. fractions ______ 
No. days _______ 
 
 
Type of transplant Bone Marrow Peripheral Blood Core Blood 
 
 
Quality of match HLA – identical 
sibling 
 
Syngenetic HLA – 
matched 
other 
relative 
HLA – 
mismatched other 
relative 
Unrelated donor  
 
GVHD prophylaxis  Yes (list) 
 
 
 
 
 
No 
 
Survival status at HSCT 
(day 0) 
Alive Dead (date) 
____ / ____ / 
____ 
Died b/n 
preparatio
n and 
HSCT (date) 
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____ /____ 
/ _____ 
Main Cause of death: 
 
Contributory Causes of death: 
 
Mucositis  
 
Yes  
 
No  
 
 
Score: Date: Tx: 
 
Score: Date: Tx: 
 
Score: Date: Tx: 
 
Score: Date: Tx: 
 
Duration of mucositis    
  
Neutropenic Sepsis  
 
Yes 
 
No 
 
Organism: Date: 
 
Tx: 
 
Organism: Date: 
 
Tx: 
 
Organism: Date: 
 
Tx: 
 
Organism: Date: 
 
Tx: 
 
 
Xerostomia  
 
Yes 
 
No  
Date: Tx: 
Date: Tx: 
Date : Tx: 
Date: Tx: 
 
Infection (bacterial, viral, 
fungal) 
Yes  
 
No 
Date: Stage: Tx: 
Date: Stage: Tx: 
Date: Stage: Tx: 
Date: Stage: Tx: 
 
Acute GVHD 
 
Yes  
 
No 
Date: Stage: Tx: 
Date: Stage: Tx: 
Date: Stage: Tx: 
Date: Stage: Tx: 
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Feeding Regime  Oral feeding solids  
Oral feeding thickened fluids   
Nasogastric tube  
Peg fed  
 
Absolute neutrophil count 
recovery 
Yes (date) No (last 
assessed) 
Never 
below 
Unknown 
 
 
 
 
Platelet reconstitution 
(>20x10*9/L) 
Yes (date)  No Never 
below 
Unknown 
 
 
 
Early Graft Loss No Yes Unknown 
 
Length of hospital stay 
(days) 
 
BMI on discharge: Weight on discharge: 
 
Survival status at 100 days 
post-HSCT 
Alive 
 
Dead (date) 
____ / ____ / ____ 
 
Main Cause of death: 
 
Contributory causes of death: 
 
 
 
Chronic GVHD between 
HSCT – 100 days (date of 
death) 
 
Yes (date of 
diagnosis) 
____ / ____ / ____ 
No  Unknown 
 
Survival Status at Annual 
Follow up 
 
 
Alive  Dead (date) 
____ / ____ / ____ 
 
Main cause of death: 
Contributory causes of death: 
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7.10 Appendix 10: FACT-BMT questionnaire  
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7.11 Appendix 11: Lee cGvHD symptom score  
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7.12 Appendix 12: OHIP-14 quality of life questionnaire 
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7.13 Appendix 13: Sample framework 
 
 
 
 
 
 
 
 
Sample Framework  
Age 
>18years 
Occupation 
Professional 
Manual Classes 
Unemployed 
Gender 
Male 
Female 
Diagnosis 
ALL 
CLL 
Lymphoma 
 
Ethnicity Graft Type 
Allogeneic 
Language 
English 
 
Treatment 
RIC/TBI 
Chemotherapy 
BMT/PBSCT/UCSCT 
Donor match 
Failed HSCT 
 
Marital Status 
Single 
Married/Cohabiting 
Divorced/Widowed 
 
Dental 
Advice only 
Extractions only 
Comprehensive care 
Children 
Yes 
No 
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7.14 Appendix 14: Eligibility framework 
 
 
 
 
Patient:
1. has recieved an allogeneic HSCT
2. has a Haemato-oncological diagnosis 
3. has been seen for a pre-HSCT dental assessment in 
SCD
4. is 100 days post-HSCT
5. has capacity to consent
6. can speak fluent English
Yes
Had dental assessment/treatment by 
CW-D 
Yes
Ineligible to 
participate
No
Eligible participant 
Discuss the research project and provide:
1. Copy of the information sheet 
2. Copy of the consent form 
3. Organise time to interview and complete 
questionnaires
No
Ineligible to 
participate 
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7.15 Appendix 15: Invitation to participate letter  
 
 
Title: 
Exploring patient views of the influence of the dental intervention 
received prior to allogeneic stem cell transplantation on their post-transplant 
outcomes. 
Invitation paragraph 
 Clatterbridge Cancer Centre would like to invite you to take part in a 
research study. Before you decide it is important to understand why the 
research is being done and what it will involve. Please take the time to read 
the following information and ask any questions that you may have about 
what this research involves. We would be grateful if you could kindly take the 
time to consider this study and decide whether you wish to take part. Thank 
you. 
Purpose of study 
 This study is being carried out as part of a research degree (DDSc in 
Special Care Dentistry) within the University of Liverpool.  
 Currently, there is a link between the Special Care Dentistry 
Department at Liverpool University Dental Hospital and the Stem Cell 
Transplantation and Cellular Therapy Unit at Clatterbridge Cancer Centre - 
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Liverpool. This link provides the opportunity for patients to have a dental 
assessment and treatment prior to their haematopoietic stem cell transplant.  
 From the study we are hoping to gain information about patients’ 
views of this on the influence of dental assessment and/or treatment on 
patient outcomes following stem cell transplant, along with patient views on 
the service currently provided.   
 This study will focus on patients’ who have had an allogeneic stem cell 
transplant.  
Why have I been invited?  
 You have been invited to take part in the study as you have 
experienced the dental service provided by the Special Care Dentistry 
Department prior to your allogeneic stem cell transplant. You are now over 
100 days post-transplant, and so may have experienced the potential post-
transplant complications that can affect your mouth. The stem cell transplant 
team also feel that medically you are able to take part in this study.  
Do I have to take part? 
 It is entirely up to you if you decide to take part in the study. The study 
will be fully explained to you and please ask any questions that you may 
have about the study. 
What will happen if I do not take part?  
 If you refuse to take part of withdraw from the study at any point, and 
any information you have provided up to that point will be destroyed.  
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 Refusal to take part or withdrawal from the study will not have any 
impact on your current and ongoing dental and medical care.   
What will happen if I do decide to take part? 
 If you would like to take part then please contact the dental research 
student (via email clwd2701@liverpool.ac.uk) and arrange a suitable time for 
the interview to take place. The attached consent form will need to be 
completed and brought with you to the interview appointment, don’t worry if 
you forget it spares will be available. If you do not have access to email/the 
internet and are interested in taking part please inform someone at the clinic.  
 The interviews will take part within an office in the Stem Cell 
Transplantation and Cellular Therapy Unit (CCC), Liverpool. Ideally the 
interview will follow one of your review appointments with the stem cell 
transplant team however if this is not possible then a further interview 
appointment can be scheduled or a telephone interview can be arranged.  
Prior to the interview you will be asked to complete 3 quality of life 
questionnaires around your bone marrow transplant, GvHD symptoms and 
your oral health. Following completion of the questionnaire then a face-to-
face interview lasting up to 1 hour will be completed. The interview will be 
recorded on to a recording device. You can stop the interview at any point.  
The risks of taking part? 
 Taking part in the interview will mean giving up some of your free time; 
following your review appointment, having a further trip to the hospital or 
speaking on the telephone. 
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 In addition, the interview process will ask questions on your 
experience of the dental service but also about the transplant process. It is 
appreciated that some people may find discussing this period stressful and 
emotional. 
 If you would like advice about whether or not to participate, please 
discuss this with the researcher or a member of the stem cell transplant 
team. 
Benefits of taking part? 
 Participation in this study allows you to discuss your views and 
experiences of the dental service and the allogeneic transplant process. In 
addition, it allows you to express your views on the service and the 
information gained may help future recipients of stem cell transplants.  
What if there is a problem? 
 If there is a problem prior to the interview appointment, please contact 
the main researcher to identify a solution.  
 If there is a problem during the interview, the interview will be stopped 
in order to seek a resolution of the problem. Having the interview within the 
Stem Cell Transplantation and Cellular Therapy Unit (CCC), allows contact 
and support from staff if required.  
Will my details be kept confidential? 
 Yes, legal and ethical policies are in place to ensure that all 
information provided remains confidential. A master document detailing all 
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the participants of the study will be stored on a password protected trust 
computer.  
 Following the interview, the information will be written up onto a word 
document. The document will only include your initials, age and diagnosis 
allowing complete anonymity. Once the interviews are documented then the 
recording will be deleted.  
What will happen to the results of the study? 
 The results of the study will be written up as part of a research degree 
and will be published in a peer-reviewed journal with either a Haematology-
oncology or dental focus. However, given anonymity and confidentiality, you 
will not be identifiable from the reports or publications. 
 
What if I need to complain? 
 If you have any concerns about the way the study has been conducted 
please contact the main researcher, who will try to answer your query. If you 
are still unhappy, then details of the complaints process can be provided to 
you. 
Who is sponsoring the research? 
 The research is being sponsored by Clatterbridge Cancer Centre and 
has received ethical approval on 17/04/18. 
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Further information and contact details? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Researcher: 
Charlotte Wilson-Dewhurst 
Academic Clinical Fellow in 
Special Care Dentistry 
Special Care Dentistry Department  
Liverpool University Dental 
Hospital  
Pembroke Place 
L3 5PS 
Supervisor: 
Dr Amit Patel  
Consultant and Senior Lecturer in 
Stem Cell Transplantation and 
Intensive Care Medicine  
Clatterbridge Cancer Centre Liverpool 
Royal Liverpool University Hospital 
Pembroke Place 
Liverpool  
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7.16 Appendix 16: Consent form  
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7.17 Appendix 17: Topic guide 
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7.18  Appendix 18: Transcription example 
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7.19  Appendix 19: Data analysis process – Powerpoint® 
example 
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7.20 Appendix 20: Data analysis 
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